documents incorporated referencedocument part annual report stockholders fiscal year parts ii ended december proxy statement annual meeting part iii stockholders held april table contents part item business item properties item legal proceedings item submission matters vote security holders part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers registrant item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions item principal accountant fees services part iv item exhibits financial statement schedules signatures ex deferral program ex incentive stock plan ex incentive stock plan ex incentive stock plan ex plan deferred payment directors ' compensation ex computation ratios earnings fixed charges ex annual report ex subsidiaries ex power attorney ex certified resolution board directors ex certification ex certification ex certification ex certificationtable contents part item business merck co inc merck company global researchdriven pharmaceutical company discovers develops manufactures markets broad range innovative products improve human animal health directly joint ventures company sells products primarily drug wholesalers retailers hospitals clinics government agencies managed health care providers health maintenance organizations institutions companys professional representatives communicate effectiveness safety value products health care professionals private practice group practices managed care organizations product sales sales category companys products follows millions atherosclerosis hypertensionheart failure osteoporosis respiratory antiinflammatoryanalgesics antibacterialantifungal vaccinesbiologicals urology ophthalmologicals human immunodeficiency virus hiv total presented net discounts returns companys products include therapeutic preventive agents generally sold prescription treatment human disorders among atherosclerosis products zocor simvastatin largestselling hypertensionheart failure products significant cozaar losartan potassium hyzaar losartan potassium hydrochlorothiazide vasotec enalapril maleate osteoporosis product fosamax alendronate sodium treatment prevention osteoporosis respiratory product singulair montelukast sodium leukotriene receptor antagonist treatment asthma relief symptoms seasonal allergic rhinitis anti inflammatoryanalgesics include vioxx rofecoxib voluntarily withdrawn market worldwide september arcoxia etoricoxib agents specifically inhibit cox enzyme responsible pain inflammation coxib antibacterialantifungal products includes primaxin imipenem cilastatin sodium cancidas caspofungin acetate invanz ertapenem sodium vaccinesbiologicals varivax varicella virus vaccine live live virus vaccine prevention chickenpox mmr ii measles mumps rubella virus vaccine live pediatric vaccine measles mumps rubella pneumovax pneumococcal vaccine polyvalent vaccine prevention pneumococcal disease recombivax hb hepatitis b vaccine recombinant largestselling urology product proscar finasteride treatment symptomatic benign prostate enlargement ophthalmologicals cosopt dorzolamide hydrochloride timolol maleate ophthalmic solution trusopt dorzolamide hydrochloride ophthalmic solution largestselling hiv products include stocrin efavirenz crixivan indinavir sulfate treatment human immunodeficiency viral infection adults primarily includes sales human pharmaceuticals pharmaceutical animal health supply sales companys joint ventures revenue companys relationship astrazeneca lp primarily relating sales nexium esomeprazole magnesium prilosec omeprazole table contents august company announced us food drug administration fda granted new indication hyzaar initial use appropriate patients severe hypertension october indications cancidas expanded fda approval empirical therapy presumed fungal infections febrile neutropenic patients voluntary withdrawal vioxx september merck announced voluntary worldwide withdrawal vioxx arthritis acute pain medication companys decision effective immediately based new threeyear data prospective randomized placebocontrolled clinical trial approve adenomatous polyp prevention vioxx trial stopped designed evaluate efficacy vioxx mg preventing recurrence colorectal polyps patients history colorectal adenomas assess cardiovascular safety vioxx study increased relative risk confirmed cardiovascular events heart attack stroke beginning months treatment patients taking vioxx compared taking placebo results first months approve study show increased risk confirmed cardiovascular events vioxx respect similar results two placebocontrolled studies described recent us labeling vioxx merck presented data approve american college rheumatology acr annual scientific meeting san antonio october company requested opportunity present data acr meeting company estimates million us prescriptions written vioxx may august based estimate company estimates number patients taken vioxx united states since launch approximately million number patients outside united states taken vioxx undetermined time october company received letter senator charles grassley chairman senate committee finance requesting certain documents information related vioxx company also received requests information congressional committees company intends cooperate inquiries company continue describe reasons companys voluntary withdrawal vioxx answer questions related companys development extensive testing medicine disclosures results studies also october company received letter group five state attorneys general raising concerns companys return refund program unused vioxx provide consumers adequate notice unduly burdensome company cooperating attorneys general respond concerns february fda held joint meeting arthritis advisory committee drug safety risk management advisory committee committees discussed overall benefit risk considerations including cardiovascular gastrointestinal safety concerns cox selective nonsteroidal antiinflammatory drugs related agents february members committees asked vote whether overall risk versus benefit profile vioxx supports marketing united states members committees voted support marketing vioxx united states company looks forward discussions fda regulatory authorities vioxx previously announced board directors company appointed special committee review companys actions prior voluntary withdrawal vioxx act board responding shareholder litigation matters related withdrawal vioxx advise board respect action taken result review table contents arcoxia arcoxia launched countries europe latin america asia october company confirmed received approvable letter fda companys new drug application nda arcoxia fda informed merck letter approval nda issued additional safety efficacy data arcoxia required october european medicines evaluation agency emea announced would conduct review cox inhibitors including arcoxia light worldwide withdrawal vioxx emea said asked conduct review european commission precautionary measure would look aspects cardiovascular safety cox inhibitors including thrombotic cardiorenal events january emeas committee medicinal products human use chmp held hearings connection review additional meetings held chmp midfebruary continue review determine whether need make european union euwide changes products marketing authorizations including labeling determine whether additional studies needed february chmp announced concluded available data show increased risk cardiovascular adverse events cox inhibitors class relative placebo nsaids according chmp data also suggested association duration use dose probability suffering cardiovascular event therefore recommended use lowest effective dose cox inhibitors shortest possible duration treatment chmp introduced contraindication cox inhibitors patients ischemic heart disease stroke expanded contraindication certain patients higher classes congestive heart failure specifically respect arcoxia chmp also introduced contraindication patients hypertension whose blood pressure control advised arcoxia may associated frequent severe effects blood pressure particularly higher doses cox inhibitors recommended monitoring blood pressure patients taking arcoxia chmp stated interim measures pending finalization class review expected april finally chmp concluded research needed field evaluate cardiovascular safety cox inhibitors ongoing cardiovascular trials continue planned merck working regulatory agencies countries arcoxia approved assess whether changes prescribing information coxib class drugs including arcoxia warranted acquisitions cid march company acquired aton pharma inc aton privately held biotechnology company focusing development novel treatments cancer serious diseases atons clinical pipeline histone deacetylase inhibitors represents class antitumor agents potential efficacy based novel mechanism action lead product candidate suberoylanilide hydroxamic acid saha currently phase ii clinical trials treatment cutaneous tcell lymphoma company wholly owned subsidiary msd japan co ltd completed tender offers acquire remaining common shares banyu pharmaceutical co ltd banyu already aggregate purchase price approximately billion march merck completed acquisition banyu full ownership banyu enhances mercks position japan worlds secondlargest pharmaceutical market joint ventures cid company scheringplough corporation scheringplough entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas december cholesterolmanagement partnership agreements expanded include countries world excluding japan october zetia ezetimibe branded ezetrol outside united states first new class cholesterollowering agents launched united states december ezetrol launched countries outside united states july vytorin ezetimibesimvastatin marketed inegy many countries outside united states combination product containing active ingredients zetia zocor approved united states december addition united states vytorin approved countries table contents november merck scheringplough announced new clinical trial vytorin improve improved reduction outcomes vytorin efficacy international trial trial evaluate vytorin reducing major cardiovascular events intensive lipid lowering ldl cholesterol patients acute coronary syndrome improve fourth largescale outcomes trial conducted vytorin company entered agreement astra ab astra develop market astra products united states company astra formed equally owned joint venture developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining company astra restructured joint venture whereby company acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership company maintains limited partner interest partnership renamed astrazeneca lp became exclusive distributor products kbi retained rights company earns certain partnership returns well ongoing revenue based sales current future kbi products partnership returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing companys share undistributed partnership gaap earnings conjunction restructuring payment million astra purchased option buy companys interest kbi products excluding companys interest gastrointestinal medicines nexium prilosec company also granted astra option shares option buy companys common stock interest kbi exercise price based net present value estimated future net sales nexium prilosec april astra merged zeneca group plc forming astrazeneca ab astrazeneca result merger exchange companys relinquishment rights future astra products existing pending us patents time merger astra paid million subject trueup calculation may require repayment portion amount merger also triggers partial redemption companys limited partner interest furthermore result merger astrazenecas option buy companys interest kbi products exercisable company right require astrazeneca purchase interest addition shares option exercisable two years astras purchase companys interest kbi products company formed joint venture johnson johnson develop market manufacture consumer health care products united states owned joint venture expanded europe canada significant joint venture products pepcid ac famotidine overthecounter form companys ulcer medication pepcid famotidine well pepcid complete overthecounter product combines companys ulcer medication antacids calcium carbonate magnesium hydroxide march company sold johnson johnson interest european joint venture discussed divestitures effective april company merck vaccine division connaught laboratories inc sanofi pasteur sa agreed collaborate development marketing combination pediatric vaccines promote selected vaccines united states research marketing collaboration enables companies pool resources expedite development vaccines combining several different antigens protect children variety diseases including haemophilus influenzae type b hepatitis b diphtheria tetanus pertussis poliomyelitis combination vaccine development efforts continue agreement vaccines currently promoted company merck vaccine division pasteur mrieux connaught sanofi pasteur sa formed joint venture market human vaccines europe collaborate development combination vaccines distribution existing eu european free trade association table contents company sanofi pasteur contributed among things european vaccine businesses equal shares joint venture known pasteur mrieux msd snc sanofi pasteur msd snc joint venture subject monitoring eu partners made certain undertakings return exemption european competition law effective december joint venture maintains presence directly affiliates branches belgium italy germany spain france austria ireland sweden united kingdom distributors rest territory company rhnepoulenc sa sanofiaventis sa combined respective animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species competition cid markets companys pharmaceutical business conducted highly competitive often highly regulated global efforts toward health care cost containment continue exert pressure product pricing access competition involves intensive search technological innovations ability market innovations effectively longstanding emphasis research development company well prepared compete search technological innovations additional resources meet competition include quality control flexibility meet customer specifications efficient distribution system strong technical information service company active acquiring marketing products joint ventures licenses refining sales marketing efforts address changing industry conditions enhance product portfolio company continues pursue external alliances earlystage latestage product opportunities including joint ventures targeted acquisitions however introduction new products processes competitors may result price reductions product replacements even products protected patents example number compounds available treat diseases typically increases time resulted slowing growth sales certain companys products legislation enacted states united states particularly area human pharmaceutical products allows encourages instances absence specific instructions prescribing physician mandates use generic products containing active chemical innovators product rather brandname products governmental pressures toward dispensing generic products significantly reduced sales certain companys products longer protected patents vasotec vaseretic enalapril maleate combination hydrochlorothiazide us rights sold addition zocor lost patent protection certain countries outside united states company experienced decline zocor sales countries distribution cid company sells human health products primarily drug wholesalers retailers hospitals clinics government agencies managed health care providers health maintenance organizations institutions vaccines also sold directly physicians companys professional representatives communicate effectiveness safety value companys products health care professionals private practice group practices managed care organizations fourth quarter company implemented new distribution program us wholesalers moderate fluctuations sales caused wholesaler investment buying improve efficiencies distribution company pharmaceutical products new program lowered previous limits average monthly purchases company pharmaceutical products us customers following implementation program fluctuations sales caused wholesaler investment buying significantly moderated raw materials cid raw materials supplies generally available multiple sources purchased worldwide normally available quantities adequate meet needs companys business table contents government regulation investigation cid pharmaceutical industry subject global regulation regional country state local agencies particular importance fda united states administers requirements covering testing approval safety effectiveness manufacturing labeling marketing prescription pharmaceuticals many cases fda requirements increased amount time money necessary develop new products bring market united states food drug administration modernization act fda modernization act passed culmination comprehensive legislative reform effort designed streamline regulatory procedures within fda improve regulation drugs medical devices food legislation principally designed ensure timely availability safe effective drugs biologics expediting premarket review process new products key provision legislation reauthorization prescription drug user fee act permits continued collection user fees prescription drug manufacturers augment fda resources earmarked review human drug applications helps provide resources necessary ensure prompt approval safe effective new drugs united states government made significant progress expanding health care access enacting medicare prescription drug improvement modernization act signed law december statute added voluntary drug discount card medicare beneficiaries june add prescription drug coverage january implementation new benefit support companys goal improving access medicines expanding insurance coverage preserving marketbased incentives pharmaceutical innovation time benefit designed assure prescription drug costs controlled competitive pressures encouraging appropriate use medicines company taken leadership role contributing success new medicareendorsed discount cards providing medicines free lowincome medicare beneficiaries exhaust transitional assistance allowance medicareendorsed drug discount cards action consistent companys longstanding patient assistance program provides free medicines patients united states lack drug coverage afford medicines company negotiating prescription drug plans new medicare drug benefit offer merck products medicare beneficiaries beginning january terms new benefit addressing cost containment outside medicare company made continuing effort demonstrate medicines help save costs overall patient health care addition pricing flexibility across companys product portfolio encouraged growing use medicines mitigated effects increasing cost pressures many years pharmaceutical industry federal state oversight approval process new drugs drug safety advertising promotion drug purchasing reimbursement programs formularies variously review company believes continue able conduct operations including introduction new drugs market regulatory environment one type federal initiative contain federal health care spending prospective capitated payment system first implemented reduce rate growth medicare reimbursement hospitals system establishes advance flat rate reimbursement health care patients payor fiscally responsible type payment system cost containment systems widely used public private payors caused hospitals health maintenance organizations customers company costconscious treatment decisions including decisions regarding medicines made available patients company continues work private federal employers slow increases health care costs companys efforts demonstrate medicines help save costs areas pricing flexibility across product portfolio encouraged use companys medicines helped offset effects increasing cost pressures also federal state governments pursued methods directly reduce cost drugs vaccines pay example federal laws require company pay specified rebates medicines reimbursed medicaid provide discounts outpatient medicines purchased certain public health service entities disproportionate share hospitals hospitals meeting certain criteria provide minimum table contents discounts defined nonfederal average manufacturer price purchases certain components federal government department veterans affairs department defense initiatives states seek rebates beyond minimum required medicaid legislation cases patients beyond eligible medicaid federal vaccines children entitlement program us centers disease control prevention cdc funds purchases recommended pediatric vaccines public sector price immunization medicaideligible uninsured native american certain underinsured children company awarded cdc contract supply million pediatric vaccines vaccines children program january patients previously eligible medicaid also medicare beneficiaries years older disabled leave stateadministered medicaid system covered new medicare prescription drug benefit outside united states company encounters similar regulatory legislative issues countries business primary thrust governmental inquiry action toward determining drug safety effectiveness often mechanisms controlling prices prescription drugs profits prescription drug companies eu adopted directives concerning classification labeling advertising wholesale distribution approval marketing medicinal products human use companys policies procedures already consistent substance directives consequently believed material effect companys business company subject jurisdiction various regulatory agencies therefore subject potential administrative actions actions may include seizures products civil criminal sanctions certain circumstances company may deem advisable initiate product recalls company believes able compete effectively within environment addition certain countries within eu recognizing economic importance researchbased pharmaceutical industry value innovative medicines society working industry representatives european commission proposals complete single market pharmaceuticals improve competitive climate variety means including market deregulation increasing amount focus privacy issues countries around world including united states eu united states eu governments pursued legislative regulatory initiatives regarding privacy including federal privacy regulations recently enacted state privacy laws concerning health personal information affected companys operations patents trademarks licenses cid patent protection considered aggregate material importance companys marketing human health products united states major foreign markets patents may cover products per se pharmaceutical formulations processes intermediates useful manufacture products uses products protection individual products extends varying periods accordance date grant legal life patents various countries protection afforded may also vary country country depends upon type patent scope coverage patent portfolios developed products introduced company normally provide market exclusivity basic patents effect following major products united states arcoxia cancidas comvax haemophilus b conjugate hepatitis b recombinant vaccine cosopt cozaar crixivan emend aprepitant fosamax hyzaar invanz maxalt rizatriptan benzoate pedvaxhib haemophilus b conjugate vaccine primaxin propecia finasteride proscar recombivax hb singulair timopticxe timolol maleate ophthalmic gel forming solution trusopt vioxx zocor basic patents also effect united states zetia vytorin developed merckscheringplough partnership basic patent also effect sustivastocrin bristolmyers squibb exclusive license company sells sustiva united states canada certain european countries company markets stocrin countries throughout world basic patent aggrastat tirofiban hydrochloride united states divested product company retains basic patents aggrastat outside united states table contents zocor lost basic patent protection canada certain countries europe including united kingdom germany company experienced decline zocor sales countries june zocor lose market exclusivity united states company expects decline us zocor sales fda modernization act includes pediatric exclusivity provision may provide additional six months market exclusivity united states indications new currently marketed drugs certain agreed upon pediatric studies completed applicant exclusivity provisions reauthorized october best pharmaceuticals children act passed january fda granted additional six months market exclusivity united states trusopt october fda granted additional six months market exclusivity united states fosamax february fosamax weekly january however january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid based court appeals decision fosamax lose market exclusivity united states february company expects decline us fosamax sales time prior decision mercks patent onceweekly administration fosamax set expire july merck disagrees decision court appeals requested reconsideration court appeals information respect companys patents see patent litigation expiration product patent normally results loss market exclusivity covered pharmaceutical product commercial benefits may continue derived latergranted patents processes intermediates related economical method manufacture active ingredient product ii patents relating use product iii patents relating novel compositions formulations iv united states market exclusivity may available federal law effect product patent expiration pharmaceutical products also depends upon many factors nature market position product growth market complexities economics process manufacture active ingredient product requirements new drug provisions federal food drug cosmetic act similar laws regulations countries additions market exclusivity sought united states countries relevant laws including laws increasing patent life benefits increases patent life partially offset general increase number incentives use generic products additionally improvements intellectual property laws sought united states countries reform patent relevant laws implementation international treaties worldwide companys important products sold trademarks considered aggregate material importance trademark protection continues countries long used countries long registered registration fixed terms renewed indefinitely royalties received patent knowhow licenses rights amounted million company also paid royalties amounting million patent knowhow licenses holds discontinued operations august company completed spinoff medco health solutions inc medco health separate publiclytraded company spinoff effected way pro rata dividend company stockholders outstanding shares common stock medco health based letter ruling company received us internal revenue service receipt medco health shares distribution taxfree us federal income tax purposes cash received lieu fractional shares taxable divestitures cid march company completed sale johnson johnson companys equity stake european nonprescription pharmaceuticals joint venture johnson johnson table contents company sold us rights aggrastat tirofiban hydrochloride injection guilford pharmaceuticals inc including basic us product patents process patents product company sold us rights vasotec vaseretic vasotec iv injection enalaprilat biovail laboratories incorporated biovail subsidiary biovail corporation time companys canadian subsidiary merck frosst canada co merck frosst biovail entered supply agreement merck frosst agreed supply biovail minimum five years bulk tablets formulated enalapril maleate enalapril maleate combination hydrochlorothiazide distribution biovail united states vasotec vaseretic basic product patents vasotec vaseretic expired united states prior transactions research development companys business characterized introduction new products new uses existing products strong research development program approximately people employed companys research activities expenditures companys research development programs billion billion billion estimated continue level fullyear expense company maintains ongoing commitment research broad range therapeutic areas clinical development support new products total expenditures period exceeded billion compound annual growth rate company maintains number longterm exploratory fundamental research programs biology chemistry well research programs directed toward product development projects related human health carried various fields bacterial fungal viral infections cardiovascular disease atherosclerosis cancer depression diabetes obesity neurodegenerative disease psychiatric disease pain inflammation immunology respiratory diseases ophthalmology respiratory diseases osteoporosis menwomen health programs endoparasitic ectoparasitic diseases companion animal diseases production improvement development human health products industry practice government regulations united states foreign countries provide determination effectiveness safety new chemical compounds preclinical tests controlled clinical evaluation new drug may marketed united states recorded data preclinical clinical experience included nda biological product license application pla fda required approval development certain products also subject government regulations covering safety efficacy united states many foreign countries assurance compound result particular program obtain regulatory approvals necessary marketed stated company maintains basic research programs number areas directed toward product development companys scientists discover new compound believe promise treat medical condition company commences preclinical testing compound preclinical testing includes laboratory testing animal safety studies gather data chemistry pharmacology toxicology compounds selected study humans must undergo testing determine metabolized excreted animals prepared stable dose form bioavailable preclinical testing phase takes six years average compound continues show promise company initiate clinical testing accordance established regulatory requirements three phases clinical testing take total six years average complete clinical testing begins phase studies used determine compound safe humans usually using healthy volunteers phase studies concerned detecting adverse effects usually provide data efficacy compound treat targeted medical condition phase studies identify human tolerability problems compound enters phase ii first time compound studied patients disease compound studied treat phase ii dose efficacy trials commenced determine appropriate dosing compound confirm compounds efficacy determine whether adverse effects limit compounds usefulness results phase ii trials satisfactory company commences largescale phase iii trials confirm compounds efficacy safety upon completion trials satisfactory table contents company submits regulatory filings appropriate regulatory agencies around world product candidate approved marketing united states fda approval process begins complete nda submitted received fda pursuant prescription drug user fee act fda review period targets efficacy ndas supplemental ndas either six months priority review ten months standard review within days receipt nda fda determines application sufficiently complete permit substantive review fda also assesses time whether application granted priority review standard review according fda guidelines priority review granted compound considered constitute significant improvement compared marketed products including nondrug productstherapies treatment diagnosis prevention disease determination whether application filable type review ie standard priority communicated company review timelines defined generally assumed fda act upon application within timelines unless major amendment submitted either companys initiative fdas request pending application occurs fda may extend review period allow review new information days extensions review period communicated company average time period start preclinical testing fda approval approximately years november company announced filed biologics license application proquad measles mumps rubella varicella okamerck virus vaccine live fda proquad investigational vaccine simultaneous vaccination measles mumps rubella varicella children months years age proquad combines two established merck vaccines mmr ii varivax companys latestage pipeline includes three phase iii vaccines expected submitted fda approval three vaccines gardasil vaccine prevent human papillomavirus hpv infection associated development cervical cancer genital warts vaccine prevention zoster shingles reduction pain associated rotateq vaccine protect rotavirus highly contagious virus common cause severe gastroenteritis infants young children company expects file plas fda zoster vaccine rotateq second quarter gardasil second half february company announced glaxosmithkline plc gsk entered crosslicense settlement agreement certain patent rights related hpv vaccines pursuant agreement gsk receive upfront payment royalties company based sales gardasil upon development launch agreement resolves competing intellectual property claims related companys gsks vaccine candidates company continue research development appropriate regulatory reviews commercialization activities approved gardasil company also studying dppiv inhibitor glucoselowering mechanism used alone combination treatment type diabetes compound currently phase iii clinical studies company expects submit nda fda companys earlystage pipeline includes candidates following areas alzheimers disease arthritis atherosclerosis cancer diabetes endocrine disorders glaucoma infectious diseases obesity osteoporosis psychiatric disease neurodegenerative disease pain respiratory disease urogenital disorders vaccines company supplements internal research aggressive licensing external alliance strategy focused entire spectrum collaborations early research latestage compounds well new technologies company completed transactions including research collaborations preclinical clinical compounds technology transactions transactions completed include agreements following companies h lundbeck lundbeck treatment sleep disorders bristolmyers squibb bms treatment type diabetes vertex pharmaceuticals incorporated vertex treatment cancer dov pharmaceutical inc dov treatment depression related psychiatric disorders nastech pharmaceutical inc nastech treatment obesity ono pharmaceutical co ltd ono treatment acute stroke table contents february company announced entered agreement lundbeck exclusive development commercialization united states gaboxadol compound licensed lundbeck third party currently phase iii development treatment sleep disorders merck lundbeck jointly complete ongoing phase iii clinical program companies anticipate merck file nda fda late early following fda approval companies plan copromote gaboxadol united states june merck lundbeck announced extension agreement exclusive development commercialization gaboxadol japan march company acquired aton privately held biotechnology company focusing development novel treatments cancer serious diseases atons clinical pipeline histone deacetylase inhibitors represents class antitumor agents potential efficacy based novel mechanism action atons lead product candidate suberoylanilide hydroxamic acid saha currently phase ii clinical trials treatment cutaneous tcell lymphoma april merck bms entered worldwide collaborative agreement muraglitazar bmss product use treating patients type diabetes merck bms globally develop market muraglitazar december bms submitted nda fda muraglitazar muraglitazar potential first novel class drugs known glitazars class dual alphagamma ppar agonists including muraglitazar thought control blood sugar clinical trials muraglitazar reduced blood glucose levels decreased triglyceride levels increased highdensity lipoprotein hdl cholesterol levels type diabetes patients generally well tolerated june merck vertex entered global collaboration develop commercialize vx vertexs lead aurora kinase inhibitor phase clinical development treatment cancer aurora kinases implicated onset progression many different human cancers novel aurora kinase inhibitors vx potential play important future role treatment management wide range tumor types august merck dov announced agreement development commercialization dovs novel tripleuptake inhibitors developed depression related psychiatric disorders merck licensed exclusive worldwide rights dov phase therapeutic indications september merck nastech announced global alliance develop commercialize peptide yy pyy nasal spray nastechs product treatment obesity currently phase development investigational pyy nasal spray designed deliver natural appetiteregulating hormone pyy directly bloodstream november merck ono announced signed agreement granting merck worldwide license ono r propyloctanoic acid novel intravenous compound currently phase ii development treatment acute stroke addition ono received exclusive rights japan develop market emend aprepitant mercks drug use combination antiemetic agents prevention acute delayed nausea vomiting associated initial repeat courses highly emetogenic cancer chemotherapy including cisplatin ono also received rights japan comarket second brand mk mercks investigational oral compound treatment diabetes yet determined trademark chart reflects companys research pipeline february candidates shown phase iii include specific products candidates shown phase ii include advanced compound specific mechanism given therapeutic area backup compounds regardless phase development additional indications therapeutic areas additional line extensions formulations inline products shown preclinical areas shown company initiated good laboratory practices studies compounds mechanisms distinct phase ii companys programs generally designed focus development novel medicines address large unmet medical needs table contents preclinical phase phase ii phase iii alzheimers disease alzheimers disease aids hpv related cervical c c cancer genital warts antibacterials arthritis alzheimers disease gardasil c c antiviral c arthritis diabetes cancer c mk arthritis c c vx atherosclerosis rotavirus gastroenteritis atherosclerosis cinv c rotateq c c cancer diabetes cancer ctcl insomnia c saha gaboxadol cardiovascular disease endocrine diabetes c c shingles diabetes c hiv vaccine zoster vaccine c multiple sclerosis glaucoma glaucoma c c obesity immunology obesity c nastech pyy c insomnia osteoporosis c c pediatric vaccine osteoporosis pain psychiatric disease c c pain c respiratory disease c c respiratory disease parkinsons disease c c stroke vaccines psychiatric disease ono dov urinary incontinence c c us u bmissions steoporosis iabetes fosamax plus vitamin muraglitazar pediatric vaccine proquad licensed product service marks appearing type form different surrounding text trademarks service marks owned licensed merck subsidiaries affiliates including zetia vytorin trademarks owned entities merckscheringplough partnership except noted cozaar hyzaar registered trademarks ei du pont de nemours company wilmington de prilosec nexium trademarks astrazeneca group us trademarks vasotec vaseretic owned biovail laboratories incorporated us trademark aggrastat owned guilford pharmaceuticals inc employees end company approximately employees worldwide approximately employed united states including puerto rico approximately worldwide employees company represented various collective bargaining groups company announced plans eliminate positions part costreduction initiative completed end december company eliminated positions company identified additional opportunities eliminate positions reduce costs additional eliminations came contractor positions action expected result approximately million savings without impacting either key productivity initiatives companys ability meet business objectives environmental mattersthe company believes compliance material respects applicable environmental laws regulations company incurred capital expenditures approximately million environmental protection facilities company also remediating environmental contamination resulting table contents past industrial activity certain sites expenditures remediation environmental liabilities million estimated million years amounts consider potential recoveries insurers parties company taken active role identifying providing costs managements opinion liabilities environmental matters probable reasonably estimable accrued although possible predict certainty outcome environmental matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess provided result material adverse effect companys financial position results operations liquidity capital resources cautionary factors may affect future results cautionary statements private securities litigation reform act report written reports oral statements made time time company may contain socalled forward looking statements subject risks uncertainties one identify forwardlooking statements use words expects plans estimates forecasts projects words similar meaning one also identify fact relate strictly historical current facts statements likely address companys growth strategy financial results product approvals development programs one must carefully consider statement understand many factors could cause actual results differ materially companys forwardlooking statements factors include inaccurate assumptions broad variety risks uncertainties including known forwardlooking statement guaranteed actual future results may vary materially although possible predict identify factors may include following september merck voluntarily withdrew vioxx market numerous product liability lawsuits well number putative class actions filed company state federal courts relating sale use vioxx addition lawsuits number purported class actions brought company several current former officers directors company alleging company made false misleading statements regarding vioxx violation federal securities laws employee retirement income security act erisa addition number shareholders filed derivative suits asserting claims board members company officers company also named defendant actions various countries outside united states company anticipates additional lawsuits relating vioxx filed company also investigated securities exchange commission sec us department justice certain congressional committees district attorneys office munich germany company stated reasonably possible insurance coverage adequate cover defensive costs losses unfavorable outcomes vioxx lawsuits defined resulting vioxx investigations defined could material adverse effect companys financial position liquidity results operations noted arcoxia currently marketed countries outside united states received approvable letter fda company currently unable time predict future action fda take respect arcoxia fda held hearing february discuss safety issues related cox inhibitors addition chmp europe conducting review aspects cardiovascular safety cox inhibitors connection review interim measures summary product characteristics cox inhibitors revised including adding new contraindications cox inhibitors generally arcoxia specifically company unable time predict final outcome chmps review outcomes reviews could materially negatively affect market potential arcoxia generic competition product patents several products recently expired united states countries zocor lost basic patent protection canada certain countries europe including united kingdom germany company experienced decline zocor sales countries june zocor lose market exclusivity united states company expects decline table contents us zocor sales fda granted additional six months market exclusivity united states fosamax february fosamax weekly january however january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid based court appeals decision fosamax lose market exclusivity united states february company expects decline us fosamax sales time prior decision mercks patent onceweekly administration fosamax set expire july merck disagrees decision court appeals requested reconsideration court appeals july opposition division european patent office rendered oral decision revoke companys patent europe covers weekly administration alendronate company appealed decision however based decision fosamax lose market exclusivity major european markets increased brand competition therapeutic areas important companys longterm business performance difficulties uncertainties inherent new product development outcome lengthy complex process new product development inherently uncertain candidate fail stage process one latestage product candidates could fail receive regulatory approval new product candidates may appear promising development fail reach market efficacy safety concerns inability obtain necessary regulatory approvals difficulty excessive cost manufacture andor infringement patents intellectual property rights others furthermore sales new products may prove disappointing fail reach anticipated levels pricing pressures united states abroad including rules practices managed care groups judicial decisions governmental laws regulations related medicare medicaid health care reform pharmaceutical reimbursement pricing general changes government laws regulations enforcement thereof affecting companys business efficacy safety concerns respect marketed products whether scientifically justified leading product recalls withdrawals declining sales legal factors including product liability claims antitrust litigation governmental investigations environmental concerns patent disputes branded generic competitors could preclude commercialization products negatively affect profitability existing products lost market opportunity resulting delays uncertainties approval process fda foreign regulatory authorities increased focus privacy issues countries around world including united states eu united states federal state governments pursued legislative regulatory initiatives regarding patient privacy including federal recently issued state privacy regulations concerning health information affected companys operations changes tax laws including changes related taxation foreign earnings well impact legislation capping ultimately repealing section internal revenue code relating earnings companys puerto rican operations changes accounting pronouncements promulgated standardsetting regulatory bodies including financial accounting standards board sec adverse company economic factors company control including changes inflation interest rates foreign currency exchange rates list considered exhaustive statement potential risks uncertainties table contents geographic area segment information companys operations principally managed products basis one reportable segment merck pharmaceutical segment includes products marketed either directly joint ventures merck pharmaceutical products consist therapeutic preventive agents sold prescription treatment prevention human disorders companys operations outside united states conducted primarily subsidiaries sales worldwide subsidiaries outside united states sales sales companys worldwide business subject risks currency fluctuations governmental actions governmental proceedings abroad company regard risks deterrent expansion operations abroad however company closely reviews methods operations adopts strategies responsive changing economic political conditions recent years company expanding operations countries located latin america middle east africa eastern europe asia pacific changes government policies economic conditions making possible company earn fair returns business developing areas sometimes less stable offers important opportunities growth time financial information geographic areas operating segments companys business incorporated reference pages beginning caption segment reporting companys annual report stockholders available information companys internet website address wwwmerckcom company make available free charge investor information portion website annual report quarterly reports form q current reports form k amendments reports filed furnished pursuant section securities exchange act amended soon reasonably practicable reports electronically filed furnished sec companys corporate governance guidelines charters board directors seven standing committees available companys website wwwmerckcomaboutcorporategovernance information available print stockholder requests company item properties companys corporate headquarters located whitehouse station new jersey companys us pharmaceutical business conducted divisional headquarters located upper gwynedd west point pennsylvania companys vaccines business conducted divisional headquarters located west point principal research facilities human health products located rahway new jersey west point company also production facilities human health products nine locations united states puerto rico branch warehouses provide services throughout country outside united states subsidiaries company owns interest manufacturing plants properties australia canada japan singapore south africa countries western europe central south america asia capital expenditures million compared million united states amounted million million abroad expenditures amounted million million table contents company subsidiaries principal facilities manufacturing plants titles consider satisfactory company considers properties good operating condition machinery equipment well maintained plants manufacture products suitable intended purposes capacities projected capacities adequate current projected needs existing company products capacity plants converted needed modification requirements newly introduced future products item legal proceedings company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions vioxx litigation product liability lawsuits previously disclosed federal state product liability lawsuits involving individual claims well several putative class actions filed company respect vioxx january company served aware named defendant approximately lawsuits include approximately plaintiff groups alleging personal injuries resulting use vioxx certain lawsuits include allegations regarding gastrointestinal bleeding cardiovascular events thrombotic events kidney damage company also named defendant approximately putative class actions alleging personal injuries seeking medical monitoring result putative class members use vioxx ii disgorgement certain profits common law unjust enrichment theories andor iii various remedies state consumer fraud fair business practice statutes including recovering cost vioxx purchased individuals thirdparty payors union health plans actions discussed paragraph collectively referred vioxx product liability lawsuits actions filed state courts california new jersey respectively transferred single judge state coordinated proceedings addition company filed motion judicial panel multidistrict litigation jpml seeking transfer single federal judge coordinate pretrial purposes federal cases alleging personal injury andor economic loss relating purchase use vioxx several plaintiffs certain vioxx product liability lawsuits pending federal court made similar requests february jpml granted motions transfer vioxx product liability lawsuits pending federal courts nationwide one multidistrict litigation mdl coordinated pretrial proceedings mdl transferred united states district court eastern district louisiana district judge eldon e fallon shareholder lawsuits previously disclosed addition vioxx product liability lawsuits number purported class action lawsuits filed late early several shareholders united states district court eastern district louisiana naming defendants company several current former officers directors company cases consolidated announcement withdrawal vioxx company named defendant additional purported securities class action lawsuits filed federal courts new jersey pennsylvania louisiana actions allege defendants made false misleading statements regarding vioxx violation sections b securities exchange act including respect withdrawal vioxx seek unspecified compensatory damages costs suit including attorneys fees plaintiffs request certification class purchasers company stock various periods may october addition two shareholders filed individual securities action united states district court central district illinois seeking compensatory damages costs certain complaints include allegations sections securities act certain officers directors made incomplete misleading statements registration statement certain prospectuses filed connection merck stock investment plan dividend reinvestment plan actions discussed paragraph collectively referred vioxx securities lawsuits several plaintiffs dismissed complaints without prejudice january total vioxx securities lawsuits pending various federal courts table contents previously disclosed march two shareholder derivative actions filed united states district court eastern district louisiana naming company nominal defendant certain members board past present together certain executive officers defendants complaints arise substantially factual allegations made vioxx securities lawsuits derivative suits purportedly brought assert rights company assert claims board members officers breach fiduciary duty waste corporate assets unjust enrichment abuse control gross mismanagement withdrawal vioxx additional shareholder derivative actions filed new jersey superior court hunterdon county united states district court district new jersey company certain officers members board past present actions discussed paragraph collectively referred vioxx derivative lawsuits two vioxx derivative lawsuits include allegations certain directors made false misleading statements connection certain proxy statements filed sec violation section securities act january total seven vioxx derivative lawsuits pending october two individual shareholders made demand board take legal action mr raymond gilmartin chairman president chief executive officer individuals allegedly causing damage company respect allegedly improper marketing vioxx response demand letter board directors determined november meeting board would take shareholders request consideration remains consideration addition shareholder actions since announcement withdrawal vioxx putative class actions filed company united states district court eastern district louisiana united states district court district new jersey vioxx erisa lawsuits together vioxx securities lawsuits vioxx derivative lawsuits vioxx shareholder lawsuits behalf certain companys current former employees participants certain companys retirement plans asserting claims employee retirement income security act erisa lawsuits make similar allegations allegations contained vioxx securities lawsuits january total vioxx erisa lawsuits pending october plaintiff one vioxx erisa lawsuits filed motion jpml transfer single federal judge coordinate pretrial purposes vioxx erisa lawsuits november company responded motion filed motion seeking coordination vioxx shareholder lawsuits february jpml granted motions transfer vioxx shareholder lawsuits pending federal courts nationwide one mdl coordinated pretrial proceedings mdl transferred united states district court district new jersey district judge stanley r chesler international lawsuits addition lawsuits discussed company named defendant actions various countries europe australia canada brazil israel related vioxx additional lawsuits based media reports sources company anticipates additional vioxx product liability lawsuits vioxx shareholder lawsuits collectively vioxx lawsuits filed andor certain current former officers directors future insurance company product liability insurance claims brought vioxx product liability lawsuits approximately million deductibles coinsurance insurance provides coverage legal defense costs potential damage amounts incurred connection vioxx product liability lawsuits company believes insurance coverage extends additional vioxx product liability lawsuits may filed future company currently believes least approximately million directors officers insurance coverage vioxx securities lawsuits table contents vioxx derivative lawsuits company fiduciary insurance vioxx erisa lawsuits stated upper limits million additional insurance coverage claims may also available upper level excess policies provide coverage variety risks likely disputes insurers availability insurance coverage time company believes reasonably possible insurance coverage respect vioxx lawsuits adequate cover defense costs losses recently merck received notice companys upper level excess insurers provide excess insurance potentially applicable vioxx lawsuits commenced arbitration seeking among things cancel policies void obligations policies respect vioxx lawsuits also void coverage obligations respect certain types losses covered policies notice also purports reserve right insurers raise coverage defenses including respect application exclusions definition loss compliance policy conditions exhaustion applicable underlying upper coverage limits satisfactory proof loss insurers also issued lower level excess policies merck likely insurers also dispute obligation provide coverage policies merck intends contest vigorously insurers claims attempt enforce rights applicable insurance policies amounts actually recovered policies discussed section may less amounts specified preceding paragraph company notes discussion contained section updates disclosure entitled contingencies environmental liabilities vioxx litigation insurance note companys consolidated financial statements filed sec february form k contained companys annual report stockholders incorporated reference investigations november company advised staff sec commencing informal inquiry concerning vioxx january company announced received notice sec issued formal notice investigation also company received subpoena us department justice requesting information related companys research marketing selling activities respect vioxx federal health care investigation criminal statutes also ongoing investigations certain congressional committees also district attorneys office munich germany notified companys subsidiary germany received complaints commenced investigation order determine whether criminal charges brought germany concerning vioxx together previously mentioned investigations vioxx investigations company cooperate vioxx investigations company predict outcome inquiries however could result potential civil disposition sec andor potential civil criminal dispositions justice department reserves company currently anticipates one vioxx product liability lawsuits may go trial first half company predict timing trials respect vioxx shareholder lawsuits company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits company established reserves potential liability relating vioxx lawsuits vioxx investigations collectively vioxx litigation company established reserve million solely future legal defense costs related vioxx litigation reserve based certain assumptions minimum amount company believes time reasonably estimate spent multiyear period company significantly increased reserve ability reasonably estimate future legal defense costs vioxx litigation significant factors considered establishment reserve vioxx litigation follows actual costs incurred company time development companys legal defense strategy structure light expanded scope vioxx litigation number cases brought company anticipated timing progression related costs pretrial activities trials vioxx product liability lawsuits company continue monitor legal defense costs review adequacy associated reserves unfavorable outcomes vioxx lawsuits resulting vioxx investigations could material adverse effect companys financial position liquidity results operations table contents commercial litigation beginning company named number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states actions except pending state courts consolidated pretrial purposes federal court chicago illinois company several defendants settled federal class action represented single largest group claims since time company settled substantially remaining cases satisfactory terms remaining cases inactive several years company engaged conspiracy admission wrongdoing made included settlement agreements previously disclosed company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels jpml ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case may court granted companys motion dismiss consolidated class action dismissed company class action case subsequent companys dismissal plaintiffs filed amended consolidated class action complaint name company defendant company pharmaceutical manufacturers remain defendants six similar complaints pending federal court massachusetts filed new york counties suffolk rockland nassau westchester onondaga new york city three cases pending kentucky alabama wisconsin company defendants filed argued motion dismiss suffolk case awaiting courts final decision motion addition company defendant cases brought behalf citizens kentucky wisconsin alleging fraudulent practices regarding awp company vigorously defend previously disclosed company named defendant antitrust cases federal court minnesota state court california alleging unlawful conspiracy among different sets pharmaceutical manufacturers protect high prices united states impeding importation united states lowerpriced pharmaceuticals canada company defendants filed motion dismiss action previously disclosed suit federal court alabama two providers health services needy patients alleges pharmaceutical companies overcharged plaintiffs class similarly situated pharmaceuticals purchased plaintiffs program established section b public health service act company defendants filed motion dismiss complaint numerous grounds previously disclosed january us department justice notified federal court new orleans louisiana going intervene time pending federal false claims act case filed seal december company court issued order unsealing complaint filed physician louisiana ordered complaint served complaint alleged companys discounting pepcid certain louisiana hospitals led increases costs medicaid dismissed amended complaint filed seal case administratively closed court seal lifted allegations contained amended complaint unknown governmental proceedings previously disclosed company received subpoena us department justice connection investigation companys marketing selling activities company also reported received civil investigative demand attorney general texas regarding companys table contents marketing selling activities relating texas april company received subpoena office inspector general district columbia connection investigation companys interactions physicians district columbia maryland virginia november company received letter request department justice connection investigation companys pricing pepcid company cooperating investigations company predict outcome investigations however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations addition time time federal state regulators may seek information practices pharmaceutical industry inquiries investigations discussed paragraph feasible predict outcome inquiries vaccine litigation company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella andor trivalent vaccines measles mumps rubella including companys mmr ii conditions include autism without inflammatory bowel disease epilepsy diabetes encephalitis encephalopathy deafness chronic fatigue syndrome transverse myelitis early september legal services commission lsc announced decision withdraw public funding litigation brought claimants decision confirmed appeal funding review committee frc september claimants application judicial review decision withdraw public funding dismissed february april trial date vacated lead claimants decided apply court appeals permission appeal decision result legal aid lead claimants discharged nonlead claimants subject show cause procedure withdraw legal aid unless claimants could show cause withdrawn frc heard show cause appeals nonlead claimants october appeals involving autism unsuccessful funding reinstated appeals involving nonautism conditions epilepsy deafness encephalitis transverse myelitis light successful appeals lsc reconsidered cases claimants date funding reinstated additional nonlead nonautism cases limited extent necessary allow solicitors provide report individual cases lsc yet known many appeals involve claimants suing company claimants conditions february give notice intention continue discontinue claims irrespective whether secured legal aid funding directions conduct litigation made case management hearing scheduled take place march company vigorously defend lawsuits previous disclosed company also party individual class action product liability lawsuits claims united states involving pediatric vaccines ie hepatitis b vaccine haemophilus influenza type b vaccine contained thimerosal preservative used vaccines merck distributed thimerosalcontaining pediatric vaccines united states since fall december approximately active thimerosal related lawsuits approximately plaintiffs defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines two state court cases two federal district court cases scheduled trial company vigorously defend lawsuits however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations company successful cases type either dismissed stayed ground action prohibited national vaccine injury compensation program nvicp nvicp prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court nvicp filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely table contents file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods company aware numerous cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders company party vaccine court proceedings petitions brought department health human services patent litigation time time generic manufacturers pharmaceutical products file abbreviated new drug applications andas fda seeking market generic forms companys products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic forms fosamax prilosec propecia prior expiration companys astrazenecas case prilosec patents concerning products generic companies andas generally include allegations noninfringement invalidity unenforceability patents generic manufacturers received fda approval market generic form prilosec company filed patent infringement suits federal court companies filing andas generic alendronate finasteride astrazeneca company filed patent infringement suits federal court companies filing andas generic omeprazole similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products trial united states respect alendronate daily product concluded november november decision issued us district court delaware finding companys patent valid infringed october us court appeals federal circuit affirmed validity infringement companys basic us patent covering use alendronate form request rehearing denied trial united states involving alendronate weekly product held march august us district court delaware upheld validity companys us patent covering weekly administration alendronate however january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid based court appeals decision fosamax lose market exclusivity united states february company expects decline us fosamax sales time prior decision mercks patent onceweekly administration fosamax set expire july merck disagrees decision court appeals requested reconsideration court appeals january high court justice england wales held patents company protecting alendronate daily weekly products invalid united kingdom november court appeals england wales affirmed ruling high court justice england wales european countries permit companies seeking approval generic product reference data innovative product certain circumstances data exclusivity regulations company granted leave appeal decision uk regulatory authority data weekly alendronate may referenced companies seeking approval generic weekly alendronate products company also filed appeal grant swedish regulatory authority approval generic weekly alendronate products referenced companys data weekly alendronate approval previously announced company july opposition division european patent office rendered oral decision revoke companys patent europe covers weekly administration alendronate august written opinion issued confirming oral decision revoking companys patent september company filed appeal decision based patents alendronate weekly product protected major european markets least table contents october action australia challenging validity companys australian patent weekly administration alendronate patent found invalid company appealed decision addition japan proceeding filed challenging validity companys japanese patent weekly administration alendronate case omeprazole trial court united states rendered opinion october upholding validity companys astrazenecas patents covering stabilized formulation omeprazole ruling one defendants omeprazole product infringe patents three defendants products found infringe formulation patents december us court appeals federal circuit affirmed decision trial court respect certain generic manufacturers omeprazole products trial date yet set case finasteride anda filed seeking approval generic version propecia alleging invalidity companys patents company filed patent infringement lawsuit district court delaware september trial anticipated litigation previously disclosed july united states district court district new jersey granted motion company medco health certain officers directors dismiss purported class action complaint involving claims related companys revenue recognition practice retail copayments paid individuals medco health provides pharmaceutical benefits well allegations complaint dismissed prejudice august court granted companys motion dismiss prejudice related shareholder derivative action plaintiffs actions appealed decisions prior spinoff medco health company medco health agreed settle class action basis series lawsuits asserting violations erisa gruer cases company medco health certain plaintiffs counsel filed settlement agreement federal district court new york cases commenced number plaintiffs including participants number pharmaceutical benefit plans medco health pharmacy benefit manager well trustees plans consolidated proposed class settlement agreed plaintiffs five cases filed medco health company proposed settlement company medco health agreed pay total million medco health agreed modify certain business practices continue certain specified business practices period five years financial compensation intended benefit members settlement class includes erisa plans medco health administered pharmacy benefit time since december district court preliminarily approved settlement held hearings hear objections fairness proposed settlement district court approved settlement yet determined number class member plans properly elected participate settlement settlement becomes final appeals resolved three notices appeal filed appellate court expected hear arguments regarding appeals march decide appeals thereafter currently certain class member plans indicated participate settlement cases initiated three plans two individuals remain pending southern district new york plaintiffs cases asserted claims based erisa well federal state laws similar claims asserted settling class members gruer cases company medco health named defendants cases medco health company agreed proposed settlement order avoid significant cost distraction prolonged litigation spinoff medco health medco health assumed substantially liability exposure matters discussed foregoing paragraph cases defended medco health table contents various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided environmental matters previously disclosed december virginia department environmental quality vadeq issued notice violation companys elkton virginia facility air permit limit exceedances reported facility result performance testing process train company currently discussions vadeq believes discussions result capital improvements together monetary sanctions immaterial exceed company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund federal state equivalents proceedings seek require operators hazardous waste disposal facilities transporters waste sites generators hazardous waste disposed sites clean sites reimburse government cleanup costs company made party proceedings alleged generator waste disposed sites case government alleges defendants jointly severally liable cleanup costs although joint several liability alleged proceedings frequently resolved allocation cleanup costs among parties nearly reflects relative contributions parties site situation companys potential liability varies greatly site site sites potential liability de minimis others costs cleanup yet determined feasible predict outcome many proceedings brought federal state agencies private litigants opinion company proceedings ultimately result liability would material adverse effect financial position results operations liquidity capital resources company company taken active role identifying providing costs amounts include reduction anticipated recoveries cleanup costs insurers former site owners operators recalcitrant potentially responsible parties item submission matters vote security holders applicable table contents executive officers registrant march raymond v gilmartin cid age june cid chairman board since november president chief executive officer david w anstice cid age january cid president human health cid responsible companys prescription drug business japan latin america canada australia new zealand companys joint venture relationship scheringplough march cid president americas us human health cid responsible one two prescription drug divisions comprising us human health well companys prescription drug business canada latin america companys joint venture relationship scheringplough january cid president human healththe americas cid responsible companys human health business united states canada latin america marcia j avedon cid age january cid senior vice president human resources september cid vice president talent management organization effectiveness prior september dr avedon held several senior human resources positions honeywell international diversified manufacturing technology company richard clark cid age june cid president merck manufacturing division cid responsible companys manufacturing information services operational excellence organizations worldwide january cid chairman president chief executive officer medco health solutions inc medco health formerly wholly owned subsidiary company january cid president medco health june cid executive vice presidentchief operating officer medco health celia colbert cid age january cid vice president secretary since september assistant general counsel since november caroline dorsa cid age august cid vice president treasurer cid responsible companys treasury tax functions providing financial support merck manufacturing merck research laboratories divisions well human resources september cid vice president treasurer cid responsible companys treasury tax functions providing financial support asia pacific division table contents kenneth c frazier cid age december cid senior vice president general counsel cid responsible legal public affairs functions merck company foundation notforprofit charitable organization affiliated company january cid vice president deputy general counsel richard c henriques jr cid age august cid vice president controller cid responsible corporate controllers group providing financial support human health operations united states canada latin america europe middle east africa japan australianew zealand merck vaccine division mvd november cid vice president controller cid responsible corporate controllers group providing financial support us human health canada latin america americas mvd february cid vice president controller cid responsible corporate controllers group providing financial support americas peter kim cid age january cid president merck research laboratories mrl february cid executive vice president research development mrl prior february dr kim served member whitehead institute professor biology massachusetts institute technology investigator howard hughes medical institute judy c lewent cid age january cid executive vice president chief financial officer president human health asia cid responsible financial corporate development functions internal auditing corporate licensing companys prescription drug business asia north asia south companys joint venture relationships merck capital ventures llc subsidiary company february cid executive vice president chief financial officer cid responsible financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc november cid senior vice president chief financial officer cid responsible financial corporate development functions internal auditing corporate licensing companys joint venture relationships merck capital ventures llc january cid senior vice president since january chief financial officer since april cid responsible financial corporate development functions internal auditing companys joint venture relationships adel mahmoud cid age may cid president merck vaccines table contents margaret g mcglynn cid age january cid president us human health cid responsible one two prescription drug divisions hospital specialty product franchises comprising us human health ushh managed care group ushh august cid executive vice president customer marketing sales ushh november cid senior vice president worldwide human health marketing bradley sheares cid age january cid president us human health cid responsible one two prescription drug divisions primary care product franchises comprising us human health ushh march cid president us human health cid responsible one two prescription drug divisions hospital specialty product franchises comprising ushh july cid vice president hospital marketing sales ushh joan e wainwright cid age january cid vice president public affairs june cid vice president corporate communications public affairs prior june ms wainwright deputy commissioner communications us social security administration per woldolsen cid age january cid president human healtheurope middle east africa cid responsible companys prescription drug business europe middle east africa worldwide human health marketing officers listed serve pleasure board directors none officers elected pursuant arrangement understanding officer board table contents part ii item market registrants common equity related stockholder matters issuer purchases equity securities required information market information dividends incorporated reference companys annual report stockholders required information number holders companys common stock incorporated reference companys annual report stockholders issuer purchases equity securities three month period ended december follows issuer purchases equity securities total number millions total shares purchased approx dollar value number average part shares may yet shares price paid publicly announced purchased period purchased per share plans programs plans programs october october november november december december total quarter date item selected financial data information required item incorporated reference data last five fiscal years company included results year yearend position selected financial data table companys annual report stockholders item managements discussion analysis financial condition results operations information required item incorporated reference pages companys annual report stockholders item quantitative qualitative disclosures market risk information required item incorporated reference pages beginning caption financial instruments market risk disclosures companys annual report stockholders table contents item financial statements supplementary data financial statements consolidated balance sheet merck co inc subsidiaries december related consolidated statements income retained earnings comprehensive income cash flows three years period ended december report dated february pricewaterhousecoopers llp independent registered public accounting firm incorporated reference pages respectively companys annual report stockholders b supplementary data selected quarterly financial data incorporated reference data contained condensed interim financial data table companys annual report stockholders item changes disagreements accountants accounting financial disclosure applicable item controls procedures management company participation chief executive officer chief financial officer evaluated effectiveness companys disclosure controls procedures based evaluation end period covered companys chief executive officer chief financial officer concluded companys disclosure controls procedures defined rules ae de securities exchange act amended effective management responsible establishing maintaining adequate internal control financial reporting term defined exchange act rule af management conducted evaluation effectiveness internal control financial reporting based framework internal control integrated framework issued committee sponsoring organizations treadway commission coso based evaluation management concluded internal control financial reporting effective december based criteria internal control integrated framework issued coso managements assessment effectiveness internal control financial reporting december audited pricewaterhousecoopers llp independent registered public accounting firm pricewaterhousecoopers llp issued attestation report managements assessment effectiveness companys internal control financial reporting incorporated reference companys annual report stockholders significant changes internal control financial reporting period covered report materially affected reasonably likely materially affect companys internal control financial reporting item b information none part iii item directors executive officers registrant required information directors nominees incorporated reference pages companys proxy statement annual meeting stockholders held april information executive officers set forth part document pages table contents required information audit committee financial expert incorporated reference heading financial expert audit committee companys proxy statement annual meeting stockholders held april required information identification audit committee incorporated reference pages caption board committees companys proxy statement annual meeting stockholders held april required information compliance section securities exchange act incorporated reference caption section beneficial ownership reporting compliance companys proxy statement annual meeting stockholders held april company adopted code conduct values standards applicable employees including principal executive officer principal financial officer principal accounting officer code conduct available companys website wwwmerckcomaboutcorporategovernance company intends post website amendments waivers code conduct printed copy sent without charge stockholder requests writing chief ethics officer merck co inc one merck drive whitehouse station nj item executive compensation information required item incorporated reference pages caption compensation directors pages beginning caption summary compensation table pages beginning caption annual benefits payable merck co inc retirement plans caption compensation committee interlocks insider participation pages caption compensation benefits committee report executive compensation caption performance graph companys proxy statement annual meeting stockholders held april item security ownership certain beneficial owners management related stockholder matters information respect securities authorized issuance equity compensation plans incorporated reference caption equity compensation plan information companys proxy statement annual meeting stockholders held april information respect security ownership certain beneficial owners management incorporated reference pages caption security ownership certain beneficial owners management companys proxy statement annual meeting stockholders held april item certain relationships related transactions information required item incorporated reference caption relationships outside firms caption indebtedness management companys proxy statement annual meeting stockholders held april item principal accountant fees services information required item incorporated reference pages beginning caption preapproval policy services independent registered public accounting firm companys proxy statement annual meeting stockholders held april table contents part iv item exhibits financial statement schedules documents filed part financial statements following consolidated financial statements report independent registered public accounting firm incorporated herein reference companys annual report stockholders noted document consolidated statement income years ended december consolidated statement retained earnings years ended december consolidated statement comprehensive income years ended december consolidated balance sheet december consolidated statement cash flows years ended december notes consolidated financial statements report pricewaterhousecoopers llp independent registered public accounting firm financial statement schedules schedules omitted either required applicable financial statements affiliates carried equity basis omitted considered individually aggregate affiliates constitute significant subsidiary exhibits exhibit number description cid master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission cid incorporated reference form q quarterly report period ended june cid restated certificate incorporation merck co inc october cid incorporated reference form q quarterly report period ended september cid bylaws merck co inc amended effective september cid incorporated reference current report form k dated september cid indenture dated april merck co inc morgan guaranty trust company new york trustee incorporated reference exhibit registration statement form cid first supplemental indenture merck co inc first trust new york national association trustee incorporated reference exhibit b registration statement form cid executive incentive plan amended effective february cid incorporated reference annual report fiscal year ended december management contract compensatory plan arrangement table contents exhibit number description cid base salary deferral plan adopted october effective january cid incorporated reference form k annual report fiscal year ended december cid merck co inc deferral program amended restated january cid incentive stock plan amended effective february cid incorporated reference annual report fiscal year ended december cid incentive stock plan amended restated february cid incentive stock plan amended restated february cid incentive stock plan amended restated february cid merck co inc change control separation benefits plan incorporated reference current report form k dated november cid nonemployee directors stock option plan amended restated february cid incorporated reference annual report fiscal year ended december cid nonemployee directors stock option plan amended april cid incorporated reference form q quarterly report period ended june cid nonemployee directors stock option plan amended april cid incorporated reference form q quarterly report period ended june cid supplemental retirement plan amended effective january cid incorporated reference annual report fiscal year ended december cid retirement plan directors merck co inc amended restated june cid incorporated reference form q quarterly report period ended june cid plan deferred payment directors compensation amended restated january cid limited liability company agreement merck capital ventures llc dated november cid incorporated reference annual report fiscal year ended december cid offer letter merck co inc peter kim dated december incorporated reference annual report fiscal year ended december management contract compensatory plan arrangement table contents exhibit number description cid amended restated license option agreement dated july astra ab astra merck inc cid incorporated reference form q quarterly report period ended june cid kbi shares option agreement dated july among astra ab merck co inc merck holdings inc cid incorporated reference form q quarterly report period ended june cid kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc cid incorporated reference form q quarterly report period ended june cid kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission cid incorporated reference form q quarterly report period ended june cid second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc cid incorporated reference form q quarterly report period ended june cid limited partnership agreement dated july kb usa lp kbi sub inc cid incorporated reference form q quarterly report period ended june cid distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp cid incorporated reference form q quarterly report period ended june cid agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp cid incorporated reference form q quarterly report period ended june cid computation ratios earnings fixed charges cid annual report stockholders portions incorporated reference document deemed filed cid code conduct values standards cid incorporated reference annual report fiscal year ended december cid subsidiaries merck co inc cid consent independent registered public accounting firm cid contained report cid power attorney cid certified resolution board directors cid rule ada certification chief executive officer table contents exhibit number description cid rule ada certification chief financial officer cid section certification chief executive officer cid section certification chief financial officer copies exhibits may obtained stockholders upon written request directed stockholder services department merck co inc po box ws ab whitehouse station new jersey table contents signatures pursuant requirements section securities exchange act registrant duly caused report signed behalf undersigned thereunto duly authorized merck co inc dated march raymond v gilmartin chairman board president chief executive officer celia colbert celia colbert attorneyinfact pursuant requirements securities exchange act report signed following persons behalf registrant capacities dates indicated signatures title date raymond v gilmartin chairman board president march chief executive officer principal executive officer director judy c lewent executive vice president chief march financial officer president human health asia principal financial officer richard c henriques jr vice president controller march principal accounting officer lawrence bossidy director march william g bowen director march johnnetta b cole director march william b harrison jr director march william n kelley director march rochelle b lazarus director march thomas e shenk director march anne tatlock director march samuel thier director march peter c wendell director march celia colbert signing name hereto hereby sign document pursuant powers attorney duly executed persons named filed securities exchange commission exhibit document behalf persons capacities date stated persons including majority directors company celia colbert celia colbert attorneyinfact table contents exhibit consent independent registered public accounting firm hereby consent incorporation reference registration statements form nos form nos merck co inc report dated february relating consolidated financial statements managements assessment effectiveness internal control financial reporting effectiveness internal control financial reporting appears annual report stockholders incorporated annual report pricewaterhousecoopers llp florham park new jersey march table contents exhibit index exhibit number description cid master restructuring agreement dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission cid incorporated reference form q quarterly report period ended june cid restated certificate incorporation merck co inc october cid incorporated reference form q quarterly report period ended september cid bylaws merck co inc amended effective september cid incorporated reference current report form k dated september cid indenture dated april merck co inc morgan guaranty trust company new york trustee incorporated reference exhibit registration statement form cid first supplemental indenture merck co inc first trust new york national association trustee incorporated reference exhibit b registration statement form cid executive incentive plan amended effective february cid incorporated reference annual report fiscal year ended december cid base salary deferral plan adopted october effective january cid incorporated reference annual report fiscal year ended december cid merck co inc deferral program amended restated january cid incentive stock plan amended effective february cid incorporated reference annual report fiscal year ended december cid incentive stock plan amended restated february cid incentive stock plan amended restated february cid incentive stock plan amended restated february cid merck co inc change control separation benefits plan incorporated reference current report form k dated november cid nonemployee directors stock option plan amended restated february cid incorporated reference annual report fiscal year ended december cid nonemployee directors stock option plan amended april cid incorporated reference form q quarterly report period ended june cid nonemployee directors stock option plan amended april cid incorporated reference form q quarterly report period ended june management contract compensatory plan arrangementtable contents exhibit number description cid supplemental retirement plan amended effective january cid incorporated reference annual report fiscal year ended december cid retirement plan directors merck co inc amended restated june cid incorporated reference form q quarterly report period ended june cid plan deferred payment directors compensation amended restated january cid limited liability company agreement merck capital ventures llc dated november cid incorporated reference annual report fiscal year ended december cid offer letter merck co inc peter kim dated december cid incorporated reference form k annual report fiscal year ended december cid amended restated license option agreement dated july astra ab astra merck inc cid incorporated reference form q quarterly report period ended june cid kbi shares option agreement dated july among astra ab merck co inc merck holdings inc cid incorporated reference form q quarterly report period ended june cid kbie asset option agreement dated july among astra ab merck co inc astra merck inc astra merck enterprises inc cid incorporated reference form q quarterly report period ended june cid kbi supply agreement dated july astra merck inc astra pharmaceuticals lp portions exhibit subject request confidential treatment filed commission cid incorporated reference form q quarterly report period ended june cid second amended restated manufacturing agreement dated july among merck co inc astra ab astra merck inc astra usa inc cid incorporated reference form q quarterly report period ended june cid limited partnership agreement dated july kb usa lp kbi sub inc cid incorporated reference form q quarterly report period ended june cid distribution agreement dated july astra merck enterprises inc astra pharmaceuticals lp cid incorporated reference form q quarterly report period ended june cid agreement incorporate defined terms dated june astra ab merck co inc astra merck inc astra usa inc kb usa lp astra merck enterprises inc kbi sub inc merck holdings inc astra pharmaceuticals lp cid incorporated reference form q quarterly report period ended june management contract compensatory plan arrangementtable contents exhibit number description cid computation ratios earnings fixed charges cid annual report stockholders portions incorporated reference document deemed filed cid code conduct values standards cid incorporated reference annual report fiscal year ended december cid subsidiaries merck co inc cid consent independent registered public accounting firm cid contained report cid power attorney cid certified resolution board directors cid rule ada certification chief executive officer cid rule ada certification chief financial officer cid section certification chief executive officer cid section certification chief financial officerexhibit merck co inc deferral program amended restated january table contents article administration article ii eligibility article iii deferral deferred compensation account article iv valuation deferred compensation accounts article v redesignation within deferred compensation account article vi distribution deferred compensation accounts article vii deductions distributions article viii beneficiary designations article ix amendments schedule deferral program investment alternatives schedule ii special provisions applicable medco health employees imerck co inc deferral program deferral program program intended permit select group management defer income would otherwise immediately payable annual base salary various incentive plans merck co inc company administration program administered compensation benefits committee companys board directors committee composed nonemployee directors committee shall responsibility determining investments available program investments shall listed schedule hereto committee shall review investment selections least every five years committee shall make decisions affecting timing price amount deferred compensation participants subject section securities exchange act amended section officers may otherwise delegate authority program ii eligibility eligibility defer program determined accordance terms companys base salary deferral plan various incentive plans however committee authority refuse permit employee participate program committee determines participation would jeopardize programs compliance applicable law programs status top hat plan employee retirement income security act iii deferral deferred compensation account election defer participants decision defer program must made base salary deferral plan prior commencement pay period base salary deferred earned ii annual incentive plans prior commencement performance year bonus monies deferred earned iii longterm incentive plans prior commencement last year award period bonus monies deferred earned purposes annual incentive plans participant hired company performance year may make election later thirtieth th day participants date hire defer bonus monies earned performance year base salary deferral plan amounts equal excess five percent annual base salary defined base salary deferral plan less equal lesser fifty percent annual base salary participants annual base salary excess amount determined section internal revenue code may deferred annual longterm incentive plans amounts excess may deferred amounts deferred known deferred compensation credited participants deferred compensation account deferred compensation shall held one account regardless plan base salary deferral incentive plan deferredb election distribution schedule timing election participant shall also elect distribution schedule hisher deferred compensation participants election distribution schedule connection deferral election annual andor longterm incentive plans shall made time participant makes election defer participants initial election distribution schedule connection deferrals base salary deferral plan shall made time initial deferral election shall irrevocable calendar year made shall apply deferrals annual base salary new distribution election becomes effective thereafter election different distribution schedule connection deferrals base salary deferral plan may made time provided however new distribution schedule shall apply prospectively deferrals annual base salary following calendar year distribution schedule participant may elect payments begin participants actual retirement date subsequent date prior thereto participant may elect lump sum schedule annual installments maximum annual installments installment however may payable fifteen years participants termination employment c election investment alternatives participant shall designate accordance procedures established company designation portion multiples deferred compensation allocated investment alternative available program iv valuation deferred compensation accounts common stock initial crediting amount allocated merck common stock shall used determine number full partial shares merck common stock amount would purchase closing price merck common stock new york stock exchange date cash payments base salary amounts deferred base salary deferral plan incentive awards amounts deferred various incentive plans would otherwise paid participant deferral date committee determine valuation deferral date would constitute fair market value committee shall decide date fair market value shall determined using valuation method set forth paragraph company shall credit participants deferred compensation account number full partial shares merck common stock determined however time prior delivery shares shall shares purchased earmarked account participant shall rights shareholder respect shares credited hisher deferred compensation account dividends company shall credit participants deferred compensation account number full partial shares merck common stock purchasable closing price merck common stock new york stock exchange date dividend paid common stock dividends would paid number shares credited account including pro rata dividends partial share shares credited issued outstanding redesignations value merck common stock purposes redesignation shall closing price merck common stock new york stock exchange day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed distributions distributions merck common stock valued closing price merck common stock new york stock exchange distribution date limitations shares merck common stock delivered provisions program may delivered company authorized unissued shares common stock common stock held treasury amount shares available year program shall onetenth onepercent outstanding shares merck common stock last business day preceding calendar year plus shares authorized program previous years used minus shares distributed executive incentive plan april adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company number kind shares merck common stock available program credited participants deferred compensation accounts shall adjusted accordingly b mutual funds initial crediting amount allocated mutual fund shall used determine number full partial mutual fund shares amount would purchase closing net asset value mutual fund shares deferral date company shall credit participants deferred compensation account number full partial mutual fund shares determined however mutual fund shares shall purchased earmarked account shall participant rights shareholder respect mutual fund shares dividends company shall credit participants deferred compensation account number full partial mutual fund shares purchasable closing net asset value mutual fund shares date dividend paid mutual fund shares dividends would paid number shares credited account including pro rata dividends partial share shares owned participant purposes computation redesignations value mutual fund shares purposes redesignation shall net asset value mutual fund close business day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed distributions mutual fund distributions valued based closing net asset value mutual fund shares distribution date adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares mutual fund number kind shares mutual fund credited participants deferred compensation accounts shall adjusted accordingly v redesignation within deferred compensation account basic redesignation rules participant beneficiary legal representative deceased participant may redesignate amounts credited deferred compensation account among investments available program accordance following rules eligible participants active employees separated employees retired participants eligible redesignate provided however redesignation shall made merck common stock frequency timing effective june limit number times participant may redesignate amounts measured mutual funds subject section b merck common stock redesignation shall take place day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed amount extent redesignation redesignation must multiples investment redesignation made beneficiaries legal representatives beneficiary legal representative deceased participant may redesignate subject rules participants however beneficiary legal representative shall one opportunity redesignate amount merck common stock without regard rule set forth section b thereafter beneficiary legal representative shall subject redesignation rules participants including limitation redesignation merck common stock b special rules redesignation common stock frequency timing section officers redesignations may made merck common stock window period established company timetotime restricted amounts held merck common stock longer six months material nonpublic information committee sole discretion advice counsel time may rescind redesignation merck common stock redesignation made participant time redesignation possession material nonpublic information respect company b committees estimation benefited information timing hisher redesignation committees determination shall final binding event rescission participants deferred compensation account shall returned status though redesignation occurred notwithstanding committee shall rescind redesignation facts reviewed participant general counsel company designee prior redesignation general counsel designee concluded participant possession adverse material nonpublic information c conversion common stock accounts committee may sole discretion convert shares merck common stock allocated participants deferred compensation account manner provided position terminated retired participant taken wishes take opinion committee would make uncertain propriety participants continued interest merck common stock date conversion shall date commencement employment date committees action whichever later conversion shall expression value shares merck common stock participants deferred compensation account expression value united states dollars another available investment value merck common stock shall based upon closing price new york stock exchange date conversion trading took place day next business day trading took place conversion paragraph shall irrevocable absolute vi distribution deferred compensation accounts distribution deferred compensation accounts shall made accordance participants distribution schedule pro rata investment distributions merck common stock made shares cash payable partial share subject limitations set forth article iv section section officers distribution amounts merck common stock also restricted amounts held merck common stock longer six months distributions mutual funds cash distributions valued fifteenth day distribution month day business day next business day paid soon thereafter practicable retirement participants retirement active service cause distributions hisher deferred compensation account commence soon administratively feasible accordance participants previously elected schedule participant retires active service prior age committee may establish different distribution schedule schedule chosen committee however shall shorter participants previously elected schedule unless would significant change participants economic circumstances attributable participants early retirement committee decides change participants distribution schedule participants deferred compensation account must distributed ratably less five years however participant retired companys request limitation preceding sentence apply b death event participants death distributions program commence soon administratively feasible accordance hisher previously elected schedule participants beneficiary legal representative however may request committee change distribution schedule c automatic distribution participant terminates employment reasons death divestiture separation due reorganization reduction force elimination participants job take position joint venture business entity defined section e eligible retire active service one companys pension plans hisher deferred compensation account automatically paid lump sum soon administratively feasible following hisher termination employment furthermore except provided schedule ii participant dies retires active service whose employment terminates result divestiture separation due reorganization reduction force elimination participants job whose deferred compensation account valued less date hisher death retirement termination due divestiture separation hisher deferred compensation account distributed lump sum soon administratively feasible following hisher death retirement termination due divestiture separation termination due divestiture separation participant employed subsidiary company sold subsidiary longer considered within controlled group company participant shall considered terminated employment company purposes program participants employment terminates result divestiture division subsidiary company result separation due reorganization reduction force elimination participants job distributions program commence soon administratively feasible termination employment accordance hisher previously elected schedule schedule committee discretion may approve accordance section g e joint venture service participants termination employment order take position joint venture business entity company shall directly indirectly fifty percent outstanding voting ownership interest shall considered termination employment company purposes distribution program f hardship distributions committee sole discretion may accelerate time distribution participants deferred compensation account participant experiences severe financial hardship due illness accident death immediate family loss damage property due casualty extraordinary unforeseeable circumstances participant provide committee statement reasonable detail nature financial hardship together statement acceleration necessary alleviate hardship g postretirement postdivestiture postseparation modifications participant retired active service whose employment terminated result divestiture separation described section may submit one petition committee requesting extension period distribution hisher deferred compensation account petition must received committee prior first distribution participant hisher previously elected distribution schedule revised distribution schedule may exceed fifteen years date actual retirement divestiture separation date effective beginning next calendar year committee shall event grant new schedule participant would cumulatively receive greater portion hisher deferred compensation account measured end calendar year except provided schedule ii participant active employee may make request paragraph vii deductions distributions company deduct distribution amounts required withheld income social security tax purposes withholding done pro rata basis per investment company may also deduct amounts participant owes company reason viii beneficiary designations participant program may designate beneficiary receive hisher deferred compensation account upon participants death beneficiary predecease participant participant name beneficiary participants deferred compensation account distributed participants estate ix amendments committee may amend program time however amendment shall materially adversely affect right obligation respect deferred compensation made theretofore schedule deferral program investment alternatives january january merck common stock mutual funds american century emerging markets fund american funds europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fund fidelity lowpriced stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn fundclass z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity fund putnam international voyager putnam vista rowe price blue chip growth fund vanguard asset allocation september september investment briefly named putnam global growth fund result merger september putnam global equity fund putnam global growth fund merged fund briefly retained name putnam global growth fund effective october merged fund changed name putnam global equity fund schedule deferral program investment alternatives effective january july merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn class z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity putnam international capital opportunities fund putnam vista rowe price blue chip growth vanguard asset allocation prior april known putnam international voyager fund redesignation deferred amounts measured putnam vista july prior pm et july participant part hisher deferred compensation account measured putnam vista investment alternative may redesignate amount investment alternative accordance article v section participant redesignate amount measured putnam vista investment alternative remaining investment alternatives pm et july amount putnam vista account shall redesignated pm et july fidelity midcap stock fund schedule deferral program investment alternatives effective july november merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund columbia acorn fund z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity putnam international capital opportunities fund rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z prior april known putnam international voyager fund redesignation deferred amounts measured putnam global equity putnam international capital opportunities fund collectively putnam funds november prior pm et november participant part hisher deferred compensation account measured putnam funds investment alternative may redesignate amount investment alternative accordance article v section participant redesignate amount measured putnam funds investment alternative remaining investment alternatives pm et november amount putnam funds investment alternative shall redesignated pm et november fidelity retirement money market portfolio schedule deferral program investment alternatives november april merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund columbia acorn class z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income pimco foreign bond institutional pimco long term us government institutional pimco total return institutional rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z schedule deferral program investment alternatives april january merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund columbia acorn class z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index janus enterprise janus growth income pimco foreign bond institutional pimco long term us government institutional pimco total return institutional rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z schedule february merck common stock fund mutual funds axa rosenberg us small capitalization account american funds europacific growth fund class columbia acorn fund class z fidelity diversified international fund fidelity freedom fund fidelity freedom fund fidelity freedom fund fidelity freedom fund fidelity freedom fund fidelity freedom fund fidelity freedom fund fidelity freedom fund fidelity lowpriced stock fund fidelity retirement money market portfolio gmo us core fund pimco total return fund institutional class ssga sp index fund rowe price blue chip growth fund near thereto administratively feasible schedule ii special provisions applicable medco health employees approved july definitions medco health medco health solutions inc medco health employee participant employed medco health prior spinoff ii employed merck prior spinoff expected employed medco health prior spinoff separated medco health employee participant deferral program employed medco health date spinoff considered terminated employment company result spinoff spinoff distribution merck shareholders equity securities medco health spinoff divestiture purposes deferral program special provisions notwithstanding anything contrary article vi section c deferral program deferred compensation account separated medco health employee shall paid accordance article vi section without regard threshold set forth section c notwithstanding anything contrary article vi section g deferral program medco health employee may submit petition extension distribution schedule permitted section g either prior spinoff medco health employee become separated medco health employee provided however medco health employee makes request new distribution schedule prior spinoff thereafter become separated medco health employee request shall effective exhibit merck co inc incentive stock plan amended restated february incentive stock plan incentive stock plan isp effective january established encourage employees merck co inc company subsidiaries affiliates joint ventures merck institute therapeutic research acquire common stock company believed isp stimulate employees efforts companys behalf tend maintain strengthen desire remain company interest company stockholders encourage employees greater personal financial investment company ownership common stock administration isp shall administered compensation benefits committee board directors company committee committee authorized subject provisions isp establish rules regulations deems necessary proper administration isp make determinations take action connection therewith relation isp deems necessary advisable consistent isp committee may delegate power authority hereunder chief executive officer senior member management committee deems appropriate provided however committee may delegate authority regard matter action affecting officer subject section securities exchange act purpose section subsequent sections isp shall deemed include plan comparable subplans established subsidiaries aggregate shall constitute one plan governed terms set forth herein eligibility regular fulltime parttime employees company subsidiaries affiliates joint ventures merck institute therapeutic research including officers whether directors company employees joint venture partner affiliate company provide services joint venture partner affiliate directors officers company purposes section securities exchange act shall eligible participate isp eligible employees designated committee delegate directors regular employees eligible incentives incentives isp may granted one combination incentive stock options statutory stock option b nonqualified stock options c stock appreciation rights restricted stock grants e performance shares together incentives incentives shall subject terms conditions set forth herein terms conditions may established committee determinations committee isp including without limitation determinations eligible employees form amount timing incentives terms provisions incentives agreements evidencing incentives need uniform may made selectively among eligible employees receive eligible receive incentives hereunder whether eligible employees similarly situated shares available incentives shares subject issuance transfer subject adjustment provided section c hereof hereby reserved issuance isp million shares companys common stock common stock shares available granting awards shall increased number shares options benefits granted plan lapsed expired terminated cancelled addition shares reserved issuance companys incentive stock plan incentive stock plan prior plans excess number shares options benefits awarded thereunder plus shares options benefits granted prior plans may lapse expire terminate cancelled shall also reserved available issuance reissuance isp shares plan may delivered company authorized unissued shares common stock common stock held treasury b limit individuals incentives given year eligible employee may receive incentives covering three million shares companys common stock number shares may adjusted accordance section c c recapitalization adjustment event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company committee shall make adjustment may deem appropriate number kind shares authorized isp number kind shares covered incentives granted case stock options option price case stock appreciation rights fair market value stock options committee may grant options qualifying incentive stock options internal revenue code amended successor code thereto code statutory options code nonqualified options collectively stock options stock options shall subject following terms conditions terms conditions committee may prescribe option price option price per share respect stock option shall determined committee shall less fair market value common stock date stock option granted determined committee b period option period stock option shall fixed committee shall exceed ten years c payment option price shall payable cash time stock option exercised shares shall issued full payment therefore made grantee stock option shall none rights stockholder shares issued exercise option shares covered stock option may purchased installments exercise dates committee delegate may determine shares purchased applicable exercise date may purchased thereafter time prior final expiration stock option event including specified paragraphs e f g section shall stock option exercisable specified expiration period e termination employment upon termination stock option grantees employment reason retirement death termination deliberate willful gross misconduct stock option privileges shall limited shares immediately exercisable date termination committee however discretion may provide stock options outstanding yet exercisable upon termination stock option grantees employment may become exercisable accordance schedule determined committee stock option privileges shall expire unless exercised surrendered stock appreciation right within period time date termination employment may established committee event later expiration date stock option stock option grantees employment terminated deliberate willful gross misconduct determined company rights stock option shall expire upon receipt notice termination f retirement upon retirement stock option grantee stock option privileges shall apply shares immediately exercisable date retirement committee however discretion may provide stock options outstanding yet exercisable upon retirement stock option grantee may become exercisable accordance schedule determined committee stock option privileges shall expire unless exercised within period time may established committee event later expiration date stock option g death upon death stock option grantee stock option privileges shall apply shares immediately exercisable time death committee however discretion may provide stock options outstanding yet exercisable upon death stock option grantee may become exercisable accordance schedule determined committee privileges shall expire unless exercised legal representatives within period time determined committee event later expiration date stock option h limits incentive stock options except may otherwise permitted code committee shall grant eligible employee incentive stock options aggregate first exercisable one calendar year extent aggregate fair market value common stock time incentive stock options granted exceeds stock appreciation rights committee may discretion grant right receive appreciation fair market value shares common stock stock appreciation right either singly combination underlying stock option granted hereunder prior plans stock appreciation rights shall subject following terms conditions terms conditions committee may prescribe time period grant stock appreciation right granted respect underlying stock option may granted time stock option grant time thereafter prior expiration stock option grant stock appreciation right granted respect underlying stock option time stock appreciation right granted committee may limit exercise period stock appreciation right period stock appreciation right shall attach underlying stock option event shall exercise period stock appreciation right granted respect underlying stock option exceed exercise period stock option stock appreciation right granted without underlying stock option period exercise stock appreciation right shall set committee b value stock appreciation right stock appreciation right granted respect underlying stock option grantee entitled surrender stock option exercisable receive exchange therefore amount equal excess fair market value common stock date election surrender received company stock option price multiplied number shares covered stock option surrendered stock appreciation right granted without underlying stock option grantee receive upon exercise stock appreciation right amount equal excess fair market value common stock date election surrender stock appreciation right received company fair market value common stock date grant multiplied number shares covered grant stock appreciation right c payment stock appreciation right payment stock appreciation right shall form shares common stock cash combination shares cash form payment upon exercise right shall determined committee either time grant stock appreciation right time exercise stock appreciation right performance share awards committee may grant awards payment may made shares common stock cash combination shares cash performance company subsidiary division affiliate company selected committee award period meets certain goals established committee performance share awards performance share awards shall subject following terms conditions terms conditions committee may prescribe award period performance goals committee shall determine include performance share award grant period time performance share award made award period committee shall also establish performance objectives performance goals met company subsidiary division award period condition payment performance share award performance goals may include earnings per share return stockholders equity return assets net income financial measurement established committee performance goals may include minimum optimum objectives single set objectives b payment performance share awards committee shall establish method calculating amount payment made performance share award performance goals met including fixing maximum payment performance share award shall expressed terms shares common stock referred performance shares completion award period performance company subsidiary division shall measured performance goals committee shall determine whether none portion performance share award shall paid committee discretion may elect make payment shares common stock cash combination shares cash cash payment shall based fair market value performance shares soon practicable prior date payment c revision performance goals time prior end award period committee may revise performance goals computation payment unforeseen events occur substantial effect performance company subsidiary division judgment committee make application performance goals unfair unless revision made requirement employment grantee performance share award must remain employ company completion award period order entitled payment performance share award provided committee may sole discretion provide partial payment exception deemed equitable e dividends committee may discretion time granting performance share award provide dividends declared common stock award period would paid respect performance shares owned grantee paid grantee ii accumulated benefit grantee used increase number performance shares grantee f limit performance share awards incentives granted performance share awards section restricted stock grants section shall exceed aggregate million shares common stock number shares may adjusted accordance section c restricted stock grants committee may award shares common stock grantee shares shall subject following terms conditions terms conditions committee may prescribe restricted stock grant requirement employment grantee restricted stock grant must remain employment company period designated committee restriction period order retain shares restricted stock grant grantee leaves employment company prior end restriction period restricted stock grant shall terminate shares common stock shall returned immediately company provided committee may time grant provide employment restriction lapse respect portion portions restricted stock grant different times restriction period committee may discretion also provide complete partial exceptions employment restriction deems equitable b restrictions transfer legend stock certificates restriction period grantee may sell assign transfer pledge otherwise dispose shares common stock except successor section hereof certificate shares common stock issued hereunder shall contain legend giving appropriate notice restrictions grant c escrow agreement committee may require grantee enter escrow agreement providing certificates representing restricted stock grant remain physical custody escrow holder restrictions removed expire lapse restrictions restrictions imposed restricted stock grant shall lapse upon expiration restriction period conditions employment set forth met grantee shall entitled legend removed certificates e dividends committee shall discretion time restricted stock grant provide dividends declared common stock restriction period shall either paid grantee ii accumulated benefit grantee paid grantee expiration restriction period f limit restricted stock grant incentives granted restricted stock grants section performance share awards section shall exceed aggregate million shares common stock number shares may adjusted accordance section c discontinuance amendment plan board directors may discontinue isp time may time time amend revise terms isp permitted applicable statutes except may revoke alter manner unfavorable grantees incentives hereunder incentives outstanding may board amend isp without stockholder approval absence approval would cause plan fail comply rule b securities exchange act requirement applicable law regulation incentive shall granted isp december incentives granted theretofore may extend beyond date nontransferability incentive stock option granted isp shall transferable laws descent distribution incentive granted isp may transferable subject terms conditions may established committee accordance regulations promulgated securities exchange act applicable law regulation right employment isp incentives granted hereunder shall confer upon eligible employee right continued employment company subsidiaries affiliates joint ventures merck institute therapeutic research affect way right entities terminate employment eligible employee time reason taxes company shall entitled withhold amount tax attributable option granted amount payable shares deliverable isp giving person entitled receive amount shares notice far advance practicable merck change control options vesting options key rd options upon occurrence change control stock option outstanding immediately prior change control key rd options shall immediately become fully vested exercisable vesting key rd options subject aii schedule upon occurrence change control key rd option shall continue subject performancebased vesting schedule applicable thereto immediately prior change control ii notwithstanding ai schedule stock options continue outstanding following change control exchanged converted options purchase securities successor entity successor options upon occurrence change control portion key rd option shall immediately vest become exercisable following percentages key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited b key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited c key rd options first second milestones reached date change control thenunvested portion key rd option shall vest become exercisable posttermination exercise period stock options continue outstanding following change control exchanged converted successor options portion stock options successor options applicable vested exercisable immediately following termination employment holder thereof change control shall remain exercisable following termination five years date termination beyond remainder term thereof provided however termination reason gross misconduct death retirement terms applied awards granted plans provisions plan applicable termination reason gross misconduct death retirement shall apply termination effect vesting pursuant section would cause stock option successor stock option terminate earlier accelerated vesting occurred term stock option shall expire earlier accelerated vesting occurred cashout stock options stock options continue outstanding following change control exchanged converted successor options holder vested exercisable option shall entitled receive soon practicable following change control share common stock subject vested exercisable option amount cash determined committee prior change control event less excess change control price exercise price thereof subject existing deferral elections effect consideration paid change control entirely shares common stock acquiring resulting corporation committee may prior change control provide cancellation outstanding stock options time change control whole part cash pursuant provision may provide exchange conversion outstanding stock options time change control whole part connection provision may shall obligated permit holders stock options make elections related thereto determines appropriate incentive stock options amended section apply incentive stock option within meaning section internal revenue code b restricted stock units performance share units vesting restricted stock units upon occurrence change control unvested restricted stock unit award outstanding immediately prior change control plan shall immediately become fully vested vesting performance share units upon occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately become vested amount equal psu pro rata amount settlement restricted stock units performance share units common stock continues widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid shares common stock securities soon practicable date change control subject existing deferral elections effect ii common stock continue widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid cash soon practicable date change control subject existing deferral elections effect c provisions except extent required applicable law entirety protection period material terms plan shall modified manner materially adverse qualifying participants understood section c schedule shall require specific type levels equity awards granted qualifying participants following change control protection period plan may amended modified reduce eliminate protections set forth section c schedule may terminated company shall pay legal fees related expenses including costs experts evidence counsel reasonably good faith incurred qualifying participant qualifying participant prevails claim relief action x qualifying participant claiming provisions section c c schedule violated avoidance doubt excluding claims plan benefits ordinary course applicable company qualifying participants employer enforce post termination covenants qualifying participant section apply incentive stock option within meaning section internal revenue code anything plan amended schedule notwithstanding company reserves right make changes may required extent required avoid adverse consequences american jobs creation act amended definitions purposes schedule following terms shall following meanings change control shall meaning set forth companys change control separation benefits plan provided however award plan consists deferred compensation subject section code definition change control shall deemed modified extent necessary comply section code change control price shall mean respect share common stock higher highest reported sales price regular way share transaction reported new york stock exchange composite tape national exchange shares listed nasdaq national market day period prior including date change control b change control result tender exchange offer merger similar corporate transaction highest price per share paid tender exchange offer merger similar corporate transaction provided extent part consideration paid transaction consists securities noncash consideration value securities noncash consideration shall determined committee key rd options shall mean performancebased options granted employees key research development program described applicable schedule rules regulations plan protection period shall mean period beginning date change control ending second anniversary date change control psu pro rata amount shall mean performance share unit award amount determined multiplying x x number target shares subject performance share unit award times assumed performance percentage fraction numerator number whole partial calendar months elapsed applicable performance period counting partial month whole month purpose denominator total number months applicable performance period assumed performance percentage shall determined averaging ranks award period follows completed performance year change control actual rank except fewer days elapsed since completion performance year target rank shall used b performance year incomplete yet begun change control target rank rounding average rank calculated pursuant foregoing clause nearest whole number using ordinary numerical rounding using final award percentage associated number determined foregoing clause target rank rank associated chart final award percentages qualifying participants shall mean individuals participate plan whether current former employees immediately prior change control e application schedule shall apply stock options restricted stock unit awards performance share unit awards plans granted prior november exhibit merck co inc incentive stock plan amended restated february incentive stock plan incentive stock plan isp effective january established encourage employees merck co inc company subsidiaries affiliates joint ventures acquire common stock company common stock believed isp stimulate employees efforts companys behalf tend maintain strengthen desire remain company interest company stockholders encourage employees greater personal financial investment company ownership common stock incentives incentives isp may granted one combination incentive stock options statutory stock options b nonqualified stock options c stock appreciation rights restricted stock grants e performance shares collectively incentives incentives shall subject terms conditions set forth herein terms conditions may established compensation benefits committee board directors committee eligibility regular fulltime parttime employees company subsidiaries affiliates joint ventures including officers whether directors company employees joint venture partner affiliate company provide services joint venture partner affiliate shall eligible participate isp eligible employees designated committee directors company regular employees eligible participate isp administration isp shall administered committee committee shall responsible administration isp including without limitation determining eligible employees receive incentives kind incentives made isp number shares terms conditions incentives determinations committee isp including without limitation determinations eligible employees form amount timing incentives terms provisions incentives agreements evidencing incentives need uniform may made selectively among eligible employees receive eligible receive incentives hereunder whether eligible employees similarly situated committee shall responsibility construing interpreting isp establishing amending rules regulations may deem necessary desirable proper administration isp decision action taken taken committee arising connection construction administration interpretation effect isp rules regulations shall maximum extent permitted applicable law within absolute discretion except otherwise specifically provided herein shall conclusive binding upon company eligible employees person claiming eligible employee committee may delegate power authority hereunder chief executive officer senior member management committee deems appropriate provided however committee may delegate authority regard matter action affecting officer subject section securities exchange act purpose section subsequent sections isp shall deemed include plan comparable subplans established subsidiaries aggregate shall constitute one plan governed terms set forth herein shares available incentives shares subject issuance transfer subject adjustment provided section c hereof hereby reserved issuance isp million shares common stock shares available granting awards shall increased number shares options benefits granted isp lapsed expired terminated canceled addition shares reserved issuance companys incentive stock plan incentive stock plan prior plans excess number shares options benefits awarded thereunder plus shares options benefits granted prior plans may lapse expire terminate canceled shall also reserved available issuance reissuance isp shares isp may delivered company authorized unissued shares common stock common stock held treasury b limit individuals incentives given year eligible employee may receive incentives covering three million shares companys common stock number shares shall adjusted accordance section c c adjustment shares event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering spin split split event identified committee committee shall make adjustments may deem appropriate number kind shares authorized issuance isp ii number kind shares subject outstanding incentives iii option price stock options iv fair market value stock appreciation rights stock options committee may grant options qualifying incentive stock options internal revenue code amended successor code thereto code statutory options code nonqualified options collectively stock options stock options shall subject following terms conditions terms conditions committee may prescribe option price option price per share respect stock option shall determined committee shall less fair market value common stock date stock option granted determined committee b period option period stock option shall fixed committee shall exceed ten years c payment shares shall issued full payment option price made option prices may paid cash committee determines shares common stock combination cash shares committee approves use shares common stock payment method committee shall establish conditions deems appropriate use common stock exercise stock option stock options awarded isp shall exercised companys brokerassisted stock option exercise program provided program available time option exercise means committee may determine time time committee may establish rules procedures permit optionholder defer recognition gain upon exercise stock option exercise option committee shall determine shares covered stock option may purchased committee may establish waiting periods dates options become exercisable vested exercise periods provided event including specified paragraphs e f g section shall stock option exercisable specified expiration period e termination employment upon termination stock option grantees employment reason retirement death termination deliberate willful gross misconduct stock option privileges shall limited shares immediately exercisable date termination committee however discretion may provide stock options outstanding yet exercisable upon termination stock option grantees employment may become exercisable accordance schedule may determined committee stock option privileges shall expire unless exercised surrendered stock appreciation right within period time date termination employment may established committee event later expiration date stock option f retirement upon retirement stock option grantee stock option privileges shall apply shares immediately exercisable date retirement committee however discretion may provide stock options outstanding yet exercisable upon retirement stock option grantee may become exercisable accordance schedule may determined committee stock option privileges shall expire unless exercised within period time may established committee event later expiration date stock option g death upon death stock option grantee stock option privileges shall apply shares immediately exercisable time death committee however discretion may provide stock options outstanding yet exercisable upon death stock option grantee may become exercisable accordance schedule may determined committee privileges shall expire unless exercised legal representatives within period time determined committee event later expiration date stock option h termination due misconduct stock option grantees employment terminated deliberate willful gross misconduct determined company rights stock option shall expire upon receipt notice termination limits incentive stock options except may otherwise permitted code committee shall grant eligible employee incentive stock options aggregate first exercisable one calendar year extent aggregate fair market value common stock time incentive stock options granted exceeds amount internal revenue service may decide time time stock appreciation rights committee may discretion grant right receive appreciation fair market value shares common stock stock appreciation right either singly combination underlying stock option granted hereunder prior plans stock appreciation rights shall subject following terms conditions terms conditions committee may prescribe time period grant stock appreciation right granted respect underlying stock option may granted time stock option grant time thereafter prior expiration stock option grant stock appreciation right granted respect underlying stock option time stock appreciation right granted committee may limit exercise period stock appreciation right period stock appreciation right shall attach underlying stock option event shall exercise period stock appreciation right granted respect underlying stock option exceed exercise period stock option stock appreciation right granted without underlying stock option period exercise stock appreciation right shall set committee b value stock appreciation right stock appreciation right granted respect underlying stock option grantee entitled surrender stock option exercisable receive exchange therefor amount equal excess fair market value common stock date election surrender received company stock option price multiplied number shares covered stock option surrendered stock appreciation right granted without underlying stock option grantee receive upon exercise stock appreciation right amount equal excess fair market value common stock date election surrender stock appreciation right received company fair market value common stock date grant multiplied number shares covered grant stock appreciation right c payment stock appreciation right payment stock appreciation right shall form shares common stock cash combination shares cash form payment upon exercise right shall determined committee either time grant stock appreciation right time exercise stock appreciation right performance share awards committee may grant awards payment may made shares common stock cash combination shares cash performance company subsidiary division affiliate joint venture company selected committee award period meets certain goals established committee performance share awards performance share awards shall subject following terms conditions terms conditions committee may prescribe award period performance goals committee shall determine include performance share award grant period time performance share award made award period committee shall also establish performance objectives performance goals met company subsidiary division joint venture award period condition payment performance share award performance goals may include earnings per share return stockholders equity return assets net income financial measurement established committee performance goals may include minimum optimum objectives single set objectives b payment performance share awards committee shall establish method calculating amount payment made performance share award performance goals met including fixing maximum payment performance share award shall expressed terms shares common stock referred performance shares completion award period performance company subsidiary division joint venture shall measured performance goals committee shall determine whether none portion performance share award shall paid committee discretion may elect make payment shares common stock cash combination shares cash cash payment shall based fair market value performance shares soon practicable prior date payment c revision performance goals time prior end award period committee may revise performance goals computation payment unforeseen events occur substantial effect performance company subsidiary division joint venture judgment committee make application performance goals unfair unless revision made requirement employment grantee performance share award must remain employ company completion award period order entitled payment performance share award provided committee may discretion provide full partial payment exception deemed equitable e dividends committee may discretion time granting performance share award provide dividends declared common stock award period would paid respect performance shares owned grantee paid grantee ii accumulated benefit grantee used increase number performance shares grantee f limit performance share awards incentives granted performance share awards section restricted stock grants section shall exceed aggregate six million shares common stock number shares shall adjusted accordance section c restricted stock grants committee may award shares common stock grantee shares shall subject following terms conditions terms conditions committee may prescribe restricted stock grant requirement employment grantee restricted stock grant must remain employment company period designated committee restriction period order retain shares restricted stock grant grantee leaves employment company prior end restriction period restricted stock grant shall terminate shares common stock shall returned immediately company provided committee may time grant provide employment restriction lapse respect portion portions restricted stock grant different times restriction period committee may discretion also provide complete partial exceptions employment restriction deems equitable b restrictions transfer legend stock certificates restriction period grantee may sell assign transfer pledge otherwise dispose shares common stock certificate shares common stock issued hereunder shall contain legend giving appropriate notice restrictions grant c escrow agreement committee may require grantee enter escrow agreement providing certificates representing restricted stock grant remain physical custody escrow holder restrictions removed expire lapse restrictions restrictions imposed restricted stock grant shall lapse upon expiration restriction period conditions employment set forth met grantee shall entitled legend removed certificates e dividends committee shall discretion time restricted stock grant provide dividends declared common stock restriction period shall either paid grantee ii accumulated benefit grantee paid grantee expiration restriction period f limit restricted stock grant incentives granted restricted stock grants section performance share awards section shall exceed aggregate six million shares common stock number shares shall adjusted accordance section c transferability incentive stock option granted isp shall transferable laws descent distribution incentive granted isp transferable assignable recipient may made subject execution attachment similar procedures laws descent distribution determined committee accordance regulations promulgated securities exchange act applicable law regulation discontinuance amendment plan board directors may discontinue isp time may time time amend revise terms isp permitted applicable statutes except may revoke alter manner unfavorable grantees incentives hereunder incentives outstanding may board amend isp without stockholder approval absence approval would cause plan fail comply rule b securities exchange act requirement applicable law regulation unless approved companys stockholders adjustments reduction exercise price outstanding incentives shall made cancellation outstanding incentives subsequent regranting incentives lower price individual incentive shall granted isp december incentives granted theretofore may extend beyond date right employment participation isp incentives granted hereunder shall confer upon eligible employee right continued employment company subsidiaries affiliates joint ventures affect way right entities terminate employment eligible employee time reason individual shall right granted incentive granted incentive receive future incentives limitation compensation nothing isp shall construed limit right company establish plans pay compensation employees cash property manner expressly authorized isp impact benefits except may otherwise specifically stated employee benefit plan policy program amount payable respect incentive shall treated compensation purposes calculating employees right plan policy program constraint corporate action nothing isp shall construed limit impair otherwise affect companys right power make adjustments reclassifications reorganizations changes capital business structure merge consolidate dissolve liquidate sell transfer part business assets ii except provided section limit right power company subsidiary take action entity deems necessary appropriate withholding taxes company shall entitled deduct payment isp regardless form payment amount applicable income employment taxes required law withheld respect payment may require eligible employee pay tax prior condition making payment accordance applicable administrative guidelines establishes committee may allow eligible employee pay amount taxes required law withheld incentive withholding payment common stock due result incentive permitting eligible employee deliver company shares common stock fair market value determined committee equal amount required withholding taxes governing law isp agreements hereunder shall construed accordance governed laws state new jersey merck change control options vesting options key rd options upon occurrence change control stock option outstanding immediately prior change control key rd options shall immediately become fully vested exercisable vesting key rd options subject aii schedule upon occurrence change control key rd option shall continue subject performancebased vesting schedule applicable thereto immediately prior change control ii notwithstanding ai schedule stock options continue outstanding following change control exchanged converted options purchase securities successor entity successor options upon occurrence change control portion key rd option shall immediately vest become exercisable following percentages key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited b key rd options first milestone reached date change control unvested portion key rd option shall vest become exercisable remainder shall forfeited c key rd options first second milestones reached date change control thenunvested portion key rd option shall vest become exercisable posttermination exercise period stock options continue outstanding following change control exchanged converted successor options portion stock options successor options applicable vested exercisable immediately following termination employment holder thereof change control shall remain exercisable following termination five years date termination beyond remainder term thereof provided however termination reason gross misconduct death retirement terms applied awards granted plans provisions plan applicable termination reason gross misconduct death retirement shall apply termination effect vesting pursuant section would cause stock option successor stock option terminate earlier accelerated vesting occurred term stock option shall expire earlier accelerated vesting occurred cashout stock options stock options continue outstanding following change control exchanged converted successor options holder vested exercisable option shall entitled receive soon practicable following change control share common stock subject vested exercisable option amount cash determined committee prior change control event less excess change control price exercise price thereof subject existing deferral elections effect consideration paid change control entirely shares common stock acquiring resulting corporation committee may prior change control provide cancellation outstanding stock options time change control whole part cash pursuant provision may provide exchange conversion outstanding stock options time change control whole part connection provision may shall obligated permit holders stock options make elections related thereto determines appropriate incentive stock options amended section apply incentive stock option within meaning section internal revenue code b restricted stock units performance share units vesting restricted stock units upon occurrence change control unvested restricted stock unit award outstanding immediately prior change control plan shall immediately become fully vested vesting performance share units upon occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately become vested amount equal psu pro rata amount settlement restricted stock units performance share units common stock continues widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid shares common stock securities soon practicable date change control subject existing deferral elections effect ii common stock continue widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid cash soon practicable date change control subject existing deferral elections effect c provisions except extent required applicable law entirety protection period material terms plan shall modified manner materially adverse qualifying participants understood section c schedule shall require specific type levels equity awards granted qualifying participants following change control protection period plan may amended modified reduce eliminate protections set forth section c schedule may terminated company shall pay legal fees related expenses including costs experts evidence counsel reasonably good faith incurred qualifying participant qualifying participant prevails claim relief action x qualifying participant claiming provisions section c c schedule violated avoidance doubt excluding claims plan benefits ordinary course applicable company qualifying participants employer enforce post termination covenants qualifying participant section apply incentive stock option within meaning section internal revenue code anything plan amended schedule notwithstanding company reserves right make changes may required extent required avoid adverse consequences american jobs creation act amended definitions purposes schedule following terms shall following meanings change control shall meaning set forth companys change control separation benefits plan provided however award plan consists deferred compensation subject section code definition change control shall deemed modified extent necessary comply section code change control price shall mean respect share common stock higher highest reported sales price regular way share transaction reported new york stock exchange composite tape national exchange shares listed nasdaq national market day period prior including date change control b change control result tender exchange offer merger similar corporate transaction highest price per share paid tender exchange offer merger similar corporate transaction provided extent part consideration paid transaction consists securities noncash consideration value securities noncash consideration shall determined committee key rd options shall mean performancebased options granted employees key research development program described applicable schedule rules regulations plan protection period shall mean period beginning date change control ending second anniversary date change control psu pro rata amount shall mean performance share unit award amount determined multiplying x x number target shares subject performance share unit award times assumed performance percentage fraction numerator number whole partial calendar months elapsed applicable performance period counting partial month whole month purpose denominator total number months applicable performance period assumed performance percentage shall determined averaging ranks award period follows completed performance year change control actual rank except fewer days elapsed since completion performance year target rank shall used b performance year incomplete yet begun change control target rank rounding average rank calculated pursuant foregoing clause nearest whole number using ordinary numerical rounding using final award percentage associated number determined foregoing clause target rank rank associated chart final award percentages qualifying participants shall mean individuals participate plan whether current former employees immediately prior change control e application schedule shall apply stock options restricted stock unit awards performance share unit awards plans granted prior november exhibit merck co inc incentive stock plan amended restated february merck co inc incentive stock plan amended november purpose incentive stock plan plan effective may established encourage employees merck co inc company subsidiaries affiliates joint ventures acquire common stock company common stock believed plan serve interests company stockholders allows employees greater personal financial interest company ownership right acquire common stock turn stimulate employees efforts companys behalf maintain strengthen desire remain company believed plan also assist recruitment employees administration plan shall administered compensation benefits committee board directors company committee director company may serve committee nonemployee director purposes rule b securities exchange act amended exchange act ii satisfies requirements outside director purposes section internal revenue code code committee shall responsible administration plan including without limitation determining eligible employees receive incentives types incentives receive plan number shares covered incentives granted plan terms conditions incentives determinations committee plan including without limitation determinations eligible employees form amount timing incentives terms provisions incentives writings evidencing incentives need uniform may made selectively among eligible employees receive eligible receive incentives hereunder whether eligible employees similarly situated committee shall responsibility construing interpreting plan including right construe disputed doubtful plan provisions establishing amending construing rules regulations may deem necessary desirable proper administration plan decision action taken taken committee arising connection construction administration interpretation effect plan rules regulations shall maximum extent permitted applicable law within absolute discretion except otherwise specifically provided herein shall final binding conclusive upon company eligible employees person claiming eligible employee committee permitted applicable state law may delegate power authority hereunder chief executive officer senior member management committee deems appropriate provided however committee may delegate authority regard matter action affecting officer subject section exchange act delegation shall made case incentives intended qualified section code purpose section subsequent sections plan shall deemed include plan comparable subplans established subsidiaries aggregate shall constitute one plan governed terms set forth herein eligibility employees regular fulltime parttime employees employed company parent subsidiaries affiliates joint ventures including officers whether directors company employees joint venture partner affiliate company provide services joint venture partner affiliate person employee shall eligible participate plan designated committee eligible employees b nonemployees term employee shall include following collectively excluded persons director employee officer person independent contractor agrees agreed heshe independent contractor person agreement understanding company affiliates joint venture partners heshe employee eligible employee even heshe previously employee eligible employee person employed temporary employment agency regardless amount control supervision training provided company affiliates leased employee defined section n code excluded person eligible employee receive incentives even court agency authority rules heshe commonlaw employee company affiliates c right continued employment nothing plan shall interfere limit way right company parent subsidiaries affiliates joint ventures terminate employment participant time confer upon participant right continue employ company parent subsidiaries affiliates joint ventures eligible employee shall right receive incentive benefit plan granted incentive benefit receive additional incentive benefit neither award incentive benefits arising incentives shall constitute employment contract company parent subsidiaries affiliates joint ventures accordingly plan benefits hereunder may terminated time sole exclusive discretion company without giving rise liability part company parent subsidiaries affiliates joint ventures severance except may otherwise specifically stated employee benefit plan policy program neither incentive plan amount realized incentive shall treated compensation purposes calculating employees benefit plan policy program term plan plan shall effective may subject approval plan affirmative vote stockholders company entitled vote thereon time approval incentive shall granted plan april term exercise incentives granted theretofore may extend beyond date incentives incentives plan may granted one combination incentive stock options b nonqualified stock options c stock appreciation rights restricted stock grants e performance shares f share awards g phantom stock awards collectively incentives incentives shall subject terms conditions set forth herein terms conditions may established committee shares available incentives shares available subject provisions section c maximum number shares common stock company may issued plan million shares plan predecessor incentive stock plans purchased awarded incentive lapsed expired terminated cancelled may used grant incentives plan incentives similar awards issued entity merged company acquired company otherwise involved similar corporate transaction company considered issued plan shares plan may delivered company authorized unissued shares common stock issued reacquired common stock held treasury stock event shall fractional shares common stock issued plan b limit individuals incentives calendar year eligible employee may receive incentives covering million shares companys common stock number shares shall adjusted accordance section c ii incentive person owns percent stock company within meaning section code iii incentive stock option defined section code would result person receiving grant incentive stock options stock would aggregate fair market value excess determined time incentive stock option granted would exercisable first time person calendar year c adjustment shares event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering spin split split event identified committee committee shall make adjustments may deem appropriate number kind shares authorized issuance plan ii number kind shares subject outstanding incentives iii option price stock options iv fair market value stock appreciation rights determination shall final binding conclusive parties stock options committee may grant options qualifying incentive stock options defined section code options incentive stock options nonqualified options collectively stock options stock options shall subject following terms conditions terms conditions committee may prescribe stock option price option price per share respect stock option shall determined committee shall less percent fair market value common stock date stock option granted determined committee b period stock option period stock option shall fixed committee provided period stock options shall exceed ten years grant provided however event death optionee prior expiration nonqualified option nonqualified option may committee determines exercisable eleven years date grant committee may subsequent granting stock option extend term thereof event shall extended term exceed ten years original grant date c exercise stock option payment therefore shares shall issued full payment option price made option price may paid cash committee determines shares common stock combination cash shares common stock committee approves use shares common stock payment method committee shall establish conditions deems appropriate use common stock exercise stock option stock options awarded plan shall exercised procedure program committee may establish define time time may include designated broker must used exercising stock options committee may establish rules procedures permit optionholder defer recognition gain upon exercise stock option first exercisable date committee shall determine shares covered stock option may purchased committee may establish waiting periods dates stock options become exercisable vested subject paragraph b section exercise periods committee may accelerate exercisability stock option portion thereof e termination employment unless determined otherwise committee upon termination stock option grantees employment reason gross misconduct stock option privileges shall limited shares immediately exercisable date termination committee however discretion may provide stock options outstanding yet exercisable upon termination stock option grantees employment may become exercisable accordance schedule determined committee stock option privileges shall expire unless exercised within period time date termination employment may established committee event later expiration date stock option f termination due misconduct stock option grantees employment terminated gross misconduct determined company rights stock option shall expire upon date termination g limits incentive stock options except may otherwise permitted code eligible employee may receive grant incentive stock options stock would aggregate fair market value excess amount internal revenue service may decide time time determined time incentive stock option granted would exercisable first time person calendar year stock appreciation rights committee may discretion grant right receive appreciation fair market value shares common stock stock appreciation right either singly combination underlying stock option granted hereunder stock appreciation right shall subject following terms conditions terms conditions committee may prescribe time period grant stock appreciation right granted respect underlying stock option may granted time stock option grant time thereafter prior expiration stock option grant stock appreciation right granted respect underlying stock option time stock appreciation right granted committee may limit exercise period stock appreciation right period stock appreciation right shall attach underlying stock option event shall exercise period stock appreciation right granted respect underlying stock option exceed exercise period stock option stock appreciation right granted without underlying stock option period exercise stock appreciation right shall set committee b value stock appreciation right stock appreciation right granted respect underlying stock option grantee entitled surrender stock option exercisable receive exchange therefor amount equal excess fair market value common stock date election surrender received company accordance exercise procedures established company stock option price spread multiplied number shares covered stock option surrendered stock appreciation right granted without underlying stock option grantee receive upon exercise stock appreciation right amount equal excess fair market value common stock date election surrender stock appreciation right received company accordance exercise procedures established company fair market value common stock date grant multiplied number shares covered grant stock appreciation right notwithstanding foregoing sole discretion committee time grants stock appreciation right may provide spread covered stock appreciation right may exceed specified amount c payment stock appreciation right payment stock appreciation right shall form shares common stock cash combination shares cash form payment upon exercise right shall determined committee either time grant stock appreciation right time exercise stock appreciation right performance share awards committee may grant awards payment may made shares common stock cash combination shares cash performance company parent subsidiary division affiliate joint venture company selected committee award period meets certain goals established committee performance share awards performance share awards shall subject following terms conditions terms conditions committee may prescribe award period performance goals committee shall determine include performance share award grant period time performance share award made award period committee also shall establish performance objectives performance goals met company parent subsidiary division affiliate joint venture company award period condition payment performance share award performance goals may include share price pre tax profits earnings per share return stockholders equity return assets sales net income combination foregoing solely award intended constitute performancebased compensation section code financial measurement established committee performance goals may include minimum optimum objectives single set objectives b payment performance share awards committee shall establish method calculating amount payment made performance share award performance goals met including fixing maximum payment performance share award shall expressed terms shares common stock referred performance shares completion award period performance company parent subsidiary division affiliate joint venture company shall measured performance goals committee shall determine accordance terms performance share award whether none portion performance share award shall paid committee discretion may elect make payment shares common stock cash combination shares cash cash payment shall based fair market value performance shares soon practicable prior date payment committee may establish rules procedures permit grantee defer recognition income upon attainment performance share award c revision performance goals award intended constitute performancebased compensation section code time prior end award period committee may revise performance goals computation payment unforeseen events occur substantial effect performance company parent subsidiary division affiliate joint venture company judgment committee make application performance goals unfair unless revision made requirement employment grantee performance share award must remain employ company parent subsidiary affiliate joint venture completion award period order entitled payment performance share award provided committee may discretion provide full partial payment exception deemed equitable e dividends committee may discretion time granting performance share award provide dividends declared common stock award period would paid respect performance shares owned grantee paid grantee ii accumulated benefit grantee used increase number performance shares grantee f limit performance share awards incentives granted performance share awards section restricted stock grants section share based awards section shall exceed aggregate million shares common stock number shares shall adjusted accordance section c restricted stock grants committee may award shares common stock eligible employee shares shall subject following terms conditions terms conditions committee may prescribe restricted stock grant requirement employment grantee restricted stock grant must remain employment company period designated committee restriction period order retain shares restricted stock grant grantee leaves employment company prior end restriction period restricted stock grant shall terminate shares common stock shall returned immediately company provided committee may time grant provide employment restriction lapse respect portion portions restricted stock grant different times restriction period committee may discretion also provide complete partial exceptions employment restriction deems equitable b restrictions transfer legend stock certificates restriction period grantee may sell assign transfer pledge otherwise dispose shares common stock certificate shares common stock issued hereunder shall contain legend giving appropriate notice restrictions grant c escrow agreement committee may require grantee enter escrow agreement providing certificates representing restricted stock grant remain physical custody escrow holder restrictions removed expire lapse restrictions restrictions imposed restricted stock grant shall lapse upon expiration restriction period conditions employment set forth met grantee shall entitled legend removed certificates committee may establish rules procedures permit grantee defer recognition income upon expiration restriction period e dividends committee shall discretion time restricted stock grant provide dividends declared common stock restriction period shall either paid grantee ii accumulated benefit grantee paid grantee expiration restriction period f performance goals committee may designate whether restricted stock grant intended performancebased compensation term used section code restricted stock grant designated performancebased compensation shall conditioned achievement one performance goals defined section extent required section g limit restricted stock grant incentives granted restricted stock grants section performance share awards section share based awards section shall exceed aggregate million shares common stock number shares shall adjusted accordance section c sharebased awards committee may grant award shares common stock share award eligible employee terms conditions committee may determine sole discretion share awards may made additional compensation services rendered eligible employee may lieu cash compensation eligible employee entitled company incentives granted share based awards section performance share awards section restricted stock grants section shall exceed aggregate million shares common stock number shares shall adjusted accordance section c transferability incentive stock option granted plan shall transferable laws descent distribution incentive granted plan transferable assignable recipient may made subject execution attachment similar procedures laws descent distribution determined committee accordance regulations promulgated securities exchange act applicable law regulation notwithstanding foregoing committee discretion may adopt rules permitting transfer solely gifts grantees lifetime stock options incentive stock options members grantees immediate family trusts family partnerships similar entities benefit immediate family members purpose immediate family member means grantees spouse parent child stepchild grandchild spouses family members terms stock option shall final binding conclusive upon beneficiaries executors administrators heirs successors grantee discontinuance amendment plan board directors may discontinue plan time may time time amend revise terms plan permitted applicable statutes except may without consent grantees affected revoke alter manner unfavorable grantees incentives hereunder incentives outstanding may board amend plan without stockholder approval absence approval would cause plan fail comply rule b exchange act requirement applicable law regulation unless approved companys stockholders otherwise specifically provided plan adjustments reduction exercise price outstanding incentives shall made event decline stock price either reducing exercise price outstanding incentives cancellation outstanding incentives connection regranting incentives lower price individual limitation compensation nothing plan shall construed limit right company establish plans pay compensation employees cash property manner expressly authorized plan constraint corporate action nothing plan shall construed limit impair otherwise affect companys right power make adjustments reclassifications reorganizations changes capital business structure merge consolidate dissolve liquidate sell transfer part business assets ii except provided section limit right power company parent subsidiary affiliate joint venture take action entity deems necessary appropriate withholding taxes company shall entitled deduct payment plan regardless form payment amount applicable income employment taxes required law withheld respect payment may require eligible employee pay tax prior condition making payment accordance applicable administrative guidelines establishes committee may allow eligible employee pay amount taxes required law withheld incentive withholding payment common stock due result incentive permitting eligible employee deliver company shares common stock fair market value determined committee equal amount required withholding taxes compliance section respect eligible employees subject section exchange act section officers transactions plan intended comply applicable conditions rule b successor exchange act extent compliance plan provision applicable solely section officers required order bring transaction section officer compliance rule b shall deemed null void transaction extent permitted law deemed advisable committee delegees extent provision plan action plan administrators involving section officers deemed comply applicable condition rule b shall deemed null void section officers extent permitted law deemed advisable plan administrators use proceeds proceeds received company sale stock plan shall added general funds company shall used corporate purposes board directors shall direct governing law plan agreements hereunder shall construed accordance governed laws state new jersey without giving effect principles conflicts laws offset suspension exercise anything contrary plan notwithstanding plan administrators may offset incentive amounts reasonably believed owed company grantee ii disallow incentive exercised otherwise payable time company investigating reasonably reliable allegations gross misconduct grantee effect change control options vesting options key rd options upon occurrence change control stock option outstanding immediately prior change control key rd options shall immediately become fully vested exercisable vesting key rd options subject section aii upon occurrence change control key rd option shall continue subject performancebased vesting schedule applicable thereto immediately prior change control ii notwithstanding section ai stock options continue outstanding following change control exchanged converted options purchase securities successor entity successor options upon occurrence change control portion key rd option shall immediately vest become exercisable following percentages key rd options first milestone reached date change control thenunvested portion keyrd option shall vest become exercisable remainder shall forfeited b key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited c key rd options first second milestones reached date change control thenunvested portion key rd option shall vest become exercisable posttermination exercise period stock options continue outstanding following change control exchanged converted successor options portion stock options successor options applicable vested exercisable immediately following termination employment holder thereof change control shall remain exercisable following termination five years date termination beyond remainder term thereof provided however termination reason gross misconduct death retirement terms applied awards granted plan provisions plan applicable termination reason gross misconduct death retirement shall apply termination cashout stock options stock options continue outstanding following change control exchanged converted successor options holder vested exercisable option shall entitled receive soon practicable following change control share common stock subject vested exercisable option amount cash determined committee prior change control event less excess change control price exercise price thereof subject existing deferral elections effect consideration paid change control entirely shares common stock acquiring resulting corporation committee may prior change control provide cancellation outstanding stock options time change control whole part cash pursuant section may provide exchange conversion outstanding stock options time change control whole part connection provision may shall obligated permit holders stock options make elections related thereto determines appropriate b restricted stock units performance share units vesting restricted stock units upon occurrence change control unvested restricted stock unit award outstanding immediately prior change control plan shall immediately become fully vested vesting performance share units upon occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately become vested amount equal psu pro rata amount settlement restricted stock units performance share units common stock continues widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid shares common stock securities soon practicable date change control subject existing deferral elections effect ii common stock continue widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid cash soon practicable date change control subject existing deferral elections effect c provisions except extent required applicable law entirety protection period material terms plan shall modified manner materially adverse qualifying participants understood section c shall require specific type levels equity awards granted qualifying participants following change control protection period plan may amended modified reduce eliminate protections set forth section c may terminated company shall pay legal fees related expenses including costs experts evidence counsel reasonably good faith incurred qualifying participant qualifying participant prevails claim relief action x qualifying participant claiming provisions section c c plan violated avoidance doubt excluding claims plan benefits ordinary course applicable company qualifying participants employer enforce posttermination covenants qualifying participant definitions purposes section following terms shall following meanings change control shall meaning set forth companys change control separation benefits plan provided however award plan consists deferred compensation subject section code definition change control shall deemed modified extent necessary comply section code change control price shall mean respect share common stock higher highest reported sales price regular way share transaction reported new york stock exchange composite tape national exchange shares listed nasdaq national market tenday period prior including date change control b change control result tender exchange offer merger similar corporate transaction highest price per share paid tender exchange offer merger similar corporate transaction provided extent part consideration paid transaction consists securities noncash consideration value securities noncash consideration shall determined committee key rd options shall mean performancebased options granted employees key research development program described applicable schedule rules regulations plan protection period shall mean period beginning date change control ending second anniversary date change control psu pro rata amount shall mean performance share unit award amount determined multiplying x x number target shares subject performance share unit award times assumed performance percentage fraction numerator number whole partial calendar months elapsed applicable performance period counting partial month whole month purpose denominator total number months applicable performance period assumed performance percentage shall determined averaging ranks award period follows completed performance year change control actual rank except fewer days elapsed since completion performance year target rank shall used b performance year incomplete yet begun change control target rank rounding average rank calculated pursuant foregoing clause nearest whole number using ordinary numerical rounding using final award percentage associated number determined foregoing clause target rank rank associated chart final award percentages qualifying participants shall mean individuals participate plan whether current former employees immediately prior change control e application section shall apply stock options restricted stock unit awards performance share unit awards granted november note incentives granted november see merck change control schedule merck change control options vesting options key rd options upon occurrence change control stock option outstanding immediately prior change control key rd options shall immediately become fully vested exercisable vesting key rd options subject aii schedule upon occurrence change control key rd option shall continue subject performancebased vesting schedule applicable thereto immediately prior change control ii notwithstanding ai schedule stock options continue outstanding following change control exchanged converted options purchase securities successor entity successor options upon occurrence change control portion key rd option shall immediately vest become exercisable following percentages key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited b key rd options first milestone reached date change control thenunvested portion key rd option shall vest become exercisable remainder shall forfeited c key rd options first second milestones reached date change control thenunvested portion key rd option shall vest become exercisable posttermination exercise period stock options continue outstanding following change control exchanged converted successor options portion stock options successor options applicable vested exercisable immediately following termination employment holder thereof change control shall remain exercisable following termination five years date termination beyond remainder term thereof provided however termination reason gross misconduct death retirement terms applied awards granted plans provisions plan applicable termination reason gross misconduct death retirement shall apply termination effect vesting pursuant section would cause stock option successor stock option terminate earlier accelerated vesting occurred term stock option shall expire earlier accelerated vesting occurred cashout stock options stock options continue outstanding following change control exchanged converted successor options holder vested exercisable option shall entitled receive soon practicable following change control share common stock subject vested exercisable option amount cash determined committee prior change control event less excess change control price exercise price thereof subject existing deferral elections effect consideration paid change control entirely shares common stock acquiring resulting corporation committee may prior change control provide cancellation outstanding stock options time change control whole part cash pursuant provision may provide exchange conversion outstanding stock options time change control whole part connection provision may shall obligated permit holders stock options make elections related thereto determines appropriate incentive stock options amended section apply incentive stock option within meaning section internal revenue code b restricted stock units performance share units vesting restricted stock units upon occurrence change control unvested restricted stock unit award outstanding immediately prior change control plan shall immediately become fully vested vesting performance share units upon occurrence change control unvested performance share unit award outstanding immediately prior change control plan shall immediately become vested amount equal psu pro rata amount settlement restricted stock units performance share units common stock continues widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid shares common stock securities soon practicable date change control subject existing deferral elections effect ii common stock continue widely held freely tradable following change control exchanged converted securities successor entity widely held freely tradable restricted stock units vested performance share units shall paid cash soon practicable date change control subject existing deferral elections effect c provisions except extent required applicable law entirety protection period material terms plan shall modified manner materially adverse qualifying participants understood section c schedule shall require specific type levels equity awards granted qualifying participants following change control protection period plan may amended modified reduce eliminate protections set forth section c schedule may terminated company shall pay legal fees related expenses including costs experts evidence counsel reasonably good faith incurred qualifying participant qualifying participant prevails claim relief action x qualifying participant claiming provisions section c c schedule violated avoidance doubt excluding claims plan benefits ordinary course applicable company qualifying participants employer enforce posttermination covenants qualifying participant section apply incentive stock option within meaning section internal revenue code anything plan amended schedule notwithstanding company reserves right make changes may required extent required avoid adverse consequences american jobs creation act amended definitions purposes schedule following terms shall following meanings change control shall meaning set forth companys change control separation benefits plan provided however award plan consists deferred compensation subject section code definition change control shall deemed modified extent necessary comply section code change control price shall mean respect share common stock higher highest reported sales price regular way share transaction reported new york stock exchange composite tape national exchange shares listed nasdaq national market day period prior including date change control b change control result tender exchange offer merger similar corporate transaction highest price per share paid tender exchange offer merger similar corporate transaction provided extent part consideration paid transaction consists securities noncash consideration value securities noncash consideration shall determined committee key rd options shall mean performancebased options granted employees key research development program described applicable schedule rules regulations plan protection period shall mean period beginning date change control ending second anniversary date change control psu pro rata amount shall mean performance share unit award amount determined multiplying x x number target shares subject performance share unit award times assumed performance percentage fraction numerator number whole partial calendar months elapsed applicable performance period counting partial month whole month purpose denominator total number months applicable performance period assumed performance percentage shall determined averaging ranks award period follows completed performance year change control actual rank except fewer days elapsed since completion performance year target rank shall used b performance year incomplete yet begun change control target rank rounding average rank calculated pursuant foregoing clause nearest whole number using ordinary numerical rounding using final award percentage associated number determined foregoing clause target rank rank associated chart final award percentages qualifying participants shall mean individuals participate plan whether current former employees immediately prior change control e application schedule shall apply stock options restricted stock unit awards performance share unit awards plans granted prior november exhibit merck co inc plan deferred payment directors compensation amended restated january table contents article purpose article ii election deferral measurement methods distribution schedule article iii valuation deferred amounts article iv redesignation within deferral account article v payment deferred amounts article vi designation beneficiary article vii plan amendment termination schedule measurement methods imerck co inc plan deferred payment directors compensation purpose provide arrangement directors merck co inc current employees may elect voluntarily defer payment annual retainers board committee meeting fees termination service director ii value compensation mandatorily deferred behalf ii e lection deferral measurement methods distribution schedule election voluntary deferral amount prior december year director entitled make irrevocable election defer termination service director receipt payment board retainer months beginning april next calendar year b committee chairperson retainer months beginning april next calendar year c audit committee member retainer months beginning april next calendar year board committee meeting fees months beginning april next calendar year prior commencement duties director director newly elected appointed board calendar year must make election paragraph portion voluntary deferral amount applicable directors first year service part thereof voluntary deferral amount shall credited follows board committee meeting fees deferred credited last business day calendar quarter board retainer committee chairperson retainer andor audit committee member retainer deferred prorata share deferred retainer credited last business day calendar quarter dates voluntary deferral amount parts thereof credited directors deferred account hereinafter referred voluntary deferral dates b mandatory deferral amount friday following companys annual meeting stockholders friday hereinafter referred mandatory deferral date director credited amount equivalent onethird annual cash retainer month period beginning april preceding annual meeting mandatory deferral amount mandatory deferral amount measured merck common stock account director newly elected appointed board mandatory deferral date credited pro rata portion mandatory deferral amountapplicable directors first year service part thereof pro rata portion shall credited directors account first day directors service c election measurement method annual election referred section shall include election measurement method methods value amounts deferred measured accordance article iii available measurement methods set forth schedule hereto election distribution schedule annual election referred article ii section shall also include election receive payment following termination service director voluntary deferral amounts mandatory deferral amounts lump sum either immediately one year termination quarterly annual installments five ten fifteen years iii valuation deferred amounts common stock initial crediting annual mandatory deferral amount shall used determine number full partial shares merck common stock amount would purchase closing price common stock new york stock exchange mandatory deferral date portion voluntary deferral amount allocated merck common stock shall used determine number full partial shares merck common stock amount would purchase closing price common stock new york stock exchange applicable voluntary deferral date however determined committee corporate governance board directors measurement merck common stock mandatory voluntary deferral date would constitute fair market value committee shall decide date fair market value shall determined using valuation method set forth article iii section time deferral period shares merck common stock purchased earmarked deferred amounts rights shareholder exist respect amounts dividends directors account credited additional number full partial shares merck common stock would purchasable dividends shares previously credited account closing price common stock new york stock exchange date dividend paid distributions distribution merck common stock account valued closing price merck common stock new york stock exchange distribution date b mutual funds initial crediting amount allocated mutual fund shall used determine full partial mutual fund shares amount would purchase closing net asset value mutual fund shares mandatory voluntary deferral date whichever applicable directors account credited number full partial mutual fund shares determined time deferral period mutual fund shares purchased earmarked deferred amounts rights shareholder exist respect amounts dividends directors account credited additional number full partial mutual fund shares would purchasable closing net asset value mutual fund shares date dividend paid mutual fund shares dividends would paid number shares previously credited account including pro rata dividends partial shares distributions mutual fund distributions valued based closing net asset value mutual fund shares distribution date c adjustments event reorganization recapitalization stock split stock dividend combination shares merger consolidation rights offering change corporate structure shares company mutual fund number kind shares units investment measurement method available plan credited directors account shall adjusted accordingly iv redesignation within deferral account general director may request change measurement methods used value portion hisher account merck common stock amounts deferred using merck common stock method earnings attributable deferrals may redesignated change effective day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed b redesignation may occur active service limit number times director may redesignate portion hisher deferred account permitted redesignated request shall irrevocable designated whole percentages dollar amount death following death director legal representative beneficiary director may redesignate subject rules active directors set forth article iv section b c valuation amounts redesignated portion directors account redesignated valued cash equivalent cash equivalent converted shares units measurement methods purposes redesignations cash equivalent value mutual fund shares shall closing net asset value mutual fund day redesignation request received pursuant administrative guidelines established human resources financial services area treasury department provided request received prior close new york stock exchange day ii next following business day request received new york stock exchange closed v payment deferred amounts payment payments directors amounts deferred cash accordance distribution schedule elected director pursuant article ii section distributions shall pro rata measurement method distributions shall valued fifteenth day distribution month day business day next business day paid soon thereafter possible b changes distribution schedule prior termination upon request director made time calendar year immediately preceding calendar year service director expected terminate committee corporate governance board directors committee sole discretion may authorize extension payment period beyond originally elected director exceed otherwise allowable article ii section andor b payment frequency different originally elected director request may made regard amounts deferred december using merck common stock method earnings attributable deferrals deferrals merck common stock made december earnings thereon may distributed accordance schedule elected director article ii section determined committee corporate governance article vi c posttermination changes distribution schedule following termination service director director may make one request extension period distribution hisher deferred compensation request must received committee corporate governance prior first distribution participant hisher previously elected distribution schedule revised distribution schedule may exceed deferral period otherwise allowable article ii section c request may granted new payment schedule determined sole discretion committee corporate governance request may made regard amounts deferred december using merck common stock method earnings attributable deferrals retired director subject us income tax may petition committee corporate governance change payment frequency including lump sum distribution committee corporate governance may grant petition discretion considers reasonable justification therefor deferrals merck common stock made december earnings thereon may distributed accordance schedule elected director article ii section determined committee corporate governance article vi forfeitures directors deferred amount attributable mandatory deferral amount earnings thereon shall forfeited upon removal director upon determination committee corporate governance sole discretion director joined board managed operated participated material way entered employment performed consulting services otherwise connected material manner company corporation enterprise firm limited partnership partnership person sole proprietorship business entity determined committee corporate governance sole discretion competitive business company subsidiaries affiliates competitor ii directly indirectly acquired equity interest five percent greater competitor iii disclosed material trade secrets material confidential information including customer lists relating company business company others including competitor vi designation beneficiary event death director deferred amount date death shall paid last named beneficiary beneficiaries designated director beneficiary designated directors legal representative one installments committee corporate governance sole discretion may determine vii p lan amendment termination committee corporate governance shall right amend terminate plan time reason schedule measurement methods january january merck common stock mutual funds american century emerging markets fund american century europacific growth fund fidelity destiny fidelity dividend growth fidelity equity income fund fidelity lowpriced stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity fund putnam international voyager putnam vista rowe price blue chip growth fund vanguard asset allocation september september investment briefly named putnam global growth fund result merger september putnam global equity fund putnam global growth fund merged fund briefly retained name putnam global growth fund effective october merged fund changed name putnam global equity fund schedule measurement methods effective january july merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income liberty acorn class z pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity putnam international capital opportunities fund putnam vista rowe price blue chip growth vanguard asset allocation prior april known putnam international voyager fund redesignation deferred amounts measured putnam vista july prior pm et july participant part hisher account measured putnam vista measurement method may redesignate amount measurement method accordance article iv participant redesignate amount measured putnam vista measurement method remaining measurement method pm et july amount putnam vista account shall redesignated pm et july fidelity midcap stock fund schedule measurement methods effective july november merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund columbia acorn class z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income pimco foreign bond institutional pimco long term us government institutional pimco total return institutional putnam global equity putnam international capital opportunities fund rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z prior april known putnam international voyager fund redesignation deferred amounts measured putnam global equity putnam international capital opportunities fund collectively putnam funds november prior pm et november participant part hisher deferred compensation account measured putnam funds investment alternative may redesignate amount investment alternative accordance article iv participant redesignate amount measured putnam funds investment alternative remaining investment alternatives pm et november amount putnam funds investment alternative shall redesignated pm et november fidelity retirement money market portfolio schedule measurement methods november april merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund columbia acorn class z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index franklin smallmid cap growth janus enterprise janus growth income pimco foreign bond institutional pimco long term us government institutional pimco total return institutional rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z schedule measurement methods april january merck common stock mutual funds american century emerging markets institutional american funds europacific growth fund columbia acorn class z fidelity destiny fidelity dividend growth fidelity equityincome fidelity lowpriced stock fidelity midcap stock fund fidelity retirement money market fidelity spartan government income fidelity spartan us equity index janus enterprise janus growth income pimco foreign bond institutional pimco long term us government institutional pimco total return institutional rowe price blue chip growth vanguard asset allocation prior october known liberty acorn class z schedule measurement methods february investment alternatives available plan shall investment alternatives available time time merck co inc deferral program exhibit merck co inc subsidiaries computation ratios earnings fixed charges millions except ratio data twelve months ended december years ended december income continuing operations taxes add subtract onethird rents interest expense gross interest capitalized net amortization equity income loss affiliates net distributions preferred stock dividends net tax earnings continuing operations onethird rents interest expense gross preferred stock dividends fixed charges continuing operations ratio earnings fixed charges continuing operations purposes computing ratios earnings consist income continuing operations taxes onethird rents deemed company representative interest factor inherent rents interest expense net amounts capitalized equity income loss affiliates net distributions dividends preferred stock subsidiary companies fixed charges consist onethird rents interest expense reported companys consolidated financial statements dividends preferred stock subsidiary companiesfinancial section contents financial review financial review description mercks business description mercks business overview merck global researchdriven pharmaceutical company voluntary product withdrawal discovers develops manufactures markets broad range competition health care environment innovative products improve human animal health directly operating results joint ventures merck sells products primarily selected joint venture affiliate information drug wholesalers retailers hospitals clinics government capital expenditures agencies managed health care providers health analysis liquidity capital resources maintenance organizations institutions companys financial instruments market risk disclosures professional representatives communicate effectiveness safety critical accounting policies matters value products health care professionals private recently issued accounting standards practice group practices managed care organizations cautionary factors may affect future results cash dividends paid per common share common stock market prices condensed interim financial data overview consolidated statement income decision announced september voluntarily consolidated statement retained earnings withdraw vioxx market discussed reflects consolidated statement comprehensive income depth sincerity mercks commitment patients consolidated balance sheet company made decision withdraw vioxx based science consolidated statement cash flows available time given availability alternative notes consolidated financial statements therapies questions raised data throughout mercks managements report history companys rigorous adherence scientific audit committees report investigation openness integrity enabled bring new report independent registered public accounting firm medicines people need responded swiftly compensation benefits committees report effectively voluntary withdrawal vioxx merck turned selected financial data focus future mercks efforts expand pipeline moving new therapeutic categories increasing licensing activities accelerating early latestage development producing positive results exception delay approval arcoxia united states company ahead schedule planned regulatory submissions phase iii development programs bristolmyers squibb company bms submitted application food drug administration fda muraglitazar new class oral agents treatment type diabetes merck bms jointly commercialize muraglitazar global basis addition merck submitted application proquad new childhood vaccine adds chickenpox existing measles mumps rubella vaccine merck currently five product candidates phase iii development three vaccines mk mercks dppiv inhibitor treatment type diabetes gaboxadol insomnia compound licensed h lundbeck merck plans submit three phase iii vaccines fda approval merck plans drive sales new established products new indications formulations clinical trials bolster products safety efficacy profiles vytorin developed marketed merckscheringplough partnership gained rapid acceptance among patients physicians payers since july us approval rapidly adopted firstline use company seeking new indications singulair asthma seasonal allergy medicine also merck expects enhance osteoporosis franchise addition fosamax plus vitamin compound combines alendronate active ingredient fosamax vitamin company disagrees january court ruling found mercks us patent claims fosamax weekly invalid request reconsideration court appeals merck process redesigning many critical business processes improving efficiencies many areas including procurement manufacturing capital investment inventory management merck positioned realize significant cost reductions future new us wholesaler distribution program launched succeeded leveling quarterlyvolume fluctuations made difficult streamline production reduce inventory levels merck co inc annual report also end merck eliminated positions february fda held joint meeting exceeding target positions announced october arthritis advisory committee drug safety risk action expected result million savings management advisory committee committees discussed without impacting either key productivity initiatives mercks overall benefit risk considerations including cardiovascular ability meet business objectives gastrointestinal safety concerns cox selective nonsteriodal earnings per common share assuming dilution antiinflammatory drugs related agents february including impact withdrawal vioxx reserves members committees asked vote whether established solely future legal defense costs vioxx litigation overall risk versus benefit profile vioxx supports marketing defined note financial statements company united states members committees voted anticipates fullyear earnings per common share assuming support marketing vioxx united states company dilution guidance reflect looks forward discussions fda regulatory establishment reserves potential liability relating authorities vioxx vioxx litigation additional reserves legal defense costs previously announced board directors company guidance also reflect changes way merck appointed special committee review companys actions accounts stockbased compensation result recently issued prior voluntary withdrawal vioxx act board accounting standards furthermore guidance include responding shareholder litigation matters related withdrawal onetime impacts may result repatriation vioxx advise board respect action permanently reinvested offshore earnings american jobs taken result review creation act competition health care environment voluntary product withdrawal markets company conducts business highly september merck announced voluntary worldwide competitive often highly regulated global efforts toward health withdrawal vioxx arthritis acute pain medication see care cost containment continue exert pressure product pricing notes financial statements information access companys decision effective immediately united states government made significant progress based new threeyear data prospective randomized expanding health care access enacting medicare prescription placebocontrolled clinical trial approve adenomatous polyp drug improvement modernization act prevention vioxx signed law december statute added voluntary trial stopped designed evaluate drug discount card medicare beneficiaries june efficacy vioxx mg preventing recurrence colorectal add prescription drug coverage january implementation polyps patients history colorectal adenomas new benefit support companys goal improving assess cardiovascular safety vioxx study access medicines expanding insurance coverage increased relative risk confirmed cardiovascular events preserving marketbased incentives pharmaceutical innovation heart attack stroke beginning months treatment time benefit designed assure prescription patients taking vioxx compared taking placebo drug costs controlled competitive pressures results first months approve study show encouraging appropriate use medicines company increased risk confirmed cardiovascular events vioxx taken leadership role contributing success new respect similar results two placebocontrolled medicareendorsed discount cards providing medicines free studies described recent us labeling vioxx lowincome medicare beneficiaries exhaust merck presented data approve american college transitional assistance allowance medicareendorsed drug rheumatology acr annual scientific meeting san antonio discount cards action consistent companys long october company requested opportunity standing patient assistance program provides free medicines present data acr meeting patients united states lack drug coverage company estimates million us afford medicines company negotiating prescriptions written vioxx may august prescription drug plans new medicare drug benefit based estimate company estimates number offer merck products medicare beneficiaries beginning january patients taken vioxx united states since terms new benefit launch approximately million number patients outside addressing cost containment outside medicare united states taken vioxx undetermined time company made continuing effort demonstrate october company received letter senator medicines help save costs overall patient health care charles grassley chairman senate committee finance addition pricing flexibility across companys product portfolio requesting certain documents information related vioxx encouraged growing use medicines mitigated effects company also received requests information increasing cost pressures congressional committees company intends cooperate outside united states difficult environments encumbered inquiries company continue describe government costcontainment actions company worked reasons companys voluntary withdrawal vioxx partnership payers allocating scarce resources optimize answer questions related companys development health care outcomes limiting potentially detrimental effects extensive testing medicine disclosures results government policies sales growth supporting discovery studies development innovative products benefit patients also october company received letter company also working governments many emerging group five state attorneys general raising concerns markets eastern europe latin america asia encourage companys return refund program unused vioxx increase investments health thereby improve provide consumers adequate notice unduly citizens access medicines countries within european burdensome company cooperating attorneys union eu recognizing economic importance research general respond concerns based pharmaceutical industry value innovative medicines society working industry representatives merck co inc annual report european commission proposals complete single market worldwide withdrawal vioxx foreign sales negatively pharmaceuticals improve competitive climate affected impact patent expirations zocor variety means including market deregulation certain countries europe including united kingdom company committed improving access medicines germany japan canada foreign sales represented enhancing quality life people around world mercks total sales african comprehensive hivaids partnerships achap worldwide sales increased total botswana collaboration government botswana reflecting favorable effect foreign exchange bill melinda gates foundation striving develop favorable effect price changes foreign sales represented comprehensive sustainable approach hiv prevention care total sales treatment catalyze access hiv medicines sales category companys products follows developing countries october company introduced new mg tablet formulation antiretroviral medicine stocrin millions price less one dollar per day least developed therosclerosis countries hardest hit hivaids epidemic hypertensionheart failure end patients developing countries osteoporosis respiratory treated antiretroviral regimens containing either antiinflammatoryanalgesics crixivan stocrin actions merck antibacterialantifungal working partners public private sectors alike focus vaccinesbiologicals critical barriers access medicines developing urology world need sustainable financing increased international ophthalmologicals assistance additional investments education training human immunodeficiency virus hiv health infrastructure capacity developing countries increasing amount focus privacy issues countries around world including united states presented net discounts returns eu united states eu governments pursued legislative regulatory initiatives regarding privacy including companys products include therapeutic preventive federal privacy regulations recently enacted state privacy laws agents generally sold prescription treatment human concerning health personal information disorders among atherosclerosis products zocor affected companys operations largestselling hyper tensionheart failure products although one predict outcome significant cozaar hyzaar vasotec legislative regulatory advocacy initiatives company well osteoporosis product fosamax treatment prevention positioned respond evolving health care environment osteoporosis respiratory product singulair leukotriene receptor market forces antagonist treatment asthma relief symptoms company anticipates worldwide trend toward cost seasonal allergic rhinitis antiinflammatoryanalgesics include containment continue resulting ongoing pressures health vioxx voluntarily withdrawn worldwide september care budgets company continues successfully launch new arcoxia agents specifically inhibit cox products contribute health care debates monitor reforms enzyme responsible pain inflammation coxib anti new products policies strategies enable maintain bacterialantifungal products includes primaxin cancidas strong position changing economic environment invanz vaccinesbiologicals varivax live virus vaccine prevention chickenpox mmr ii pediatric operating results vaccine measles mumps rubella pneumovax vaccine sales prevention pneumococcal recombivax hb hepatitis b worldwide sales increased total reflecting vaccine recombinant largestselling urology product favorable effect foreign exchange favorable effect proscar treatment symptomatic benign prostate enlargement price changes volume decline connection ophthalmologicals cosopt trusopt largest companys voluntary worldwide withdrawal vioxx selling hiv products include stocrin crixivan september sales unfavorably impacted treatment human immunodeficiency viral infection adults million estimated customer returns product previously primarily includes sales human pharmaceuticals sold approximately million foregone sales pharmaceutical animal health supply sales companys fourth quarter see note financial statements joint ventures revenue companys relationship information overall increase sales reflects strong azlp primarily relating sales nexium prilosec revenue growth singulair asthma seasonal allergic rhinitis azlp billion billion billion fosamax osteoporosis cozaarhyzaar high blood respectively pressure sales growth also includes favorable singulair mercks onceaday oral medication indicated comparison affected million treatment chronic asthma relief symptoms seasonal wholesaler buyout following implementation new allergic rhinitis hay fever continued strong performance distribution program us wholesalers fourth quarter singulair asthma controller terms total prescriptions fluctuations sales caused wholesaler investment united states patients physicians managed care buying significantly moderated overall growth offset organizations continue recognize value singulair offers part lower revenues companys relationship suffer asthma seasonal allergic rhinitis total astrazeneca lp azlp primarily driven generic overthe sales singulair billion increase counter competition prilosec singulair performance includes favorable comparison domestic sales growth foreign sales grew affected us wholesaler including eight percentage point favorable effect foreign exchange domestic foreign sales include unfavorable effect associated voluntary merck co inc annual report buyout us mailorderadjusted prescription levels singulair increased new formulation expected help drive future growth approximately cozaarhyzaar hyzaar mg submitted approval merck seeking new indications singulair new indication fda december better address need titration flexibility perennial allergic rhinitis filed fda second half intermediate step cozaar mg hyzaar merck also plans file additional indications singulair mg filings new formulation markets outside united prevention exerciseinduced bronchospasm states anticipated throughout acute asthma second half respiratory zocor mercks statin modifying cholesterol achieved syncytial viral bronchiolitis worldwide sales billion increase fosamax prescribed medicine worldwide zocor performance includes favorable comparison treatment postmenopausal male glucocorticoidinduced affected us wholesaler buyout excluding effect zocor osteoporosis continued strong growth sales experienced volume decline sales zocor affected billion increase fosamax performance patent expirations outside united states increased includes favorable comparison affected us competition us cholesterolmodifying market mailorder wholesaler buyout us mailorderadjusted prescription levels adjusted prescription levels united states zocor increased fosamax increased approximately approximately zocor available percent april journal internal medicine published findings managed care lives percent targeted managed care first international headtohead study compared efficacy contracts renewed june zocor fosamax weekly alendronate mg evista lose market exclusivity united states company raloxifene mg daily showed fosamax provided expects decline us zocor sales significantly greater increases bone mineral density bmd company continues promote landmark heart lumbar spine total hip protection study hps physicians consumers hps results fosamax actonel comparison trial fact demonstrated zocor mg along diet proven reduce presented october american society bone mineral risk heart attacks stroke people heart disease research meeting first headtohead study conducted regardless cholesterol level united states comparing fdaapproved onceweekly july national cholesterol education program osteoporosis treatments postmenopausal women ncep issued report recommending modifications adult osteoporosis fact showed fosamax demonstrated treatment panel iii atp iii guidelines report based significantly greater increases bmd sites measured early five major studies including hps endorsed six months greater reductions markers boneturnover american heart association american college cardiology onceweekly actonel fosamax increased bmd percent national heart lung blood institute new report actonel hip trochanter hip bone similar may lead increase number people tolerability bmd major determinant bone strength lower cholesterollowering medicines considered bmd score greater risk fracture ncep atp iii guidelines estimated million people would merck expects enhance osteoporosis franchise eligible cholesterollowering medication zocor addition fosamax plus vitamin compound combines cholesterol management according new report high risk alendronate active ingredient fosamax vitamin persons recommended ldlc goal mgdl report company submitted new drug application nda fda also indicates risk high patient product vitamin critical calcium absorption established cardiovascular disease plus multiple major risk factors aids bone strength estimated percent osteoporosis especially diabetes ldlc goal mgdl reasonable patients inadequate levels vitamin compliance among clinical strategy physicians prescribed supplements poor combining fosamax sales arcoxia companys onceaday coxib reached vitamin could help ensure adequate weekly dose vitamin million outside united states arcoxia convenient manner patients osteoporosis launched countries europe latin america asia fda granted additional six months market october company received approvable letter fda exclusivity united states fosamax february companys nda arcoxia fda informed fosamax weekly january however january company letter approval nda issued us court appeals federal circuit additional safety efficacy data arcoxia required washington dc found companys patent claims also october european medicines evaluation agency weekly administration fosamax invalid based court emea announced would conduct review cox appeals decision fosamax lose market exclusivity inhibitors including arcoxia light worldwide withdrawal united states february company expects decline vioxx emea said asked conduct review us fosamax sales time prior decision mercks european commission precautionary measure patent onceweekly administration fosamax set expire would look aspects cardiovascular safety cox july merck disagrees decision court inhibitors including thrombotic cardiorenal events appeals request reconsideration court appeals january emeas committee medicinal products global sales cozaar companion agent hyzaar human use chmp held hearings connection review combination cozaar diuretic hydrochlorothiazide additional meetings held chmp midfebruary continue treatment hypertension strong reaching billion review determine whether need make euwide increase us mailorderadjusted prescription changes products marketing authorizations including labeling levels cozaar hyzaar increased approximately determine whether additional studies needed february chmp announced concluded cozaar hyzaar compete fastestgrowing class available data show increased risk cardiovascular adverse antihypertensive market angiotension ii antagonists aiia cozaar events cox inhibitors class relative placebo continues largestselling branded aiia europe nsaids according chmp data also suggested secondmostfrequently prescribed aiia united states association duration use dose probability suffering cardiovascular event therefore recommended use lowest effective dose cox inhibitors shortest possible duration treatment merck co inc annual report chmp introduced contraindication cox inhibitors company records results interest patients ischemic heart disease stroke expanded merckscheringplough partnership equity income affiliates contraindication certain patients higher classes congestive heart failure specifically respect arcoxia chmp costs expenses also introduced contraindication patients hypertension whose blood pressure control advised arcoxia may associated frequent severe effects blood millions change change pressure particularly higher doses cox aterials production marketing inhibitors recommended monitoring blood pressure administrative patients taking arcoxia chmp stated interim research measures pending finalization class review development expected april finally chmp concluded research equity income needed field evaluate cardiovascular safety cox affiliates inhibitors ongoing cardiovascular trials continue income expense planned net merck working regulatory agencies countries arcoxia approved assess whether changes prescribing information coxib class drugs including greater arcoxia warranted products experiencing growth include cancidas treat certain lifethreatening fungal infections proscar materials production treatment symptomatic benign prostate enlargement cosopt materials production costs increased compared treat glaucoma stocrin treatment hiv infections propecia sales growth rate excluding effects exchange male pattern hair loss invanz treatment selected moderate inflation costs increased compared decrease severe infection adults emend prevention acute sales volume increase costs relative sales delayed nausea vomiting associated highly emetogenic volume change reflects unfavorable effects associated cancer chemotherapy also contributing mercks total sales withdrawal vioxx impact changes product mix revenue resulting companys relationship materials production costs increased compared azlp primarily relating sales nexium sales growth rate excluding effects exchange global sales zetia branded ezetrol outside united states inflation costs increased compared sales volume cholesterolabsorption inhibitor developed marketed level increase costs relative sales merckscheringplough partnership reached billion volume reflects effect changes product mix well december zetia accounted approximately total change mix domestic foreign sales attributable part prescriptions lipidlowering market according ims health implementation new distribution program us reimbursed nearly percent patients managed wholesalers gross margin compared care plans united states date ezetrol launched withdrawal vioxx countries outside united states continues unfavorable effect gross margin achieve solid sales market share growth vytorin marketed inegy many countries outside marketing administrative united states developed marketed merckschering marketing administrative expenses increased plough partnership approved fda july vytorin excluding effects exchange inflation costs accounted nearly new prescriptions december increased including impact additional million us lipidlowering market according ims health worldwide sales reserve solely future legal defense costs vioxx litigation vytorin million addition united million estimated costs undertake withdrawal states vytorin approved countries vioxx excluding costs well restructuring costs related vytorin single tablet provide powerful ldl previously announced position eliminations described cholesterol reduction dual inhibition two sources million million respectively cholesterol inhibiting production cholesterol liver marketing administrative blocking absorption cholesterol intestine including expenses decreased cholesterol food two separate clinical trials vytorin provided greater reductions ldl cholesterol lipitor zocor across dosing ranges november merck scheringplough announced new clinical trial vytorin improve improved reduction outcomes vytorin efficacy international trial trial evaluate vytorin reducing major cardiovascular events intensive lipid lowering ldl cholesterol patients acute coronary syndrome improve fourth largescale outcomes trial conducted vytorin merck co inc annual report million charge taken fourth quarter mercks latestage pipeline includes three phase iii vaccines increased companys reserve solely future legal defense expected submitted fda approval costs related vioxx litigation million three vaccines rotateq vaccine protect rotavirus december reserve based certain assumptions disease gardasil vaccine prevent incidence human minimum amount company believes time papillomavirus hpv infection associated development reasonably estimate spent multiyear period cervical cancer genital warts vaccine prevention company continue monitor legal defense costs review zoster shingles reduction pain associated adequacy associated reserves company vaccines provide significant new opportunities merck established reserves potential liability relating pediatric adolescent adult vaccine markets vioxx litigation see note financial statements estimated age children worldwide become information infected rotavirus highly contagious virus causes october merck announced plans eliminate gastroenteritis results hospitalization nearly positions part costreduction initiative completed children age annually united states worldwide end december company eliminated rotavirus responsible estimated deaths year positions company identified additional opportunities planned filing rotateq vaccine fda eliminate positions reduce costs additional second quarter eliminations came contractor positions action expected hpv predominant causative agent cervical cancer result approximately million savings without results approximately deaths worldwide year merck impacting either key productivity initiatives mercks ability meet expects file gardasil fda second half business objectives merck also redeployed sales prevention hpv related cervical cancer genital warts representatives previously supported vioxx capitalize estimated million women united states opportunities grow inline products support upcoming european union ages expected age launches range initial indication gardasil marketing administrative expenses increased analysis data investigational hpv vaccine studied excluding effects exchange inflation impact merck presented interscience conference million restructuring costs related position eliminations antimicrobial agents chemotherapy november vaccine costs increased studied clinical trial investigational monovalent vaccine developed prevent infection hpv type component mercks investigational quadrivalent hpv types l research development vlp vaccine gardasil study women aged research development expenses increased hpv nave baseline vaccine percent excluding effects exchange inflation expenses efficacious preventing development hpv related cin increased research development expense growth reflects highgrade cervical precancer immediate precursor invasive companys ongoing commitment basic clinical cervical cancer administration hpv vaccine also resulted research well impact companys external percent reduction combined incidence persistent collaborations augment mercks internal research efforts hpv infection hpv related cervical precancerous lesions h lundbeck lundbeck bristolmyers squibb cervical intraepithelial neoplasia cin final results company bms vertex pharmaceuticals incorporated vertex study completion months followup dov pharmaceutical inc dov nastech pharmaceutical inc active study participants nastech ono pharmaceutical co ltd ono also contributing february company announced increase higher acquired research expense primarily related glaxosmithkline gsk entered crosslicense settlement acquisition aton pharma inc aton compared agreement certain patent rights related hpv vaccines acquired research expense related increase pursuant agreement gsk receive upfront payment companys ownership banyu pharmaceutical co ltd banyu royalties company based upon sales gardasil upon development launch agreement resolves competing companys efforts expand pipeline moving new intellectual property claims related companys gsks therapeutic categories increasing licensing activities vaccine candidates company continue research accelerating early latestage development continue produce development appropriate regulatory reviews positive results commercialization activities approved gardasil november company announced filed biologics shingles reactivation chickenpox virus herpes zoster licenseapplication proquad measles mumps rubella adults affects estimated people united states varicella okamerck virus vaccine live fda proquad annually merck plans seek approval zoster vaccine investigational vaccine simultaneous vaccination people age older approximately measles mumps rubella varicella children months million united states european union planned years age proquad combines two established merck vaccines filing zoster vaccine fda second quarter mmr ii measles mumps rubella virus vaccine live varivax varicella okamerck virus vaccine live company also studying dppiv inhibitor glucose new study presented national immunization lowering mechanism used alone combination conference may single dose proquad yearolds treatment type diabetes compound currently phase iii used place routinely administered second dose mmr ii clinical studies company expects submit nda generally welltolerated resulted antibody response fda similar developed mmr ii varivax separately merck co inc annual report mercks earlystage pipeline includes candidates onset progression many different human cancers following areas alzheimers disease arthritis atherosclerosis novel aurora kinase inhibitors vx potential cancer diabetes endocrine disorders glaucoma infectious play important future role treatment management diseases obesity osteoporosis psychiatric disease wide range tumor types vertex received million upfront neurodegenerative disease pain respiratory disease urogenital payment term agreement could receive disorders vaccines additional million research funding next two merck continues augment internal research efforts years addition vertex could receive additional milestone capitalizing external growth opportunities ranging research payments based upon achievement significant development collaborations preclinical clinical compounds technology events regulatory filings events approvals transactions drive near longterm growth august merck dov announced agreement company completed transactions across range development commercialization dovs novel tripleuptake therapeutic areas including neuroscience diabetes obesity inhibitors developed depression related psychiatric oncol ogy well earlystage technology transactions disorders dov received million upfront payment compares total transactions merck continues term agreement could receive additional milestone evaluate opportunities actively monitoring payments based upon achievement significant development landscape range targeted acquisitions meet events regulatory filings events approvals merck companys strategic criteria licensed exclusive worldwide rights dov phase february company announced entered therapeutic indications agreement lundbeck exclusive development september merck nastech announced global alliance commercialization united states gaboxadol compound develop commercialize peptide yy pyy nasal spray licensed lundbeck third party currently phase iii nastechs product treatment obesity currently development treatment sleep disorders terms phase development investigational pyy nasal spray agreement lundbeck received initial payment million designed deliver natural appetiteregulating hormone pyy term agreement could receive directly bloodstream million additional milestone payments merck november merck ono announced signed lundbeck jointly complete ongoing phase iii clinical program agreement granting merck worldwide license ono merck funding majority remaining development r propyloctanoic acid novel intravenous compound currently activities companies anticipate merck file nda phase ii development treatment acute stroke fda late early following fda approval terms agreement ono received initial upfront payment companies plan copromote gaboxadol united states term agreement could receive milestone payments lundbeck receive share gaboxadol sales united addition royalties net sales addition ono received states june merck lundbeck announced extension exclusive rights japan develop market emend aprepitant agreement exclusive development mercks drug use combination antiemetic agents commercialization gaboxadol japan merck lundbeck prevention acute delayed nausea vomiting associated jointly conduct clinical program required filing nda initial repeat courses highly emetogenic cancer japan merck funding majority development activities chemotherapy including cisplatin ono also received rights japan following approval companies plan copromote gaboxadol comarket second brand mk mercks investigational oral japan lundbeck receive share japanese gaboxadol sales compound treatment diabetes yet april merck bms entered worldwide collaborative determined trademark agreement muraglitazar bmss product use treating march company acquired aton privately held patients type diabetes merck bms globally develop biotechnology company focusing development novel market muraglitazar bms submitted nda fda treatments cancer serious diseases atons clinical december muraglitazar muraglitazar potential pipeline histone deacetylase inhibitors represents class anti first novel class drugs known glitazars class dual tumor agents potential efficacy based novel mechanism alphagamma ppar agonists including muraglitazar thought action lead product candidate suberoylanilide hydroxamic control blood sugar clinical trials muraglitazar reduced blood acid saha currently phase ii clinical trials treatment glucose levels decreased triglyceride levels increased high cutaneous tcell lymphoma acquisition resulted density lipoprotein hdl cholesterol levels type diabetes million acquired research expense former shareholders patients generally welltolerated estimated aton may receive additional payments contingent upon million people united states currently suffer type regulatory filing approval sales certain aton products diabetes bms received million upfront payment chart reflects companys current research pipeline term agreement could receive million february candidates shown phase iii include additional payments based achievement certain regulatory specific products candidates shown phase ii include milestones merck bms share equally development advanced compound specific mechanism given commercialization costs muraglitazar companies co therapeutic area backup compounds regardless phase promote product physicians global basis merck development additional indications therapeutic areas receive payments based net sales levels additional line extensions formulations inline products june merck vertex entered global collaboration shown preclinical areas shown company develop commercialize vx vertexs lead aurora kinase initiated good laboratory practices studies compounds inhibitor phase clinical development treatment mechanisms distinct phase ii companys cancer aurora kinases implicated programs generally designed focus development novel medicines address large unmet medical needs merck co inc annual report research development expenses increased excluding research pipeline effects exchange inflation expenses increased p reclinical research development pharmaceutical industry inherently longterm process following data show unbroken trend yeartoyear lzheimers disease increases companys research development spending antibacterials period compounded annual growth rate research antiviral development arthritis atherosclerosis cancer cardiovascular disease diabetes glaucoma immunology insomnia osteoporosis pain respiratory disease vaccines p hase lzheimers disease c arthritis c c cancer c vx cinv c diabetes c endocrine c c c glaucoma c obesity nastech pyy osteoporosis c pain c c c parkinsons disease c psychiatric disease dov urinary incontinence c c p hase ii ids c alzheimers disease c arthritis c c equity income affiliates atherosclerosis c c equity income affiliates reflects performance companys joint cancer ctcl saha ventures partnership returns azlp increase equity diabetes c income affiliates reflects successful performance zetia hiv vaccine merckscheringplough partnership well higher partnership returns multiple sclerosis c azlp relative equity income also includes results vytorin obesity c c c launches merckscheringplough partnership pediatric vaccine decrease equity income affiliates reflected lower partnership returns azlp primarily resulting impact generic competition psychiatric disease c prilosec respiratory disease c c stroke ono p hase iii h pv related cervical cancer genital warts gardasil diabetes mk rotavirus gastroenteritis rotateq insomnia gaboxadol shingles zoster vaccine us submissions iabetes muraglitazar osteoporosis fosamax plus vitamin pediatric vaccine proquad licensed merck co inc annual report income expense net increase income expense net primarily reflects million gain sale companys percent equity stake european joint venture johnson johnson increase income expense net primarily attributable million gain sale aggrastat product rights united states lower minority interest expense resulting banyu shares acquisitions realized gains companys investment portfolios relating favorable interest rate environment earnings millions except per share amounts change change ncome continuing operations sales net income average total selected joint venture affiliate information assets earnings per common expand research base realize synergies combining share assuming dilution capabilities opportunities assets company formed continuing number joint ventures see note financial statements operations information company scheringplough corporation scheringplough entered agreements create separate companys effective income tax rate equallyowned partnerships develop market united lower tax rate states new prescription medicines cholesterolmanagement resulted change mix domestic foreign income respiratory therapeutic areas included impact vioxx withdrawal cholesterolmanagement partnership agreements expanded included impact restructuring costs wholesaler include countries world excluding japan distribution program ezetimibe first new class cholesterollowering agents august merck completed spinoff medco launched united states zetia branded ezetrol outside health solutions inc medco health income medco health united states december ezetrol launched presented separately discontinued operations countries outside united states sales totaled million million billion million million income continuing operations declined july combination product containing active ingredients compared decline income continuing zetia zocor approved united states operations percentage sales compared vytorin marketed inegy many countries outside united decline ratios states vytorin approved countries outside driven increased spending research development united states sales totaled million results well effect changes product mix reduction companys interest merckscheringplough partnership also reflects unfavorable effect withdrawal vioxx recorded equity income affiliates income partially offset increase equity income affiliates million losses million million reduction also reflects impact implementation respectively new wholesaler distribution program restructuring costs company entered agreement astra ab related position eliminations net income percentage astra develop market astra products united states average total assets company astra formed equallyowned joint venture developed marketed astras new prescription earnings per common share assuming dilution continuing medicines united states including prilosec first class operations declined compared decline medications known proton pump inhibitors slows lower relative declines earnings per common share production acid cells stomach lining assuming dilution continuing operations compared income company astra restructured joint venture continuing operations result treasury stock purchases whereby company acquired astras interest joint venture renamed kbi inc kbi contributed kbis operating assets new us limited partnership named astra pharmaceuticals lp partnership company maintains limited partner interest partnership renamed astrazeneca lp azlp became exclusive distributor products kbi retained rights merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns aggregated million million million respectively lower amount attributable reduction preferential return primarily resulting impact generic competition prilosec merck co inc annual report merck rhnepoulenc sa sanofiaventis depreciation billion billion sa combined animal health poultry genetics businesses million million respectively applied form merial limited merial fully integrated animal health locations united states company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species sales joint venture products follows millions f ipronil products avermectin products products merck pasteur mrieux connaught sanofi pasteur sa established owned joint venture market vaccines europe collaborate development combination vaccines distribution europe sales joint venture products follows millions h epatitis vaccines viral vaccines vaccines merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned joint venture expanded europe canada march merck sold equity stake european joint venture johnson johnson million recorded million gain analysis liquidity capital resources income expense net merck continue benefit mercks strong financial profile enables company fully fund royalties certain products also regained rights potential research development focus external alliances support future products switch prescription overthecounter line products maximize upcoming launches providing status europe sales joint venture products follows significant cash returns shareholders cash provided operating millions activities billion continues companys primary g astrointestinal products source funds finance capital expenditures treasury stock products purchases dividends paid stockholders december total worldwide cash investments billion includes sales european joint venture march including billion cash cash equivalents shortterm investments billion longterm investments capital expenditures selected data capital expenditures billion billion expenditures united states billion millions billion expenditures included w orking capital million production facilities million research total debt total liabilities equity development facilities million environmental projects cash provided operations total debt million administrative safety general site projects capital expenditures approved yet spent december working capital levels adequate meet billion capital expenditures estimated operating requirements company ratios total debt billion total liabilities equity cash provided operations total debt reflect strength companys operating cash flows ability company cover contractual obligations companys contractual obligations december follows payments due period millions total l oans payable current portion longterm debt longterm debt operating leases merck co inc annual report loans payable current portion longterm debt includes financial instruments market risk disclosures million notes final maturity foreign currency risk management annual basis either repurchased holders us dollar functional currency companys option remarketing agent remarketed redeemed foreign subsidiaries significant portion companys revenues company loans payable current portion longterm debt also denominated foreign currencies merck relies sustained reflects million longdated notes subject cash flows generated foreign sources support longterm repayment option holders annual basis required commitment us dollarbased research development funding obligations relating companys pension extent dollar value cash flows diminished result postretirement benefit plans expected material strengthening dollar companys ability fund research companys billion shelf registration statement dollar based strategic initiatives consistent level may filed securities exchange commission sec impaired company established revenue hedging issuance debt securities became effective february balance sheet risk management programs protect volatility company issued million threeyear notes future foreign currency cash flows changes fair value shelf time company entered interest rate caused volatility foreign exchange rates swap contract effectively converts fixedrate notes objective revenue hedging program reduce floatingrate instruments february march company potential longerterm unfavorable changes foreign exchange issued total million variablerate notes shelf decrease us dollar value future cash flows derived december companys new billion shelf registration foreign currency denominated sales primarily euro japanese statement filed sec issuance debt securities yen achieve objective company partially hedge became effective february company issued anticipated thirdparty sales expected occur additional billion tenyear notes shelf planning cycle typically three years future remaining capacity companys shelf registration statement company layer hedges time increasing portion approximately billion sales hedged gets closer expected date february company established billion year transaction probable hedged transaction occur revolving credit facility provide backup liquidity commercial portion sales hedged based assessments costbenefit paper borrowing facility general corporate purposes profiles consider natural offsetting exposures revenue company drawn funding facility exchange rate volatilities correlations cost hedging companys voluntary withdrawal vioxx instruments hedged anticipated sales specified september moodys standard poors component portfolio similarly denominated foreign currency conducted review companys longterm credit ratings upon based sales transactions responds hedged risk completion reviews companys longterm credit ratings manner merck manages anticipated transaction downgraded aa moodys aa standard exposure principally purchased local currency put options poors ratings continue allow access capital markets provide company right obligation sell foreign flexibility obtaining funds competitive terms company currencies future predetermined price us dollar continues maintain conservative financial profile total cash strengthens relative currency hedged anticipated sales investments billion exceeds sum loans payable total changes options cash flows fully offset decline longterm debt billion company also longterm credit expected future us dollar cash flows hedged foreign currency ratings remain among top rated nonfinancial sales conversely us dollar weakens options value corporations despite strong financial profile certain contingent reduces zero company benefits increase events realized discussed note could value anticipated foreign currency cash flows weaker material adverse impact companys liquidity capital us dollar would result net benefit market value resources company participate offbalance companys hedges would declined million sheet arrangements involving unconsolidated subsidiaries million respectively uniform weakening provide financing potentially expose company unrecorded us dollar december market value financial obligations determined using foreign exchange option pricing model december company redeemed variablerate holding factors except exchange rates constant merck preferred units subsidiary billion par value plus principally uses purchased local currency put options uniform accrued dividends also december company extended weakening us dollar yield largest overall potential million variablerate borrowing due loss market value options sensitivity additional five years measurement assumes change one foreign currency relative july board directors approved purchases us dollar would affect foreign currencies relative time billion merck shares us dollar although predictive nature company company purchased billion treasury shares previously believes threshold reflects reasonably possible nearterm authorized completed programs billion changes mercks major foreign currency exposures relative program total treasury stock purchased million us dollar cash flows contracts reported operating activities consolidated statement cash flows primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed merck co inc annual report exchange rates economically offset consequences point increase interest rates december changes foreign exchange amount us dollar cash flows would positively impacted net aggregate market value derived net assets merck routinely enters contracts instruments million million respectively fully offset effects exchange exposures denominated one percentage point decrease december developed country currencies primarily euro japanese yen would negatively impacted net aggregate market value exposures developing country currencies company million million respectively fair value enter forward contracts limited basis companys debt determined using pricing models reflecting one deemed economical based costbenefit analysis percentage point shifts appropriate yield curves fair value considers magnitude exposure volatility companys investments determined using combination exchange rate cost hedging instrument company pricing duration models whereas duration linear also minimize effect exchange monetary assets approximation works well modest changes yields liabilities managing operating activities net asset positions generates symmetrical result pricing models reflecting local level company also uses forward contracts hedge convexity priceyield relationship provide greater precision changes fair value certain foreign currency denominated reflect asymmetry price movements interest rate changes availablefor sale securities attributable fluctuations foreign opposite directions impact convexity pronounced currency exchange rates sensitivity analysis changes longerterm maturities low interestrate environments value us dollar foreign currency denominated derivatives investments monetary assets liabilities indicated critical accounting policies matters us dollar uniformly strengthened currency consolidated financial statements include certain amounts exposures company december income based managements best estimates judgments continuing operations taxes would declined estimates used determining items provisions sales million million respectively merck net discounts returns depreciable amortizable lives long position relative major foreign currencies recoverability inventories produced preparation product consideration forward contracts uniform strengthening launches amounts recorded contingencies environmental us dollar yield largest overall potential net loss earnings liabilities reserves pension postretirement due exchange measurement assumes change one benefit plan assumptions taxes income foreign currency relative us dollar would affect uncertainty inherent estimates actual results may differ foreign currencies relative us dollar although predictive estimates application following accounting policies nature company believes threshold reflects result accounting estimates potential reasonably possible nearterm changes mercks major foreign significant impact financial statements currency exposures relative us dollar cash flows contracts reported operating activities consolidated statement cash flows revenue recognition revenues sales products recognized title risk loss passes customer revenues domestic interest rate risk management pharmaceutical sales recognized time shipment addition revenue hedging balance sheet risk many foreign subsidiaries well vaccine sales revenues management programs company may use interest rate swap recognized time delivery recognition revenue also contracts certain investing borrowing transactions manage requires reasonable assurance collection sales proceeds net exposure interest rate changes reduce overall completion performance obligations domestically sales cost borrowing company use leveraged swaps discounts issued customers direct discounts pointof general leverage investment activities sale indirectly intermediary wholesale purchaser would put principal capital risk december known chargebacks indirectly form rebates company party four payfloating receivefixed interest rate additionally sales generally made limited right return swap contracts designated fair value hedges fixed rate notes certain conditions revenues recorded net provisions maturing respectively notional sales discounts returns established time amounts swaps match amount hedged sale fixed rate notes million million million provision aggregate indirect customer discounts covers million respectively swaps effectively convert fixed chargebacks rebates chargebacks discounts occur rate obligations floating rate instruments cash flows contracted customer purchases directly contracts reported operating activities intermediary wholesale purchaser contracted customer consolidated statement cash flows generally purchases product contracted price plus markup companys investment portfolio includes cash equivalents wholesaler wholesaler turn charges company short term investments market values back difference price initially paid significantly impacted changes interest rates market value wholesaler contract price paid wholesaler companys medium long term fixedrate investments customer provision chargebacks based expected sell modestly impacted changes us interest rates changes levels companys wholesale customers contracted medium longterm us interest rates would customers well estimated wholesaler inventory levels rebates significant impact market value companys fixedrate amounts owed based upon definitive contractual agreements borrowings generally longer maturities sensitivity legal requirements private sector public sector medicaid analysis measure potential changes market value benefit providers final dispensing product companys investments debt related swap contracts pharmacy benefit plan participant provision based change interest rates indicated one percentage expected payments driven patient usage contract performance benefit provider customers merck co inc annual report company assumes firstin firstout movement inventory inventories produced preparation product launches within supply chain purposes estimating aggregate company capitalizes inventories produced preparation indirect customer discount accrual addition company uses product launches sufficient support initial market demand historical customer segment mix adjusted known events typically capitalization inventory begin order estimate expected provision amounts accrued related product candidates phase iii clinical trials aggregate indirect customer discounts evaluated quarterly considered high probability regulatory approval basis comparison information provided wholesalers december inventories produced preparation product customers amounts accrued adjustments launches consisted three vaccine products recorded trends significant events indicate change phase iii clinical trials well new formulation existing estimated provision appropriate vaccine product company continues monitor status company continually monitors provision aggregate respective product within regulatory approval process indirect customer discounts material adjustments however company generally disclose specific timing estimates associated aggregate indirect customer discount regulatory approval company aware specific risks provision contingencies normal regulatory approval process summarized information changes aggregate indirect specific issues identified research process customer discount accrual follows relating safety efficacy manufacturing marketing labeling related inventory would generally capitalized significant issues respect products expiry dates b alance january inventory impacted stage completion current provision company manages levels inventory stage optimize adjustments relating prior years shelf life inventory relation anticipated market demand payments order avoid product expiry issues shelf lives b alance december products range minimum years anticipated future sales products support realization inventory value accruals chargebacks reflected direct reduction inventory shelf life sufficient meet initial product launch accounts receivable accruals rebates accrued expenses requirements accrued balances relative provisions included addition company produced inventory preparation accounts receivable accrued current liabilities launch arcoxia united states arcoxia million million respectively december launched countries europe latin america asia million million respectively october company received approvable letter december fda companys nda arcoxia fda informed company maintains returns policy allows customers company letter approval nda issued return product within specified period prior subsequent additional safety efficacy data arcoxia required expiration date generally six months twelve months addition merck working regulatory agencies countries product expiration estimate provision returns arcoxia approved assess whether changes based upon historical experience actual returns additionally prescribing information coxib class drugs including company considers factors levels inventory arcoxia warranted minimum shelf life arcoxia distribution channel product dating expiration period whether approximately years anticipated worldwide market demand products discontinued entrance market countries arcoxia approved supports value additional generic competition changes formularies launch inventory capitalized buildup inventory arcoxia overthecounter products name product returns inventories produced preparation product launches provision well actual returns approximately net material effect companys liquidity sales distribution program us wholesalers contingencies environmental liabilities implemented company incents wholesalers align company involved various claims legal proceedings purchases underlying demand maintain inventories within nature considered normal business including product liability specified levels terms program allow wholesalers intellectual property commercial litigation well additional earn fees upon providing visibility inventory levels well matters antitrust actions see note financial achieving certain performance parameters inventory statements information company records accruals management customer service levels reducing shortage claims contingencies probable liability incurred reducing product returns information provided amount reasonably estimated accruals wholesaler distribution program includes items sales trends adjusted periodically assessments change additional inventory onhand onorder quantity product returns information becomes available product liability claims portion wholesalers generally provide mentioned data overall accrual actuarially determined considers company regulatory requirement report lot level factors past experience number claims reported estimates information manufacturers level information claims incurred yet reported individually significant needed determine remaining shelf life original sale date contingent losses accrued probable reasonably inventory given current wholesaler inventory levels estimable generally less month company believes collection legal defense costs expected incurred connection order lot information across wholesale customers would loss contingency accrued probable reasonably limited use estimating sales discounts returns estimable december companys reserve solely future legal defense costs related vioxx litigation million reserve based certain assumptions minimum amount company believes time reasonably estimate spent multiyear period company merck co inc annual report significantly increased reserve solely future legal defense pensions postretirement benefit plans costs vioxx ability reasonably estimate net pension postretirement benefit cost totaled future legal defense costs vioxx litigation million million pension significant factors considered establishment postretirement benefit plan information financial reporting reserve vioxx litigation follows actual costs purposes calculated using actuarial assumptions including incurred company time development discount rate plan benefit obligations expected rate companys legal defense strategy structure light return plan assets expanded scope vioxx litigation number cases company reassesses benefit plan assumptions brought company anticipated timing regular basis pension postretirement benefit progression related costs pretrial activities trials plans discount rate evaluated annually modified reflect vioxx product liability lawsuits company continue prevailing market rate december portfolio high monitor legal defense costs review adequacy quality fixedincome debt instruments would provide future associated reserves company established reserves cash flows needed pay benefits included benefit potential liability relating vioxx litigation obligation come due december company company party number proceedings brought changed discount rate us comprehensive environmental response compensation pension postretirement benefit plans respectively liability act comonly known superfund legitimate expected rate return pension claim contribution asserted liability initially accrued based postretirement benefit plans represents average rate return upon estimated transaction costs manage site accruals earned plan assets period benefits included adjusted feasibility studies related cost assessments benefit obligation paid developing expected rate remedial techniques completed extent return company considers longterm compound annualized potentially responsible parties prps may jointly returns historical market data well actual returns severally liable expected contribute determined companys plan assets applies adjustments reflect company also remediating environmental contamination recent capital market experience using reference information resulting past industrial activity certain sites takes company develops forwardlooking return expectations active role identifying providing costs asset category weighted average expected longterm rate worldwide survey initially performed assess sites return targeted portfolio allocated across investment potential contamination resulting past industrial activities categories expected portfolio performance reflects assessment indicated physical investigation warranted contribution active management appropriate result investigation performed providing better evaluation analysis companys expected rate return need remedial action need identified remained unchanged us pension remedial action initiated estimates extent postretirement benefit plans contamination site initially made preinvestigation target investment portfolio companys us pension stage liabilities potential cost remediation accrued postretirement benefit plans allocated time definitive information became available us equities international equities course investigations andor remedial efforts site fixedincome investments real estate estimates refined accruals adjusted accordingly cash investments portfolios equity weighting estimates related accruals continue refined consistent longterm nature plans benefit obligation annually expected annual standard deviation returns target company believes compliance material portfolio approximates reflects equity allocation respects applicable environmental laws regulations diversification benefits among asset classes expenditures remediation environmental liabilities portfolio invests million estimated million years actuarial assumptions based upon managements best managements opinion liabilities estimates judgment reasonably possible change plus environmental matters probable reasonably estimable minus basis points discount rate assumption accrued totaled million million assumptions held constant would estimated million december december respectively favorable unfavorable impact net pension postretirement liabilities undiscounted consider potential recoveries benefit cost reasonably possible change plus minus basis insurers parties paid periods points expected rate return assumption remediation applicable sites expected occur assumptions held constant would estimated million primarily next years although possible predict favorable unfavorable impact net pension postretirement certainty outcome matters ultimate costs benefit cost company expect minimum remediation management believe reasonably pension funding requirement internal revenue code possible expenditures may incurred excess liabilities preceding hypothetical changes discount rate accrued exceed million aggregate management expected rate return assumptions would impact also believe expenditures result companys funding requirements material adverse effect companys financial position results operations liquidity capital resources year merck co inc annual report unrecognized net loss amounts reflect experience differentials december foreign earnings billion primarily relating differences expected actual returns domestic earnings million retained indefinitely plan assets well effects changes actuarial subsidiary companies reinvestment provision made assumptions expected returns based calculated market income taxes would payable upon distribution related value assets methodology asset gainslosses earnings october american jobs creation act resulting actual returns differ companys expected ajca signed law ajca creates temporary returns recognized marketrelated value assets ratably incentive us multinationals repatriate accumulated income fiveyear period total unrecognized net loss amounts earned outside united states december excess certain thresholds amortized net pension december financial accounting standards board postretirement benefit cost average remaining service life fasb issued fasb staff position accounting disclosure employees amortization total unrecognized net losses guidance foreign earnings repatriation provision within companys us plans december expected increase american jobs creation act fsp fsp net pension postretirement benefit cost approximately allows companies additional time evaluate effect law million annually december company provided deferred taxes foreign earnings earnings intended indefinitely reinvested outside united states taxes income whether company ultimately take advantage companys effective tax rate based pretax income temporary incentive depends number factors including statutory tax rates tax planning opportunities available analyzing us internal revenue service guidance decision various jurisdictions company operates event made company expects position finalize significant unusual onetime item recognized decisions regarding temporary incentive expected recognized companys operating results time company make change current intention tax attributable item would separately calculated indefinitely reinvest accumulated earnings foreign subsidiaries recorded time unusual onetime item becomes apparent company repatriate significant judgment required determining companys earnings amount billion onetime tax effective tax rate evaluating tax positions company charge companys results operations approximately establishes reserves despite belief tax return billion could occur ultimate tax charge dependent positions fully supportable certain positions likely number factors currently consideration including challenged may succeed see note financial passage pending legislation contains certain technical statements information company adjusts corrections ajca company changed intention reserves light changing facts circumstances indefinitely reinvest accumulated earnings earned subsequent closing tax audit effective tax rate includes impact december provision made income taxes reserve provisions changes reserves considered would payable upon distribution earnings appropriate well related interest rate applied practicable determine amount related unrecognized companys quarterly operating results deferred income tax liability tax regulations require items included tax return different times items reflected financial statements result effective tax rate reflected financial recently issued accounting standards statements different reported tax return november fasb issued statement inventory differences permanent expenses costsan amendment arb chapter fas deductible tax return timing differences effective beginning january fas requires abnormal depreciation expense timing differences create deferred tax amounts idle facility expense freight handling costs wasted assets liabilities deferred tax assets generally represent items material recognized current period charges statement used tax deduction credit tax return also requires allocation fixed production overhead future years company already recorded tax based normal capacity production facilities effect benefit financial statements company establishes statement companys financial position results valuation allowances deferred tax assets amount operations yet determined expected future taxable income likely support use december fasb issued statement r share deduction credit deferred tax liabilities generally represent tax based payment fas r effective beginning july expense recognized financial statements payment fas r requires sharebased payments employees deferred expense company already expensed requisite service period based grant taken deduction tax return yet recognized date fair value awards statement allows either expense financial statements prospective retrospective adoption requires unvested portion outstanding awards upon adoption recognized using fair value attribution methodologies previously determined statement accounting stockbased compensation company currently evaluating transition alternatives valuation methodologies future grants result pro forma compensation expense reflected note may indicative future expense recognized fas r effect adoption fas r companys financial position results operations yet determined merck co inc annual report cautionary factors may affect future results condensed interim financial data annual report written reports oral statements millions except made time time company may contain socalled per share amounts th q rd q nd q st q forwardlooking statements subject risks uncertainties one identify forwardlooking statements ales use words expects plans estimates materials production costs forecasts projects words similar meaning one marketing administrative also identify fact relate strictly expenses historical current facts statements likely address research development expenses companys growth strategy financial results product approvals equity income affiliates development programs one must carefully consider income expense net statement understand many factors could cause income continuing actual results differ companys forwardlooking operations taxes statements factors include inaccurate assumptions net income broad variety risks uncertainties including basic earnings per common known forwardlooking statement share guaranteed actual future results may vary materially earnings per common share assuming dilution company assume obligation update forwardlooking statement one carefully evaluate statements light factors described companys filings ales materials production costs securities exchange commission especially forms k marketing administrative q k item companys annual report form expenses k year ended december filed research development march company discusses detail various important expenses factors could cause actual results differ expected equity income affiliates historic results company notes factors investors income expense net permitted private securities litigation reform act income continuing prior filing year ended december operations taxes income continuing reference made item companys annual operations report year ended december one income discontinued understand possible predict identify operations net taxes factors consequently reader consider list net income complete statement potential risks uncertainties basic earnings per common share continuing operations discontinued operations cash dividends paid per common share net income year th q rd q nd q st q earnings per common share assuming dilution continuing operations discontinued operations net income common stock market prices amounts include impact implementation new th q rd q nd q st q distribution program us wholesalers restructuring costs related h igh position eliminations amounts include impact withdrawal vioxx see note low amount add result rounding h igh low principal market trading common stock new york stock exchange nyse symbol mrk common stock market price information based historical nyse market prices adjusted reflect spinoff medco health holders merck common stock close business august received shares medco health common stock every one share merck common stock held date august merck common stock began trade postdistribution basis merck co inc annual report consolidated statement income merck co inc subsidiaries years ended december millions except per share amounts ales c osts expenses materials production marketing administrative research development equity income affiliates income expense net ncome continuing operations taxes taxes income ncome continuing operations income discontinued operations net taxes n et income b asic earnings per common share continuing operations discontinued operations net income e arnings per common share assuming dilution continuing operations discontinued operations net income amount add result rounding consolidated statement retained earnings merck co inc subsidiaries years ended december millions b alance january n et income common stock dividends declared spinoff medco health b alance december consolidated statement comprehensive income merck co inc subsidiaries years ended december millions n et income ther comprehensive loss income net unrealized loss derivatives net tax net income realization net unrealized loss gain investments net tax net income realization minimum pension liability net tax cumulative translation adjustment relating equity investees net tax c omprehensive income accompanying notes integral part consolidated financial statements consolidated balance sheet merck co inc subsidiaries december millions ssets current assets cash cash equivalents shortterm investments accounts receivable inventories prepaid expenses taxes otal current assets nvestments p roperty plant equipment cost land buildings machinery equipment office furnishings construction progress less allowance depreciation g oodwill ther intangibles net ther assets l iabilities stockholders equity current liabilities loans payable current portion longterm debt trade accounts payable accrued current liabilities income taxes payable dividends payable otal current liabilities l ongterm debt eferred income taxes noncurrent liabilities inority interests tockholders equity common stock one cent par value authorized shares issued shares paidin capital retained earnings accumulated comprehensive loss income less treasury stock cost shares shares otal stockholders equity accompanying notes integral part consolidated financial statement consolidated statement cash flows merck co inc subsidiaries years ended december millions c ash flows operating activities continuing operations net income less income discontinued operations net taxes ncome continuing operations adjustments reconcile income continuing operations net cash provided operating activities continuing operations depreciation amortization deferred income taxes net changes assets liabilities accounts receivable inventories trade accounts payable accrued current liabilities income taxes payable noncurrent liabilities n et cash provided operating activities continuing operations c ash flows investing activities continuing operations capital expenditures purchase securities subsidiaries investments proceeds sale securities subsidiaries investments acquisitions banyu shares n et cash used investing activities continuing operations c ash flows financing activities continuing operations net change shortterm borrowings proceeds issuance debt payments debt redemption preferred units subsidiary purchase treasury stock dividends paid stockholders proceeds exercise stock options n et cash used financing activities continuing operations e ffect exchange rate changes cash cash equivalents iscontinued operations net cash provided medco health dividend received medco health net intercompany settlements cash transferred n et cash provided discontinued operations n et increase decrease cash cash equivalents cash cash equivalents beginning year c ash cash equivalents end year accompanying notes integral part consolidated financial statement notes consolidated financial statements merck co inc subsidiaries millions except per share amounts nature operations merck global researchdriven pharmaceutical company discovers develops manufactures markets broad range innovative products improve human animal health directly joint ventures companys products include therapeutic preventive agents generally sold prescription treatment human disorders summary accounting policies principles consolidation consolidated financial statements include accounts company subsidiaries controlling interest maintained controlling interest determined majority ownership interest absence substantive thirdparty participating rights case variable interest entities majority exposure expected losses residual returns consolidated subsidiaries merck ownership less outside stockholders interests shown minority interests investments affiliates company significant influence controlling interest interests entities owned equally company third party shared control carried equity basis foreign currency translation us dollar functional currency companys foreign subsidiaries cash cash equivalents cash equivalents comprised certain highly liquid investments original maturities less three months inventories substantially domestic pharmaceutical inventories valued lower lastin firstout lifo cost market book tax purposes foreign pharmaceutical inventories valued lower firstin firstout fifo cost market inventories consist currently marketed products certain products awaiting regulatory approval evaluating recoverability inventories produced preparation product launches company considers probability revenue obtained future sale related inventory together status product within regulatory approval process investments investments classified availableforsale reported fair value unrealized gains losses extent hedged reported net tax minority interests accumulated comprehensive income investments debt securities classified heldto maturity consistent managements intent reported cost impairment losses charged income expense net thantemporary declines fair value company considers available evidence evaluating potential impairment investments including duration extent fair value less cost companys ability intent hold investment revenue recognition revenues sales products recognized title risk loss passes customer revenues domestic pharmaceutical sales recognized time shipment many foreign subsidiaries well vaccine sales revenues recognized time delivery recognition revenue also requires reasonable assurance collection sales proceeds completion performance obligations domestically sales discounts issued customers direct discounts pointofsale indirectly intermediary wholesale purchaser known chargebacks indirectly form rebates additionally sales generally made limited right return certain conditions revenues recorded net provisions sales discounts returns established time sale accruals chargebacks reflected direct reduction accounts receivable accruals rebates accrued expenses accrued balances relative provisions included accounts receivable accrued current liabilities million million respectively december million million respectively december depreciation depreciation provided estimated useful lives assets principally using straightline method tax purposes accelerated methods used estimated useful lives primarily range years buildings years machinery equipment office furnishings goodwill intangibles goodwill represents excess acquisition costs fair value net assets businesses purchased goodwill amortized rather assigned reporting units within companys segments evaluated impairment least annual basis using fair value based test acquired intangibles recorded cost amortized straightline basis estimated useful lives see note events circumstances warrant review company assess recoverability future operations intangibles using undiscounted cash flows derived lowest appropriate asset groupings generally subsidiary level impairments recognized operating results extent carrying value exceeds fair value determined based net present value estimated future cash flows research development research development expensed incurred upfront milestone payments made third parties connection research development collaborations prior regulatory approval expensed incurred payments made third parties subsequent regulatory approval capitalized amortized shorter remaining license product patent life stockbased compensation employee stockbased compensation recognized using intrinsic value method generally employee stock options granted purchase shares company stock fair market value time grant accordingly compensation expense recognized companys stockbased compensation plans performancebased awards restricted stock units options granted employees certain equity method investees effect net income earnings per common share company applied fair value method recognizing employee stock based compensation follows years ended december n et income reported compensation expense net tax reported fair value method p ro forma net income e arnings per common share continuing operations assuming dilution reported assuming dilution pro forma earnings per common share basic reported basic pro forma assuming dilution reported assuming dilution pro forma prior pro forma compensation expense options graded vesting terms calculated using blackscholes model based singleoption valuation approach using straightline method amortization company revised assumptions utilized blackscholes model determining pro forma compensation expense based historical data expense determined using separate expected term assumptions vesting tranche result pro forma compensation expense stock options granted since january calculated using accelerated amortization method prescribed financial accounting standards board fasb interpretation accounting stock appreciation rights variable stock option award plans connection medco health solutions inc medco health spinoff options granted medco health employees prior february options granted february became fully vested accordance original terms grants result pro forma compensation expense reflects accelerated vesting options addition certain stock options granted medco health employees converted medco health options terms amounts maintained option holders positions therefore pro forma compensation expense options reflected date spinoff average fair value employee nonemployee director options granted respectively fair value estimated using blackscholes optionpricing model based weighted average market price grant date following weighted average assumptions years ended december ividend yield riskfree interest rate volatility expected life years legal defense costs legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable use estimates consolidated financial statements prepared conformity accounting principles generally accepted united states gaap accordingly include certain amounts based managements best estimates judgments estimates used determining items provisions sales discounts returns depreciable amortizable lives recoverability inventories produced preparation product launches amounts recorded contingencies environmental liabilities reserves pension postretirement benefit plan assumptions taxes income uncertainty inherent estimates actual results may differ estimates reclassifications certain reclassifications made prior year amounts conform current year presentation voluntary product withdrawal september company announced voluntary worldwide withdrawal vioxx arthritis acute pain medication companys decision effective immediately based new threeyear data prospective randomized placebocontrolled clinical trial approve adenomatous polyp prevention vioxx connection withdrawal company recorded unfavorable adjustment net income million per share adjustment pretax income million amount million related estimated customer returns product previously sold recorded reduction sales million related writeoffs inventory held company recorded materials production expense million related estimated costs undertake withdrawal product recorded marketing administrative expense tax benefit adjustment million reflects geographical mix vioxx returns cost withdrawal adjustment include charges future legal defense costs see note december million remaining accrued balance reported accrued current liabilities million reported reduction accounts receivable restructuring october company announced plans eliminate positions part costreduction initiative completed end december company eliminated positions company identified additional opportunities eliminate positions reduce costs additional eliminations came contractor positions company recorded restructuring costs million million marketing administrative expense amounts respectively million million related employee severance benefits million million related curtailment settlement termination charges companys pension postretirement benefit plans see note million million related modification terms certain employees stock option grants summarized information relative employee severance benefits accrual follows b alance january expense payments b alance december december accrued balance primarily relates committed employee severance benefits obligations accordance certain local laws paid time strategic initiatives november merck ono pharmaceutical co ltd ono announced signed agreement granting merck worldwide license ono r propyloctanoic acid novel intravenous compound currently phase ii development treatment acute stroke terms agreement ono received initial upfront payment term agreement could receive milestone payments addition royalties net sales addition ono received exclusive rights japan develop market emend aprepitant mercks drug use combination antiemetic agents prevention acute delayed nausea vomiting associated initial repeat courses highly emetogenic cancer chemotherapy including cisplatin ono also received rights japan comarket second brand mk mercks investigational oral compound treatment diabetes yet determined trademark april merck bristolmyers squibb company bms entered worldwide collaborative agreement muraglitazar bmss product use treating patients type diabetes merck bms globally develop market muraglitazar bms submitted new drug application nda food drug administration fda december muraglitazar terms agreement bms received million upfront payment term agreement could receive million additional payments based upon achievement certain regulatory milestones company recorded upfront payment research development expense companies share equally future development commercialization costs march company acquired aton pharma inc aton privately held biotechnology company focusing development novel treatments cancer serious diseases atons clinical pipeline histone deacetylase inhibitors represents class antitumor agents potential efficacy based novel mechanism action atons lead product candidate suberoylanilide hydroxamic acid known saha extensively studied treatment cutaneous tcell lymphoma consideration acquisition consisted upfront payment may include contingent payments based upon regulatory filing approval sale products connection transaction company recorded charge million acquired research associated products development acquisition date technological feasibility established alternative future use existed charge recorded research development expense determined based upon present value projected future cash flows utilizing income approach reflecting appropriate riskadjusted discount rate based product candidates stage completion probability technical marketing success remaining net assets acquired transaction material aton development stage company commenced planned principal operations transaction accounted acquisition assets rather business combination therefore goodwill recorded atons results operations included companys since acquisition date february merck h lundbeck lundbeck entered agreement exclusive us development commercialization gaboxadol compound treatment sleep disorders terms agreement lundbeck received initial payment million term agreement could receive million additional milestone payments inthe future company recorded upfront payment research development expense merck fund majority remaining development activities june merck lundbeck extended agreement exclusive development commercialization gaboxadol japan company wholly owned subsidiary msd japan co ltd launched tender offers acquire remaining common shares banyu pharmaceutical co ltd banyu already aggregate purchase price approximately billion substantially shares acquired march merck completed acquisition banyu full ownership banyu strengthens mercks position japan worlds secondlargest pharmaceutical market companys acquisitions banyu shares accounted purchase method pro forma information provided impact transactions material effect companys consolidated results operations aggregate purchase price allocated based upon fair values portion assets liabilities acquired allocation aggregate purchase price resulted reversal billion minority interest liability recognition million intangibles million goodwill million deferred income tax liabilities million net assets principally property plant equipment intangibles included million inline product rights year weighted average useful life million representing year life tradename connection transactions company also incurred charge million acquired research recorded research development expense associated products development acquisition date technological feasibility established alternative future use existed approximately million total acquired research charge related merck products banyu developing sale japanese market products merck could choose exclusively license rights banyu event generally would reimburse banyu associated research development expenditures accordingly products valued using cost approach adjusted reflect probability regulatory approval remaining portion acquired research charge represented banyudeveloped product candidates fair value product determined based upon present value projected future cash flows utilizing income approach reflecting appropriate riskadjusted discount rate based applicable products stage completion probability technical marketing success august merck completed spinoff medco health income medco health presented separately discontinued operations spinoff effected way pro rata dividend merck stockholders holders merck common stock close business august received dividend shares medco health common stock every one share merck common stock held date fractional shares medco health common stock issued shareholders entitled fractional share medco health common stock distribution received cash value instead based letter ruling merck received us internal revenue service irs receipt medco health shares distribution taxfree us federal income tax purposes cash received lieu fractional shares taxable prior spinoff merck received billion dividend medco health merck paid million settlement net intercompany payable medco health addition date spinoff million cash cash equivalents included net assets medco health spun summarized financial information discontinued operations follows years ended december otal net revenues income taxes taxes income income net taxes includes operations august following summary assets liabilities discontinued operations spun august ssets c ash cash equivalents current assets property plant equipment net goodwill intangibles net assets l iabilities c urrent liabilities longterm debt deferred income taxes n et assets transferred financial instruments foreign currency risk managementwhile us dollar functional currency companys foreign subsidiaries significant portion companys revenues denominated foreign currencies merck relies sustained cash flows generated foreign sources support longterm commitment us dollarbased research development extent dollar value cash flows diminished result strengthening dollar companys ability fund research dollarbased strategic initiatives consistent level may impaired company established revenue hedging balance sheet risk management programs protect volatility future foreign currency cash flows changes fair value caused volatility foreign exchange rates objective revenue hedging program reduce potential longerterm unfavorable changes foreign exchange decrease us dollar value future cash flows derived foreign currency denominated sales primarily euro japanese yen achieve objective company partially hedge anticipated thirdparty sales expected occur planning cycle typically three years future company layer hedges time increasing portion sales hedged gets closer expected date transaction probable hedged transaction occur portion sales hedged based assessments costbenefit profiles consider natural offsetting exposures revenue exchange rate volatilities correlations cost hedging instruments hedged anticipated sales specified component portfolio similarly denominated foreign currencybased sales transactions responds hedged risk manner merck manages anticipated transaction exposure principally purchased local currency put options provide company right obligation sell foreign currencies future predetermined price us dollar strengthens relative currency hedged anticipated sales total changes options cash flows fully offset decline expected future us dollar cash flows hedged foreign currency sales conversely us dollar weakens options value reduces zero company benefits increase value anticipated foreign currency cash flows designated hedge relationship based total changes options cash flows accordingly entire fair value change options deferred accumulated comprehensive income aoci reclassified sales hedged anticipated revenue recognized hedge relationship perfectly effective therefore hedge ineffectiveness recorded fair values currency options reported accounts receivable assets primary objective balance sheet risk management program protect us dollar value foreign currency denominated net monetary assets effects volatility foreign exchange might occur prior conversion us dollars merck principally utilizes forward exchange contracts enable company buy sell foreign currencies future fixed exchange rates economically offset consequences changes foreign exchange amount us dollar cash flows derived net assets merck routinely enters contracts fully offset effects exchange exposures denominated developed country currencies primarily euro japanese yen exposures developing country currencies company enter forward contracts limited basis deemed economical based costbenefit analysis considers magnitude exposure volatility exchange rate cost hedging instrument company also minimize effect exchange monetary assets liabilities managing operating activities net asset positions local level foreign currency denominated monetary assets liabilities remeasured spot rates effect balance sheet date effects changes spot rates reported income expense net forward contracts designated hedges marked market income expense net accordingly fair value changes forward contracts help mitigate changes value remeasured assets liabilities attributable changes foreign currency exchange rates except extent spotforward differences differences significant due shortterm nature contracts typically average maturities inception less one year company also uses forward contracts hedge changes fair value certain foreign currency denominated availableforsale securities attributable fluctuations foreign currency exchange rates changes fair value hedged securities due fluctuations spot rates offset income expense net fair value changes forward contracts attributable spot rate fluctuations hedge ineffectiveness material changes contracts fair value due spotforward differences excluded designated hedge relationship recognized income expense net amounts significant years ended december fair values forward exchange contracts reported following four balance sheet line items accounts receivable current portion gain position assets noncurrent portion gain position accrued current liabilities current portion loss position deferred income taxes noncurrent liabilities noncurrent portion loss position interest rate risk management company may use interest rate swap contracts certain investing borrowing transactions manage net exposure interest rate changes reduce overall cost borrowing company use leveraged swaps general leverage investment activities would put principal capital risk december company party four payfloating receivefixed interest rate swap contracts designated fair value hedges fixedrate notes maturing respectively notional amounts swaps match amount hedged fixedrate notes million million million million respectively swaps effectively convert fixedrate obligations floatingrate instruments fair value changes notes fully offset interest expense fair value changes swap contracts july sevenyear combined interest rate currency swap contract company party matured immaterial impact contract used convert foreign currency denominated investment us dollar investment interest rate component swap designated hedge currency swap component designated hedge changes fair value investment attributable exchange accordingly changes fair value investment due fluctuations spot rates offset income expense net fair value changes currency swap hedge ineffectiveness significant fair values contracts reported accounts receivable assets accrued current liabilities deferred income taxes noncurrent liabilities fair value financial instruments summarized carrying values fair values companys financial instruments december fair values estimated based market prices available dealer quotes carrying fair carrying fairvalue value value value ssets c ash cash equivalents shortterm investments longterm investments purchased currency options forward exchange contracts interest rate swaps l iabilities l oans payable current portion longterm debt longterm debt written currency options forward exchange contracts currency swap summary carrying values fair values companys investments december follows carrying fair carrying fair value value value value vailableforsale debt securities equity securities heldtomaturity securities summary december gross unrealized gains losses companys availableforsale investments recorded net tax minority interests aoci follows gross unrealized gross unrealized gains losses gains losses ebt securities equity securities availableforsale debt securities heldtomaturity securities maturing within one year totaled billion million respectively december remaining debt securities billion mature within five years concentrations credit risk part ongoing control procedures company monitors concentrations credit risk associated corporate issuers securities financial institutions conducts business credit risk minimal credit exposure limits established avoid concentration single issuer institution four us customers represented aggregate approximately onefourth companys accounts receivable december company monitors creditworthiness customers grants credit terms normal course business bad debts minimal company normally require collateral security support credit sales inventories inventories december consisted f inished goods raw materials work process supplies otal approximates current cost reduction lifo cost r ecognized inventories assets inventories valued lifo method comprised approximately inventories december respectively amounts recognized assets comprised entirely raw materials work process inventories include vaccine inventories produced preparation product launches inventories products principally vaccines arcoxia expected sold within one year intangibles intangibles december consisted p atents product rights otal acquired cost p atents product rights otal accumulated amortization aggregate amortization expense substantially recorded materials production expense million million million estimated aggregate amortization expense next five years follows million million million million million joint ventures equity method affiliates company scheringplough corporation scheringplough entered agreements create separate equallyowned partnerships develop market united states new prescription medicines cholesterolmanagement respiratory therapeutic areas cholesterolmanagement partnership agreements expanded include countries world excluding japan ezetimibe first new class cholesterollowering agents launched united states zetia branded ezetrol outside united states december ezetrol launched countries outside united states sales totaled billion million million july combination product containing active ingredients zetia zocor approved united states vytorin marketed inegy many countries outside united states vytorin approved countries outside united states sales totaled million results companys interest merckscheringplough partnership recorded equity income affiliates income million losses million million respectively mercks respiratory partnership scheringplough reported results phase iii clinical trials fixed combination tablet containing singulair claritin scheringploughs nonsedating antihistamine demonstrate sufficient added benefits treatment seasonal allergic rhinitis merck entered agreement astra ab astra develop market astras products royaltybearing license companys total sales astra products reached level triggered first step establishment joint venture business carried astra merck inc ami merck astra owned share joint venture formed developed marketed astras new prescription medicines united states including prilosec first class medications known proton pump inhibitors slows production acid cells stomach lining merck astra completed restructuring ownership operations joint venture whereby company acquired astras interest ami renamed kbi inc kbi contributed kbis operating assets new us limited partnership astra pharmaceuticals lp partnership exchange limited partner interest astra contributed net assets wholly owned subsidiary astra usa inc partnership exchange general partner interest partnership renamed astrazeneca lp azlp upon astras merger zeneca group plc astrazeneca merger became exclusive distributor products kbi retained rights maintaining limited partner interest azlp merck consent protective rights intended preserve business economic interests including restrictions power general partner make certain distributions dispositions furthermore limited events default additional rights granted company including powers direct actions remove replace partnerships chief executive officer chief financial officer merck earns ongoing revenue based sales current future kbi products revenue billion billion billion respectively primarily relating sales nexium prilosec addition merck earns certain partnership returns recorded equity income affiliates returns include priority return provided partnership agreement variable returns based part upon sales certain former astra usa inc products preferential return representing mercks share undistributed azlp gaap earnings returns aggregated million million million respectively decrease attributable reduction preferential return primarily resulting impact generic competition prilosec astrazeneca merger triggers partial redemption mercks limited partnership interest upon redemption azlp distribute kbi amount based primarily multiple mercks average annual variable returns derived sales former astra usa inc products three years prior redemption limited partner share agreed value conjunction restructuring payment million deferred astra purchased option asset option buy mercks interest kbi products excluding gastrointestinal medicines nexium prilosec asset option exercisable exercise price equal net present value march projected future pretax revenue received company kbi products appraised value merck also right require astra purchase interest appraised value addition company granted astra option buy mercks common stock interest kbi exercise price based net present value estimated future net sales nexium prilosec option exercisable two years astras purchase mercks interest kbi products astrazeneca merger constituted trigger event kbi restructuring agreements result merger exchange mercks relinquishment rights future astra products existing pending us patents time merger astra paid million advance payment subject trueup calculation may require repayment portion amount trueup amount directly dependent fair market value astra product rights retained company accordingly recognition contingent income deferred realizable amount determinable anticipated prior provisions kbi restructuring agreements trigger event occurred sum limited partner share agreed value appraised value trueup amount guaranteed minimum billion distribution limited partner share agreed value payment trueup amount occur astrazenecas purchase mercks interest kbi products contingent upon exercise either mercks option astrazenecas option therefore payment appraised value may may occur merck rhnepoulenc sa sanofiaventis sa combined animal health poultry genetics businesses form merial limited merial fully integrated animal health company standalone joint venture equally owned party merial provides comprehensive range pharmaceuticals vaccines enhance health wellbeing performance wide range animal species merial sales billion billion billion merck pasteur mrieux connaught sanofi pasteur sa established equallyowned joint venture market vaccines europe collaborate development combination vaccines distribution europe joint venture vaccine sales million million million merck formed joint venture johnson johnson develop market broad range nonprescription medicines us consumers owned venture expanded europe canada march merck sold equitystake european joint venture johnson johnson million recorded million gain income expense net see note merck continue benefit royalties certain products also regained rights potential future products switch prescription overthecounter status europe sales product marketed joint venture including sales european joint venture march million million million investments affiliates accounted using equity method including joint ventures totaled billion december billion december amounts reported assets dividends distributions received affiliates million million million summarized information affiliates follows years ended december ales materials production costs expense net income taxes december c urrent assets noncurrent assets current liabilities noncurrent liabilities loans payable longterm debt commitments loans payable december included million million respectively commercial paper borrowings million million respectively longdated notes subject repayment option holders annual basis million notes annual interest rate resets final maturity annual basis notes either repurchased holders option remarketing agent remarketed redeemed company december loans payable also included billion fixedrate notes due december loans payable also included million variablerate borrowing due december variablerate borrowing extended additional five years weighted average interest rate borrowings december respectively longterm debt december consisted astra note due notes due notes due debentures due debentures due notes due variablerate borrowing due debentures due notes due euronotes due company party interest rate swap contracts effectively convert fixedrate notes floatingrate instruments see note december consisted primarily million million respectively borrowings variable rates averaging respectively borrowings million subject repayment option holders beginning million subject repayment option holders beginning years also included foreign borrowings varying rates aggregate maturities longterm debt next five years follows billion million million billion million rental expense companys operating leases net sublease income million minimum aggregate rental commitments noncancellable leases follows million million million million million thereafter million company significant capital leases contingencies environmental liabilities company involved various claims legal proceedings nature considered normal business including product liability intellectual property commercial litigation well additional matters antitrust actions company records accruals contingencies probable liability incurred amount reasonably estimated accruals adjustedperiodically assessments change additional information becomes available product liability claims portion overall accrual actuarially determined considers factors past experience number claims reported estimates claims incurred yet reported individually significant contingent losses accrued probable reasonably estimable legal defense costs expected incurred connection loss contingency accrued probable reasonably estimable companys decision obtain insurance coverage dependent market conditions including cost availability existing time decisions made result number factors product liability insurance become less available cost increased significantly company evaluated risks determined cost obtaining product liability insurance outweighs likely benefits coverage available insurance certain product liabilities effective august including liability products first sold date company continue evaluate insurance needs costs availability benefits product liability insurance future vioxx litigation product liability lawsuits previously disclosed federal state product liability lawsuits involving individual claims well several putative class actions filed company respect vioxx january company served aware named defendant approximately lawsuits include approximately plaintiff groups alleging personal injuries resulting use vioxx certain lawsuits include allegations regarding gastrointestinal bleeding cardiovascular events thrombotic events kidney damage company also named defendant approximately putative class actions alleging personal injuries seeking medical monitoring result putative class members use vioxx ii disgorgement certain profits common law unjust enrichment theories andor iii various remedies state consumer fraud fair business practice statutes including recovering cost vioxx purchased individuals thirdparty payors union health plans actions discussed paragraph collectively referred vioxx product liability lawsuits actions filed state courts california new jersey respectively transferred single judge state coordinated proceedings addition company filed motion judicial panel multidistrict litigation jpml seeking transfer single federal judge coordinate pretrial purposes federal cases alleging personal injury andor economic loss relating purchase use vioxx several plaintiffs certain vioxx product liability lawsuits pending federal court made similar requests february jpml granted motions transfer vioxx product liability lawsuits pending federal courts nationwide one multidistrict litigation mdl coordinated pretrial proceedings mdl transferred united states district court eastern district louisiana district judge eldon e fallon shareholder lawsuits previously disclosed addition vioxx product liability lawsuits number purported class action lawsuits filed late early several shareholders united states district court eastern district louisiana naming defendants company several current former officers directors company cases consolidated announcement withdrawal vioxx company named defendant additional purported securities class action lawsuits filed federal courts new jersey pennsylvania louisiana actions allege defendants made false misleading statements regarding vioxx violation sections b securities exchange act including respect withdrawal vioxx seek unspecified compensatory damages costs suit including attorneys fees plaintiffs request certification class purchasers company stock various periods may october addition two shareholders filed individual securities action united states district court central district illinois seeking compensatory damages costs certain complaints include allegations sections securities act certain officers directors made incomplete misleading statements registration statement certain prospectuses filed connection merck stock investment plan dividend reinvestment plan actions discussed paragraph collectively referred vioxx securities lawsuits several plaintiffs dismissed complaints without prejudice january total vioxx securities lawsuits pending various federal courts previously disclosed march two shareholder derivative actions filed united states district court eastern district louisiana naming company nominal defendant certain members board past present together certain executive officers defendants complaints arise substantially factual allegations made vioxx securities lawsuits derivative suits purportedly brought assert rights company assert claims board members officers breach fiduciary duty waste corporate assets unjust enrichment abuse control gross mismanagement withdrawal vioxx additional shareholder derivative actions filed new jersey superior court hunterdon county united states district court district new jersey company certain officers members board past present actions discussed paragraph collectively referred vioxx derivative lawsuits two vioxx derivative lawsuits include allegations certain directors made false misleading statements connection certain proxy statements filed sec violation section securities act january total seven vioxx derivative lawsuits pending october two individual shareholders made demand board take legal action mr raymond gilmartin chairman president chief executive officer individuals allegedly causing damage company respect allegedly improper marketing vioxx response demand letter board directors determined november meeting board would take shareholders request consideration remains consideration addition shareholder actions since announcement withdrawal vioxx putative class actions filed company united states district court eastern district louisiana united states district court district new jersey vioxx erisa lawsuits together vioxx securities lawsuits vioxx derivative lawsuits vioxx shareholder lawsuits behalf certain companys current former employees participants certain companys retirement plans asserting claims employee retirement income security act erisa lawsuits make similar allegations allegations contained vioxx securities lawsuits january total eleven vioxx erisa lawsuits pending october plaintiff one vioxx erisa lawsuits filed motion jpml transfer single federal judge coordinate pretrial purposes vioxx erisa lawsuits november company responded motion filed motion seeking coordination vioxx shareholder lawsuits hearing motions held january international lawsuitsin addition lawsuits discussed company named defendant actions various countries europe australia canada brazil israel related vioxx additional lawsuits based media reports sources company anticipates additional vioxx product liability lawsuits vioxx shareholder lawsuits collectively vioxx lawsuits filed andor certain current former officers directors future insurance company product liability insurance claims brought vioxx product liability lawsuits approximately million deductibles coinsurance insurance provides coverage legal defense costs potential damage amounts incurred connection vioxx product liability lawsuits company believes insurance coverage extends additional vioxx product liability lawsuits may filed future certain companys insurers reserved rights take contrary position respect certain coverage could disputes insurers coverage matters company currently believes least approximately million directors officers insurance coverage vioxx securities lawsuits vioxx derivative lawsuits least approximately million insurance coverage vioxx erisa lawsuits additional insurance coverage claims may also available upper level excess policies provide coverage variety risks may disputes insurers availability insurance coverage time company believes reasonably possible insurance coverage respect vioxx lawsuits adequate cover defense costs losses investigations november company advised staff securities exchange commission sec commencing informal inquiry concerning vioxx january company announced received notice sec issued formal notice investigation also company received subpoena us department justice requesting information related companys research marketing selling activities respect vioxx federal health care investigation criminal statutes also ongoing investigations certain congressional committees also district attorneys office munich germany notified companys subsidiary germany received complaints commenced investigation order determine whether criminal charges brought germany concerning vioxx together previously mentioned investigations vioxx investigations company cooperate vioxx investigations company predict outcome inquiries however could result potential civil disposition sec andor potential civil criminal dispositions justice department reserves company currently anticipates one vioxx product liability lawsuits may go trial first half company predict timing trials respect vioxx shareholder lawsuits company believes meritorious defenses vioxx lawsuits vigorously defend view inherent difficulty predicting outcome litigation particularly many claimants claimants seek indeterminate damages company unable predict outcome matters time reasonably estimate possible loss range loss respect vioxx lawsuits company established reserves potential liability relating vioxx lawsuits vioxx investigations collectively vioxx litigation company established reserve million solely future legal defense costs related vioxx litigation reserve based certain assumptions minimum amount company believes time reasonably estimate spent multiyear period company significantly increased reserve ability reasonably estimate future legal defense costs vioxx litigation significant factors considered establishment reserve vioxx litigation follows actual costs incurred company time development companys legal defense strategy structure light expanded scope vioxx litigation number cases brought company anticipated timing progression related costs pretrial activities trials vioxx product liability lawsuits company continue monitor legal defense costs review adequacy associated reserves unfavorable outcomes vioxx lawsuits resulting vioxx investigations could material adverse effect companys financial position liquidity results operations commercial litigation beginning company named number antitrust suits certain certified class actions instituted nations retail pharmacies consumers several states actions except pending state courts consolidated pretrial purposes federal court chicago illinois company several defendants settled federal class action represented single largest group claims since time company settled substantially remaining cases satisfactory terms remaining cases inactive several years company engaged conspiracy admission wrongdoing made included settlement agreements previously disclosed company joined ongoing litigation alleging manipulation pharmaceutical manufacturers average wholesale prices awp sometimes used calculations determine public private sector reimbursement levels judicial panel multidistrict litigation ordered transfer consolidation pending federal awp cases federal court boston massachusetts plaintiffs filed one consolidated class action complaint aggregated claims previously filed various federal district court actions also expanded number manufacturers include like company defendants prior pending case may court granted companys motion dismiss consolidated class action dismissed company class action case subsequent companys dismissal plaintiffs filed amended consolidated class action complaint name company defendant company thirty pharmaceutical manufacturers remain defendants six similar complaints pending federal court massachusetts filed new york counties suffolk rockland nassau westchester onondaga new york city three cases pending kentucky alabama wisconsin company defendants filed argued motion dismiss suffolk case awaiting courts final decision motion addition company defendant cases brought behalf citizens kentucky wisconsin alleging fraudulent practices regarding awp company vigorously defend previously disclosed company named defendant antitrust cases federal court minnesota state court california alleging unlawful conspiracy among different sets pharmaceutical manufacturers protect high prices united states impeding importation united states lowerpriced pharmaceuticals canada company defendants filed motion dismiss action previously disclosed suit federal court alabama two providers health services needy patients alleges pharmaceutical companies overcharged plaintiffs class similarly situated pharmaceuticals purchased plaintiffs program established section b public health service act company defendants filed motion dismiss complaint numerous grounds previously disclosed january us department justice notified federal court new orleans louisiana going intervene time pending federal false claims act case filed seal december company court issued order unsealing complaint filed physician louisiana ordered complaint served complaint alleged companys discounting pepcid certain louisiana hospitals led increases costs medicaid dismissed amended complaint filed seal case administratively closed court seal lifted allegations contained amended complaint unknown governmental proceedings previously disclosed company received subpoena us department justice connection investigation companys marketing selling activities company also reported received civil investigative demand attorney general texas regarding companys marketing selling activities relating texas april company received subpoena office inspector general district columbia connection investigation companys interactions physicians district columbia maryland virginia november company received letter request department justice connection investigation companys pricing pepcid company cooperating investigations company predict outcome investigations however possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations addition time time federal state regulators may seek information practices pharmaceutical industry inquiries investigations discussed paragraph feasible predict outcome inquiries vaccine litigation company party claims brought consumer protection act united kingdom allege certain children suffer variety conditions result vaccinated various bivalent vaccines measles rubella andor trivalent vaccines measles mumps rubella including companys mmr ii conditions include autism without inflammatory bowel disease epilepsy diabetes encephalitis encephalopathy deafness chronic fatigue syndrome transverse myelitis early september legal services commission lsc announced decision withdraw public funding litigation brought claimants decision confirmed appeal funding review committee frc september claimants application judicial review decision withdraw public funding dismissed february april trial date vacated lead claimants decided apply court appeal permission appeal decision result legal aid lead claimants discharged nonlead claimants subject show cause procedure withdraw legal aid unless claimants could show cause withdrawn frc heard show cause appeals nonlead claimants october appeals involving autism unsuccessful funding reinstated appeals involving nonautism conditions epilepsy deafness encephalitis transverse myelitis light successful appeals lsc reconsidered cases claimants date funding reinstated additional nonlead nonautism cases limited extent necessary allow solicitors provide report individual cases lsc yet known many appeals involve claimants suing company claimants conditions february give notice intention continue discontinue claims irrespective whether secured legal aid funding directions conduct litigation made case management hearing scheduled take place march company vigorously defend lawsuits previously disclosed company also party individual class action product liability lawsuits claims united states involving pediatric vaccines ie hepatitis b vaccine haemophilus influenza type b vaccine contained thimerosal preservative used vaccines merck distributed thimerosalcontaining pediatric vaccines united states since fall december approximately active thimerosal related lawsuits approximately plaintiffs defendants include vaccine manufacturers produced pediatric vaccines containing thimerosal well manufacturers thimerosal actions plaintiffs allege among things suffered neurological injuries result exposure thimerosal pediatric vaccines two state court cases two federal district court cases scheduled trial company vigorously defend lawsuitshowever possible unfavorable outcomes could material adverse effect companys financial position liquidity results operations company successful cases type either dismissed stayed ground action prohibited national vaccine injury compensation program nvicp nvicp prohibits person filing maintaining civil action state federal court seeking damages vaccine manufacturer vaccinerelated injuries unless petition first filed united states court federal claims hereinafter vaccine court nvicp filing civil action vaccine manufacturer petitioner must either pursue petition conclusion vaccine court timely file election proceed civil action lieu accepting vaccine courts adjudication petition b timely exercise right withdraw petition prior vaccine court adjudication accordance certain statutorily prescribed time periods company aware numerous cases pending vaccine court involving allegations thimerosalcontaining vaccines andor mmr ii vaccine cause autism spectrum disorders company party vaccine court proceedings petitions brought department health human services patent litigation time time generic manufacturers pharmaceutical products file abbreviated new drug applications andas fda seeking market generic forms companys products prior expiration relevant patents owned company generic pharmaceutical manufacturers submitted andas fda seeking market united states generic form fosamax prilosec propecia prior expiration companys astrazenecas case prilosec patents concerning products generic companies andas generally include allegations noninfringement invalidity unenforceability patents generic manufacturers received fda approval market generic form prilosec company filed patent infringement suits federal court companies filing andas generic alendronate finasteride astrazeneca company filed patent infringement suits federal court companies filing andas generic omeprazole similar patent challenges exist certain foreign jurisdictions company intends vigorously defend patents believes valid infringement generic companies attempting market products prior expiration dates patents litigation assurance outcomes adverse could result significantly shortened periods exclusivity products trial united states respect alendronate daily product concluded november november decision issued us district court delaware finding companys patent valid infringed october us court appeals federal circuit affirmed validity infringement companys basic us patent covering use alendronate form request rehearing denied trial united states involving alendronate weekly product held march august us district court delaware upheld validity companys us patent covering weekly administration alendronate however january us court appeals federal circuit washington dc found companys patent claims onceweekly administration fosamax invalid based court appeals decision fosamax lose market exclusivity united states february company expects decline us fosamax sales time prior decision mercks patent onceweekly administration fosamax set expire july merck disagrees decision court appeals request reconsideration court appeals january high court justice england wales held patents company protecting alendronate daily weekly products invalid united kingdom november court appeals england wales affirmed ruling high court justice england wales european countries permit companies seeking approval generic product reference data innovative product certain circumstances data exclusivity regulations company granted leave appeal decision uk regulatory authority data weekly alendronate may referenced companies seeking approval generic weekly alendronate products company also filed appeal grant swedish regulatory authority approval generic weekly alendronate products referenced companys data weekly alendronate approval previously announced company july opposition division opposition division european patent office epo rendered oral decision revoke companys patent europe covers weekly administration alendronate august written opinion issued confirming oral decision revoking companys patent september company filed appeal decision based patents alendronate weekly product protected major european markets least october action australia challenging validity companys australian patent weekly administration alendronate patent found invalid company appealed decision addition japan proceeding filed challenging validity companys japanese patent weekly administration alendronate case omeprazole trial court united states rendered opinion october upholding validity companys astrazenecas patents covering stabilized formulation omeprazole ruling one defendants omeprazole product infringe patents three defendants products found infringe formulation patents december us court appeals federal circuit affirmed decision trial court respect certain generic manufacturers omeprazole products trial date yet set case finasteride anda filed seeking approval generic version propecia alleging invalidity companys patents company filed patent infringement lawsuit district court delaware september trial notanticipated litigation previously disclosed july united states district court district new jersey granted motion company medco health solutions inc medco health certain officers directors dismiss purported class action complaint involving claims related companys revenue recognition practice retail copayments paid individuals medco health provides pharmaceutical benefits well allegations complaint dismissed prejudice august court granted companys motion dismiss prejudice related shareholder derivative action plaintiffs actions appealed decisions prior spinoff medco health company medco health agreed settle class action basis series lawsuits asserting violations erisa gruer cases company medco health certain plaintiffs counsel filed settlement agreement federal district court new york cases commenced number plaintiffs including participants number pharmaceutical benefit plans medco health pharmacy benefit manager well trustees plans consolidated proposed class settlement agreed plaintiffs five cases filed medco health company proposed settlement company medco health agreed pay total million medco health agreed modify certain business practices continue certain specified business practices period five years financial compensation intended benefit members settlement class includes erisa plans medco health administered pharmacy benefit time since december district court preliminarily approved settlement held hearings hear objections fairness proposed settlement district court approved settlement yet determined number class member plans properly elected participate settlement settlement becomes final appeals resolved three notices appeal filed appellate court expected hear arguments regarding appeals march decide appeals thereafter currently certain class member plans indicated participate settlement cases initiated three plans two individuals remain pending southern district new york plaintiffs cases asserted claims based erisa well federal state laws similar claims asserted settling class members gruer cases company medco health named defendants cases medco health company agreed proposed settlement order avoid significant cost distraction prolonged litigation spinoff medco health medco health assumed substantially liability exposure matters discussed foregoing paragraph cases defended medco health various legal proceedings principally product liability intellectual property suits involving company pending feasible predict outcome proceedings proceedings discussed note opinion company proceedings either adequately covered insurance covered ultimately result liability would material adverse effect financial position liquidity results operations company proceedings separate assessment provided note environmental matters company party number proceedings brought comprehensive environmental response compensation liability act commonly known superfund legitimate claim contribution asserted liability initially accrued based upon estimated transaction costs manage site accruals adjusted feasibility studies related cost assessments remedial techniques completed extent potentially responsible parties prps may jointly severally liable expected contribute determined company also remediating environmental contamination resulting past industrial activity certain sites takes active role identifying providing costs worldwide survey initially performed assess sites potential contamination resulting past industrial activities assessment indicated physical investigation warranted investigation performed providing better evaluation need remedial action need identified remedial action initiated estimates extent contamination site initially made preinvestigation stage liabilities potential cost remediation accrued time definitive information became available course investigations andor remedial efforts site estimates refined accruals adjusted accordingly estimates related accruals continue refined annually managements opinion liabilities environmental matters probable reasonably estimable accrued totaled million million december respectively liabilities undiscounted consider potential recoveries insurers parties paid periods remediation applicable sites expected occur primarily next years although possible predict certainty outcome matters ultimate costs remediation management believe reasonably possible expenditures may incurred excess liabilities accrued exceed million aggregate management also believe expenditures result material adverse effect companys financial position results operations liquidity capital resources year preferred stock subsidiary companies december company redeemed variablerate preferred units subsidiary billion par value plus accrued dividends preferred securities held subsidiary level previously included minority interests consolidated financial statements connection restructuring ami see note company assumed billion par value preferred stock obligation dividend rate per annum carried kbi included minority interests small portion preferred stock carried kbi convertible kbi common shares none preferred securities convertible companys common shares therefore included common shares issuable purposes computing earnings per common share assuming dilution see note stockholders equityother paidin capital decreased million increased million million respectively changes primarily reflect impact shares issued upon exercise stock options related income tax benefits summary treasury stock transactions shares millions follows shares cost shares cost shares cost b alance jan purchases issuances b alance dec issued primarily stock option plans december million shares preferred stock without par value authorized none issued stockbased compensation plans company stockbased compensation plans employees nonemployee directors employees certain companys equity method investees may granted options purchase shares company common stock fair market value time grant plans approved companys shareholders option grants beginning generally vest ratably three years grants prior generally vest five years options expire ten years date grant subject terms applicable awards part ongoing compensation review company made certain changes stockbased compensation plans new approach company began granting performance share units psus restricted stock units rsus addition stock options certain management level employees financial value individual stockbased incentive grants new approach designed equivalent prior approach mix stockbased compensation awards changed psu rsu payouts shares company stock end threeyear period subject terms applicable awards additionally psu payouts contingent companys performance preset objective set objectives company granted psus weightedaverage grant date fair value rsus weightedaverage grant date fair value connection medco health spinoff number exercise prices outstanding options proportionately adjusted maintain option holders positions spinoff result adjustment number outstanding options increased million average exercise price decreased approximately addition certain stock options granted medco health employees converted medco health options terms amounts maintained option holders positions summarized information relative companys stock option plans options thousands follows number average options price utstanding december granted exercised forfeited utstanding december granted exercised forfeited converted medco health spinoff adjustment utstanding december granted exercised forfeited utstanding december weighted average exercise price includes million options converted medco health options number options average price options exercisable december million options million options million options respectively december million shares million shares respectively available future grants terms companys stockbased compensation plans summarized information stock options outstanding exercisable december options thousands follows exercise outstanding exercisable price number average average number average range options life price options price u nder weighted average contractual life remaining years weighted average exercise price pension postretirement benefit plans company defined benefit pension plans covering eligible employees united states certain international subsidiaries pension benefits united states based formula considers final average pay years credited service addition company provides medical dental life insurance benefits principally eligible us retirees similar benefits dependents postretirement benefit plans company uses december measurement date substantially pension plans postretirement benefit plans accordance fasb staff position accounting disclosure requirements related medicare prescription drug improvement modernization act act company began accounting effect federal subsidy act reduced benefit obligation certain postretirement benefit plans million service cost interest cost net amortization components net postretirement benefit cost reduced million million million respectively company recognizing subsidy accordance current accounting requirements continue evaluate act regulations follow determine optimal approach incorporating impact act company changed participant contributions service recognized eligibility postretirement benefit plans amendments generated curtailment gains million million million company recorded settlement loss million pension plans curtailment loss million postretirement benefit plans resulting reductions employment levels primarily connection restructuring activities company also recorded termination charges million million respectively pension plans million million respectively postretirement benefit plans related expanded eligibility certain employees exiting primarily restructuring action see note addition company recorded settlement loss million certain domestic pension plans resulting employees electing receive pension benefits lump sum payments net cost companys pension plans consisted following components years ended december ervice cost interest cost expected return plan assets net amortization settlements termination benefits n et pension cost net pension cost attributable us plans included table million million million net cost postretirement benefits pensions consisted following components years ended december ervice cost interest cost expected return plan assets net amortization curtailments termination benefits n et postretirement benefit cost cost health care life insurance benefits active employees million million million summarized information changes plan assets benefit obligation follows postretirement pension benefits benefits f air value plan assets january actual return plan assets company contributions benefits paid plan assets discontinued operations f air value plan assets december b enefit obligation january subsidy act service cost interest cost actuarial losses benefits paid plan amendments curtailments termination benefits discontinued operations b enefit obligation december fair value us pension plan assets included preceding table billion billion pension benefit obligation us plans included table billion billion reconciliation plans funded status net asset liability recognized december follows postretirement pension benefits benefits p lan assets less benefit obligation unrecognized net loss unrecognized plan changes n et asset liability r ecognized assets accrued current liabilities deferred income taxes noncurrent liabilities accumulated comprehensive loss weighted average asset allocations investment portfolio pension postretirement benefit plans december follows postretirement pension benefits benefits u equities international equities fixed income investments real estate cash investments target investment portfolios companys pension plans determined country based nature liabilities considering demographic composition plan participants average age years service active versus retiree status accordance local regulations weighted average target allocation us equities international equities fixed income investments real estate investments cash investments include insurance contracts certain international pension plans target investment portfolio companys postretirement benefit plans allocated us equities international equities fixedincome investments cash investments portfolios asset allocation consistent longterm nature plans benefit obligation well diversified among asset classes portfolio invests contributions pension plans postretirement benefit plans expected million million respectively expected benefit payments follows postretirement pension benefits benefits expected benefit payments based assumptions used measure benefit obligations include estimated future employee service expected receipts subsidy act reflected expected postretirement benefit payments included preceding table follows million million million million millionat december accumulated benefit obligation billion billion respectively pension plans billion billion respectively us pension plans company minimum pension liability million million december respectively representing extent accumulated benefit obligation exceeded plan assets certain companys pension plans pension plans benefit obligations excess plan assets december fair value plan assets billion billion respectively benefit obligation billion billion respectively plans accumulated benefit obligations excess plan assets december fair value plan assets million million respectively accumulated benefit obligation million million respectively unrecognized net loss amounts reflect experience differentials primarily relating differences expected actual returns plan assets well effects changes actuarial assumptions unrecognized net loss amounts excess certain thresholds amortized net pension postretirement benefit cost average remaining service life employees amortization unrecognized net losses companys us plans december expected increase net pension postretirement benefit cost approximately million annually company reassesses benefit plan assumptions regular basis weighted average assumptions used determining pension plan information follows december n et cost iscount rate expected rate return plan assets salary growth rate b enefit obligation iscount rate salary growth rate assumptions used determining us pension plan postretirement benefit plan information follows december n et cost iscount rate expected rate return plan assets salary growth rate b enefit obligation iscount rate salary growth rate used postretirement benefit plans expected rate return pension postretirement benefit plans represents average rate return earned plan assets period benefits included benefit obligation paid determined country basis developing expected rate return within country longterm historical returns data considered well actual returns plan assets capital markets experience using reference information longterm return expectations asset category weighted average expected return countrys target portfolio developed according allocation among investment categories expected portfolio performance reflects contribution active management appropriate companys expected rate return remain unchanged us pension postretirement benefit plans health care cost trend rate assumptions postretirement benefit plans follows december h ealth care cost trend rate assumed next year rate cost trend rate assumed decline year rate reached ultimate trend rate one percentage point change health care cost trend rate would following effects one percentage point increase decrease e ffect total service interest cost components effect benefit obligation income expense net years ended december nterest income interest expense exchange gains minority interests net minority interests include third parties share exchange gains losses arising translation financial statements us dollars reduced minority interests attributable effect banyu shares acquisitions see note net reflects million gain sale companys percent equity stake european joint venture johnson johnson increase net primarily reflects million gain sale aggrastat product rights united states realized gains companys investment portfolios relating favorable interest rate environmentinterest paid million million million taxes income reconciliation companys effective tax rate us statutory rate follows tax rate amount u statutory rate applied income continuing operations taxes differential arising foreign earnings tax exemption puerto rico operations state taxes domestic companies contributed approximately consolidated income continuing operations taxes taxes income continuing operations consisted years ended december c urrent provision federal foreign state eferred provision federal foreign state deferred income taxes december consisted assets liabilities assets liabilities ther intangibles inventory related accelerated depreciation advance payment equity investments pensions opeb compensation related vioxx legal cost reserve net operating losses ubtotal valuation allowance otal deferred taxes n et deferred tax liabilities r ecognized prepaid expenses taxes assets income taxes payable deferred income taxes noncurrent liabilities income taxes paid billion billion billion respectively stock option exercises reduced income taxes paid million million million respectively december foreign earnings billion domestic earnings million retained indefinitely subsidiary companies reinvestment provision made income taxes would payable upon distribution earnings earnings include income manufacturing operations ireland taxexempt taxed thereafter addition company subsidiaries operating puerto rico singapore tax incentive grants expire respectively october american jobs creation act ajca signed law ajca creates temporary incentive us multinationals repatriate accumulated income earned outside united states december december fasb issued fasb staff position accounting disclosure guidance foreign earnings repatriation provision within american jobs creation act fsp fsp allows companies additional time evaluate effect law december company provided deferred taxes foreign earnings earnings intended indefinitely reinvested outside united states whether company ultimately take advantage temporary incentive depends number factors including analyzing irs guidance decision made company expects position finalize decisions regarding temporary incentive time company make change current intention indefinitely reinvest accumulated earnings foreign subsidiaries becomes apparent company repatriate earnings amount billion onetime tax charge companys consolidated results operations approximately billion could occur ultimate tax charge dependent number factors currently consideration including passage pending legislation contains certain technical corrections ajca company changed intention indefinitelyreinvest accumulated earnings earned subsequent december provision made income taxes would payable upon distribution earnings practicable determine amount related unrecognized deferred income tax liability companys federal income tax returns audited previously disclosed irs substantially completed examination companys tax returns years april issued preliminary notice deficiency respect partnership transaction entered specifically irs proposing disallow certain royalty expenses claimed deductions tax returns company company anticipates receiving similar notice shortly irs ultimately prevails positions companys income tax due years would increase approximately million plus interest approximately million irs likely make similar claims years subsequent future audits respect transaction potential disallowance later years computed similar basis disallowances would approximately million plus interest approximately million irs proposed penalties company respect periods examined company anticipates irs would seek impose penalties periods company vigorously disagrees proposed adjustments intends aggressively contest matter applicable irs judicial procedures appropriate although final resolution proposed adjustments uncertain involves unsettled areas law based currently available information company provided best estimate probable tax liability matter resolution issue may result tax liabilities significantly higher lower reserves established matter management currently believes resolution material effect companys financial position liquidity however unfavorable resolution could material effect companys results operations cash flows quarter adjustment recorded tax due paid earnings per share weighted average common shares used computations basic earnings per common share earnings per common share assuming dilution shares millions follows years ended december verage common shares outstanding common shares issuable verage common shares outstanding assuming dilution issuable primarily stockbased compensation plans million million million common shares issuable companys stockbased compensation plans excluded computation earnings per common share assuming dilution effect would antidilutive comprehensive income components comprehensive loss income follows pretax tax tax ear ended december n et unrealized loss derivatives net loss realization erivatives n et unrealized gain investments net income realization nvestments inimum pension liability c umulative translation adjustment relating equity investees ear ended december n et unrealized loss derivatives net loss realization erivatives n et unrealized gain investments net income realization nvestments inimum pension liability ear ended december n et unrealized loss derivatives net income realization erivatives n et unrealized gain investments net income realization nvestments inimum pension liability net applicable minority interest components accumulated comprehensive loss income follows december n et unrealized loss derivatives net unrealized gain investments minimum pension liability cumulative translation adjustment relating equity investees december million net unrealized loss derivatives associated options maturing next months hedge anticipated foreign currency denominated sales period segment reporting companys operations principally managed products basis merck pharmaceutical segment includes products marketed either directly joint ventures products consist therapeutic preventive agents sold prescription treatment human disorders merck sells human health products primarily drug wholesalers retailers hospitals government agencies managed health care providers health maintenance organizations institutions includes nonreportable human animal health segments revenues profits segments follows merck pharm aceutical total ear ended december egment revenues segment profits included segment profits equity income affiliates depreciation amortization ear ended december egment revenues segment profits included segment profits equity income affiliates depreciation amortization ear ended december egment revenues segment profits included segment profits equity income affiliates depreciation amortization segment profits comprised segment revenues less certain elements materials production costs operating expenses including components equity income loss affiliates depreciation amortization expenses internal management reporting presented chief operating decision maker company allocate vast majority indirect production costs research development expenses general administrative expenses well cost financing activities separate divisions maintain responsibility monitoring managing costs including depreciation related fixed assets utilized divisions therefore included segment profits reconciliation total segment revenues consolidated sales follows years ended december egment revenues revenues revenues primarily comprised miscellaneous corporate revenues sales related divested products businesses supply sales sales category companys products follows therosclerosis hypertensionheart failure osteoporosis respiratory antiinflammatoryanalgesics antibacterialantifungal vaccinesbiologicals urology ophthalmologicals human immunodeficiency virus hiv presented net discounts returns includes vioxx voluntarily withdrawn worldwide september primarily includes sales human pharmaceuticals pharmaceutical animal health supply sales companys joint ventures revenue companys relationship azlp primarily relating sales nexium prilosec revenue azlp billion billion billion respectively consolidated revenues geographic area derived follows years ended december u nited states europe middle east africa japan reconciliation total segment profits consolidated income continuing operations taxes follows years ended december egment profits profits adjustments unallocated interest income interest expense equity income loss affiliates depreciation amortization research development expenses net profits primarily comprised miscellaneous corporate profits well operating profits related divested products businesses supply sales adjustments represent elimination effect double counting certain items income expense equity income loss affiliates includes taxes paid joint venture level portion equity income reported segment profits expenses net include expenses corporate manufacturing cost centers miscellaneous income expense net property plant equipment net geographic area located follows december u nited states europe middle east africa japan company disaggregate assets products services basis internal management reporting therefore information presented managements report managements responsibility financial statements managements report internal control financial reporting responsibility integrity objectivity companys management responsible establishing maintaining financial statements rests management financial adequate internal control financial reporting term statements report managements stewardship company defined exchange act rule af management conducted assets statements prepared conformity generally evaluation effectiveness internal control financial accepted accounting principles accordingly include amounts reporting based framework internal controlintegrated based managements best estimates judgments framework issued committee sponsoring organizations nonfinancial information included annual report also treadway commission coso based evaluation prepared management consistent financial management concluded internal control financial reporting statements effective december based criteria internal assure financial information reliable assets controlintegrated framework issued coso managements safeguarded management maintains effective system internal assessment effectiveness internal control financial controls procedures important elements include reporting december audited careful selection training development operating financial pricewaterhousecoopers llp independent registered public managers organization provides appropriate division accounting firm pricewaterhousecoopers llp issued responsibility communications aimed assuring company attestation report managements assessment effectiveness policies procedures understood throughout organization companys internal control financial reporting staff internal auditors regularly monitors adequacy included herein application internal controls worldwide basis ensure personnel continue understand system internal controls procedures policies concerning good prudent business practices company periodically conducts managements stewardship program key management financial personnel program reinforces importance raymond v gilmartin judy c lewent understanding internal controls reviewing key corporate chairman president executive vice president policies procedures systems addition company chief executive officer chief financial officer compliance programs including ethical business practices president human health asia program reinforce companys longstanding commitment high ethical standards conduct business financial statements financial information included annual report fairly present material respects companys financial condition results operations cash flows formal certification securities exchange commission included companys filing audit committees report audit committee comprised independent directors met discussed independent auditors judgments regarding independent registered public accounting firm independent quality acceptability companys accounting principles auditors management internal auditors assure clarity disclosures degree aggressiveness carrying respective responsibilities audit committee conservatism accounting principles underlying estimates discussed received letter independent auditors audit committee reviewed discussed audited financial confirming independence independent auditors statements management recommended board internal auditors full access committee including directors financial statements included regular meetings without management present companys filing securities exchange audit committee met independent auditors commission discuss fees scope results audit work including adequacy internal controls quality financial peter c wendell thomas e shenk reporting committee also chairperson samuel thier wendell p weeks merck co inc annual report report independent registered public accounting firm stockholders based criteria established internal controlintegrated board directors merck co inc framework issued coso companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal completed integrated audit merck co incs control financial reporting responsibility express consolidated financial statements internal control opinions managements assessment effectiveness financial reporting december audits companys internal control financial reporting based consolidated financial statements accordance audit conducted audit internal control financial standards public company accounting oversight board reporting accordance standards public company united states opinions based audits presented accounting oversight board united states standards require plan perform audit obtain reasonable assurance whether effective internal control financial consolidated financial statements reporting maintained material respects audit internal opinion accompanying consolidated balance sheets control financial reporting includes obtaining understanding related consolidated statements income retained earnings internal control financial reporting evaluating managements comprehensive income cash flows present fairly assessment testing evaluating design operating material respects financial position merck co inc effectiveness internal control performing subsidiaries company december procedures consider necessary circumstances results operations cash flows believe audit provides reasonable basis opinions three years period ended december conformity companys internal control financial reporting process accounting principles generally accepted united states designed provide reasonable assurance regarding reliability america financial statements responsibility financial reporting preparation financial statements companys management responsibility express opinion external purposes accordance generally accepted accounting financial statements based audits conducted principles companys internal control financial reporting audits statements accordance standards includes policies procedures pertain public company accounting oversight board united states maintenance records reasonable detail accurately standards require plan perform audit obtain fairly reflect transactions dispositions assets reasonable assurance whether financial statements company ii provide reasonable assurance transactions free material misstatement audit financial statements recorded necessary permit preparation financial statements includes examining test basis evidence supporting accordance generally accepted accounting principles amounts disclosures financial statements assessing receipts expenditures company made accounting principles used significant estimates made accordance authorizations management directors management evaluating overall financial statement company iii provide reasonable assurance regarding presentation believe audits provide reasonable basis prevention timely detection unauthorized acquisition use opinion disposition companys assets could material effect financial statements internal control financial reporting inherent limitations internal control financial also opinion managements assessment included reporting may prevent detect misstatements also projections accompanying managements report internal control evaluation effectiveness future periods subject financial reporting company maintained effective internal risk controls may become inadequate changes control financial reporting december based conditions degree compliance policies criteria established internal controlintegrated framework issued procedures may deteriorate committee sponsoring organizations treadway commission coso fairly stated material respects based criteria furthermore opinion company maintained material respects effective internal control financial reporting december florham park new jersey pricewaterhousecoopers llp february compensation benefits committees report compensation benefits committee comprised longterm focus inherent companys rdbased independent directors approves compensation objectives pharmaceutical business policy committee make policies employees sets compensation companys high proportion executive officer compensation dependent long executive officers committee seeks ensure rewards term performance enhancing stockholder value closely linked company division team individual performances committee also seeks ensure lawrence bossidy william g bowen compensation benefits set levels enable merck chairperson johnnetta b cole attract retain highly qualified employees committee views william n kelley stock ownership vehicle align interests employees companys stockholders consistent merck co inc annual report selected financial data merck co inc subsidiaries millions except per share amounts r esults year sales materials production costs marketing administrative expenses research development expenses equity income affiliates income expense net income continuing operations taxes taxes income income continuing operations income discontinued operations net taxes net income basic earnings per common share continuing operations discontinued operations net income earnings per common share assuming dilution continuing operations discontinued operations net income cash dividends declared cash dividends paid per common share capital expenditures depreciation earend position working capital property plant equipment net total assets longterm debt stockholders equity f inancial ratios income continuing operations sales net income average total assets earend statistics average common shares outstanding millions average common shares outstanding assuming dilution millions number stockholders record number employees amounts include impact withdrawal vioxx amounts include impact implementation new distribution program us wholesalers restructuring costs related position eliminations amount add result rounding decrease primarily reflects impact spinoff medco health merck co inc annual report exhibit merck co inc subsidiaries following list subsidiaries company business name stated country state name incorporation algonquin sarl luxembourg amrad pharmaceuticals pty ltd australia aton pharma inc delaware banyu pharmaceutical company ltd japan banyuasc co ltd japan blue jay investments cv netherlands brc ltd bermuda british united turkeys limited great britain france sarl france charles e frosst new zealand ltd new zealand charles e frosst uk limited great britain chibret denmark chibret pharmazeutische gmbh germany chippewa holdings llc delaware cloverleaf international holdings sa luxembourg cm delaware llc delaware comsort inc delaware coophavet sas france coordinated patient care scandinavia norway crosswinds bv netherlands dieckmann arzneimittel gmbh germany european insurance risk excess limited ireland farmacoxcompanhia farmaceutica lda portugal farmasixprodutos farmaceuticos lda portugal financiere msd sas france fontelaborprodutos farmaceuticos lda portugal fregenal holdings sa panama frosst iberica sa spain frosst laboratories inc delaware frosst portuguesa produtos farmaceuticos lda portugal hangzhou msd pharmaceutical company limited china hawk falcon llc delaware hubbard nederland bv netherlands infodoc norway international indemnity ltd bermuda istituto di richerche di biologia molecolare spa italy istituto gentili spainc italydelaware johnson johnson merck consumer pharmaceuticals company new jersey kbi inc delaware kbi sub inc delaware kbie inc delaware kbip inc delaware kiinteisto oy viistotie finland laboratoires merck sharp dohmechibret snc france laboratorios abello sa spain laboratorios biopat sa spain laboratorios chibret sa spain laboratorios frosst sa spain laboratorios neurogard sa spain laboratorios quimicofarmaceuticos chibret lda portugal maple leaf holdings srl barbados mcm vaccine co pennsylvania medco de mexico managed care de rl de cv mexico medco holdings de rl de cv mexico medco managed care sl spain medco servicios de mexico de rl de cv mexico merck company incorporated delaware merck borinquen holdings inc delaware merck capital resources inc delaware merck capital ventures llc delaware merck cardiovascular health company nevada merck enterprises canada ltd canada merck finance co inc delaware merck foreign sales corporation ltd bermuda merck frosst canada co canada merck frosst canada ltd canada merck hamilton inc california merck holdings ii corp delaware merck holdings inc delaware merck institute vaccinology delaware merck investment co inc delaware merck liability management company delaware merck lmc cash management bermuda ltd bermuda merck lmc cash management inc delaware merck oncology holdings inc delaware merck resource management inc delaware merck respiratory health company nevada merck sh inc delaware merck sharp dohme france merck sharp dohme lebanon sal lebanon merck sharp dohme argentina inc delaware merck sharp dohme asia limited hong kong merck sharp dohme australia pty limited australia merck sharp dohme china limited hong kong merck sharp dohme enterprises bv netherlands merck sharp dohme europe inc delaware merck sharp dohme holdings bv netherlands merck sharp dohme holdings limited great britain merck sharp dohme ia corp delaware merck sharp dohme international limited bermuda merck sharp dohme investments bv netherlands merck sharp dohme ireland ltd bermuda merck sharp dohme israel company ltd israel merck sharp dohme italia spa italy merck sharp dohme middle east limited cyprus merck sharp dohme new zealand limited new zealand merck sharp dohme panama sa panama merck sharp dohme philippines inc philippines merck sharp dohme puerto rico ltd bermuda merck sharp dohme singapore ltd bermuda merck sharp dohme sweden ab sweden merck sharp dohme asia pacific services pte ltd singapore merck sharp dohme bv netherlands merck sharp dohme chibret ag switzerland merck sharp dohme comercializadora de rl de cv mexico merck sharp dohme doo croatia merck sharp dohme de espana sa spain merck sharp dohme de mexico sa de cv mexico merck sharp dohme de venezuela srl venezuela merck sharp dohme farmaceutica ltda brazil merck sharp dohme finance europe limited great britain merck sharp dohme gmbh austria merck sharp dohme holdings de mexico sa de cv mexico merck sharp dohme idea inc switzerland merck sharp dohme industria quimica e veterinaria limitada brazil merck sharp dohme inovativna zdravila doo slovenia merck sharp dohme international services bv netherlands merck sharp dohme ireland human health ltd ireland merck sharp dohme sland hf iceland merck sharp dohme llc russian federation merck sharp dohme limited great britain merck sharp dohme pakistan limited pakistan merck sharp dohme ou estonia merck sharp dohme overseas finance nv neth antilles merck sharp dohme peru srl peru merck sharp dohme quimica de puerto rico inc delaware merck sharp dohme de rl de cv mexico merck sharp dohme sia latvia merck sharp dohme tunisie sarl tunisia merck sharp dohme limitada portugal merck sharp dohme ilaclari limited sirketi turkey merck technology us company inc nevada merck ventures inc delaware merial animal health co ltd china merial animal health ltd great britain merial australia pty ltd australia merial argentina sa argentina merial asia pte ltd singapore merial belgium belgium merial bv netherlands merial colombia sa colombia merial distribution sas france merial gmbh germany merial hong kong limited hong kong merial ia llp puerto rico merial inc delaware merial international trading shanghai co ltd china merial italia spa italy merial japan limited japan merial korea ltd korea merial laboratorios sa spain merial limitedllc great britaindelaware merial nanjing animal health co ltd china merial new zealand limited new zealand merial norden denmark merial philippines inc philippines merial portuguesa saude animal lda portugal merial sa uruguay merial sas france merial saude animal ltda brazil merial taiwan co ltd taiwan merial thailand ltd thailand merial venezuela ca venezuela msd japan co ltd japan msd nippon holdings bv netherlands msd norge norway msd proprietary limited south africa msd thailand ltd thailand msd australia pty ltd australia msd chibropharm gmbh germany msd finance bv netherlands msd finance mexico llc delaware msd international holdings inc delaware msd ireland holdings sa luxembourg msd ireland investment ltd bermuda msd korea ltd koreadelaware msd lakemedel scandinavia aktiebolog sweden msd latin america services ltd bermuda msd latin america services de rl de cv mexico msd magyarorszg kereskedelmi szolgltat kft hungary msd overseas manufacturing co ireland ireland msd overseas manufacturing co bermuda msd pembroke ltd bermuda msd pharmaceuticals private limited india msd polska sp zoo poland msd sa morocco morocco msd sharp dohme gmbh germany msd somerset ltd bermuda msd technology singapore pte ltd singapore msd technology lp delaware msd unterstutzungskasse gmbh germany msd ventures singapore pte ltd singapore msd warwick manufacturing ltd bermuda msdessex gmbh switzerland msdsp ltd great britain msp distribution services c llc nevada msp distribution services r llc nevada msp marketing services c llc nevada msp marketing services r llc nevada msp singapore company llc delaware msp singaporesub llc delaware msp technology us company llc delaware neopharmed spa italy nippon merckbanyu co ltd japan pasteur vaccins sa france pt merck sharp dohme indonesia indonesia readington holdings inc new jersey readington investments inc new jersey rosetta inpharmatics llc delaware ruskin limited bermuda sanofi pasteur msd denmark sanofi pasteur msd gestion sa france sanofi pasteur msd gmbh austria sanofi pasteur msd gmbh germany sanofi pasteur msd ltd great britain sanofi pasteur msd ltd ireland sanofi pasteur msd nvsa belgium sanofi pasteur msd sa spain sanofi pasteur msd spa italy sanofi pasteur msd snc france seneca llc delaware sharp dohme sa spain stellarx inc nevada suomen msd oy finland telerx marketing inc pennsylvania msd foundation limited great britain thomas morson son limited great britain tradewinds manufacturing srl barbados transrow manufacturing ltd bermuda uab merck sharp dohme lithuania varipharm arzneimittel gmbh germany less exhibit power attorney undersigned hereby appoint celia colbert kenneth c frazier severally hisher true lawful attorney attorneys execute behalf undersigned whether behalf company officer director thereof attesting seal company otherwise annual report merck co inc fiscal year ended december securities exchange act including amendments thereto